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Abstract 
 
Parkinson’s disease (PD) is a neurodegenerative movement disorder characterized by the loss of 
dopaminergic neurons in the substantia nigra of the midbrain. Although the aetiology of PD is still 
not fully understood, it is thought to involve a combination of environmental (such as exposure to 
pesticides and neurotoxins) and genetic factors. A number of PD-causing genes have been found 
including SNCA, LRRK2, EIF4G1 and VPS35 (for autosomal dominant forms of PD) and parkin, PINK1, 
DJ-1 and ATP13A2 (for autosomal recessive forms of PD – arPD). Mutations in the parkin gene are 
the predominant cause of arPD. Parkin plays a role in the ubiquitin-proteasomal system which 
degrades damaged and unwanted proteins in the cell and it is also thought to be involved in 
maintaining healthy mitochondria. Numerous studies have implicated mitochondrial function in the 
pathogenesis of PD. Therefore the aim of the present study was to investigate the role of 
mitochondrial dysfunction in PD patients with parkin-null mutations.  
 
Four South African PD patients, each harbouring two parkin-null mutations, were recruited for this 
study. A muscle biopsy was performed for analysis of mitochondrial morphology using histology and 
transmission electron microscopy (TEM). Skin biopsies were taken, from which fibroblasts were 
cultured. These fibroblasts were used in i) mitochondrial morphological assessments using TEM, ii) 
mitochondrial network analysis, iii) functional studies via ROS measurement and iv) analysis of the 
proteome using a LTQ Orbitrap Velos mass spectrometer. In addition, RNA was isolated from 
peripheral blood samples for gene expression studies using the RT² Profiler PCR Array 
(SABiosciences, USA) and the RT² PCR Primer Assay (SABiosciences, USA). Heterozygous family 
members (carriers) and wild-type controls were also recruited for this study. 
 
Results from the histological and TEM analysis from the muscle biopsy observed subtle 
mitochondrial changes including the presence of type II fibres, atrophic fibres, the presence of lipids, 
and wrinkling of the sarcolemmal membrane. Enlarged mitochondria were also observed in one 
patient. TEM analysis on the patient’s fibroblasts observed an increase in the number of electron 
dense vacuoles, speculated to be autolysosomes. The mitochondrial network in two of the patients’ 
fibroblasts showed fragmented and dot-like networks which are indicative of damaged 
mitochondria. An increase in mitochondrial ROS levels was observed in three of the four patients. 
Expression studies found down-regulation of 14 genes from four of the five mitochondrial complexes 
and a total of 688 proteins were found only in the control and not in the patient fibroblasts. Some of 
these proteins are known to be part of the ‘mitochondrial dysfunction’ pathway. 
 
Taken together, these results indicate that the absence of parkin results in a number of 
mitochondrial alterations. Based on these findings, a model of PD was proposed: It is speculated that 
when parkin is absent, electron transport chain complex genes are down-regulated. This results in 
impaired oxidative phosphorylation, causing an increase in the production of mitochondrial ROS and 
subsequent oxidative stress. Mitochondria are then damaged; resulting in the fragmentation of the 
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mitochondrial network. The impaired mitochondria are thus tagged for degradation, causing the 
recruitment of autolysosomes which engulf the mitochondria via mitophagy. Ultimately, as the 
compensatory mechanisms fail, this triggers the consequential cascade of cellular apoptotic events. 
 
This study has elucidated the effect of parkin on the mitochondria, and can act as a ‘stepping stone’ 
towards future development of therapeutic strategies and/or biochemical markers that will benefit 
not only patients with PD but also other neurodegenerative disorders. 
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Opsomming 
 
Parkinson se siekte (PS) is ‘n neurodegeneratiewe bewegings-afwyking gedefineer deur die verlies 
van dopaminergiese neurone in die substantia nigra van die midde brein. Alhoewel die spesifieke 
oorsprong van die afwyking nog nie ten volle begryp is nie, word bydraes van beide omgewings 
faktore (bv. blootstelling aan plaagdoders en neurotoksienes) asook genetiese faktore gespekuleer. 
Vanuit ‘n genetiese aspek is ‘n aantal gene al geassosieer met PS. Hierdie gene sluit in SNCA, LRRK2, 
EIF4G1 en VPS35 (vir outosomale dominante vorms van PS) en parkin, PINK1, DJ-1, en ATP13A2 (vir 
outosomale resessiewe vorms van PS - orPS). Mutasies in die parkin geen is aangedui as die hoof 
oorsaak van orPS. Parkin speel ‘n rol in die ubiquitine-proteasomale sisteem wat beskadige en 
ongewensde proteïne binne in die sel verwyder en is verdink om by te dra tot die instandhouding 
van gesonde mitokondria. Mitokondriese wanfunksionering is ook deur talle studies gewys as ‘n 
bydraende faktor in die patologie van PS. Die doel van die studie is om ondersoek in te stel tot die 
spesifieke rol wat mitokondriese wanfunsionering speel in PS pasiënte met parkin-nul mutasies. 
 
Vier Suid-Afrikaanse PS-pasiënte, elk met twee parkin-nul mutasies, is gebruik vir die studie. Deur 
middel van spierbiopsies is monsters verkry vir mitokondriese morfologiese analises met behulp van 
histologiese en elektron-oordrag mikroskopie tegnieke (TEM). Vel biopsies is ook geneem en 
fibroblaste is gekweek vir die gebruik in: i) mitokondriese morfologiese assesering; ii) mitokondriese 
netwerk analiese; iii) funksionele studies waar vlakke van reaktiewe suurstof spesies (ROS) gemeet 
is; iv) proteoom analiese met behup van ‘n LTQ Orbitrap Velos massa spektrometer. RNA is ook 
geisoleer vanaf perifere bloedmonsters vir die gebruik in geen-uitdrukkings studies met behulp van 
‘n RT² Profiler PCR Array en ‘n RT² Primer Assay. Selle vanaf famielie lede wat heterosigotiese draers 
is van die mutasie, asook normale (geen parkin mutasie) selle is gebruik as kontroles in die studie. 
 
TEM resultate vanaf die spier monsters het subtiele mitokondriese veranderinge getoon. Hierdie 
sluit in die teenwoordigheid van tipe II vesels, atrofiese vesels, teenwoordigheid van lipiedes, assook 
waarnemings van rimpeling van die sarcolemmal membraan. Vergrote mitokondrias is ook in een 
van die pasiënte opgelet. TEM resultate vanaf die fibroblaste het toename in die aantal elektron-
digte vakuole vertoon, moontlik geidentifiseer as autolisosome. Gefragmenteerde en onderbreekte 
mitokondria netwerke is gelet tydens netwerk analiese van die fibroblaste, ‘n indikasie van 
beskadigde mitokondria. ‘n Toename in mitokondriese ROS vlakke is gevind in drie van die vier 
pasiënte. Af-regulering van 14 gene, geassosieerd met vier uit die vyf mitokondria komplekse, is 
verneem tydens die geen-uitdrukkings studie. Saam met dit is ‘n totaal van 688 proteïene 
geidentifiseer wat slegs teenwoordig is in die kontrole monsters en nie in die pasiënt monsters nie. 
Hierdie proteïene is almal uitgedruk en betrokke in die mitokondriese wanfunsionerings-weë.  
 
Hierdie resultate dui dat die afwesigheid van parkin mitokondriese afwykings tot gevolg het wat kan 
lei tot die afsterwing van selle. Dit dra ook by tot die vorming van ‘n beter-verstaande siekte-model 
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vir PS: Mutasies in parkin (wat lei tot die afwesigheid van parkin) kan dus moontlik lei tot die af-
regulasie van gene geassosieerd met die elektron-vervoer ketting komplekse in die mitokondria. Dit 
lei tot gebrekkige oksidatiewe fosforilering en veroorsaak ‘n toename in die vorming van ROS, wat 
dan ‘n toename in oksidatiewe stres binne in die sel tot gevolg het. Uiteindelik lei dit dus tot die 
beskadiging van die mitokondria wat gepaard gaan met fragmentering van die mitokondriese 
netwerk. Beskadigde mitokondrias word geetiketeer vir afbraking. Hierdie etiketering aktiveer 
omringende autophagosome wat die beskadigde mitokondrias dan verwyder deur middel van ‘n 
verswelgende proses genaamd mitophagy. Dit veroorsaak die aktivering van ‘n aantal gekorreleerde 
sellulêre prosesse wat lei tot apoptose (afsterwing van die sel). 
 
Hierdie studie dra by tot die verklaring van die spesifieke effek wat parkin mutasies het op die 
funksionering van die mitokondria. Resultate hier lê ook die grondslag vir toekomstige studies met 
die doel tot die ontwikkeling van terapeutiese strategeë en biochemiese merkers wat kan bydrae tot 
die genesing van beide pasiënte met PS, asook pasiënte met ander neurodegeneratiewe afwykings. 
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Parkinson’s disease (PD) is a progressive, neurodegenerative disease caused by a loss of 
dopaminergic neurons in the brain. It is the second most common neurodegenerative disorder after 
Alzheimer’s disease. In 1817, a physician in London, Dr. James Parkinson (Figure 1.1) first described 
the disease in the published essay “An Essay on the Shaking Palsy” and this was the first modern 
description of the disorder (Parkinson, 1817). Dr. Parkinson described six cases in his essay, and he 
noted the clinical motor symptoms including resting tremor, abnormal posture and gait, and 
diminished muscle strength. For one of these patients he documented the following: 
 
Case II: “The subject of the case which was next noticed was casually met with in the street. It was a 
man sixty-two years of age; the greater part of whose life had been spent as an attendant at a 
magistrate's office. He had suffered from the disease about eight or ten years. All the extremities 
were considerably agitated, the speech was very much interrupted, and the body much bowed and 
shaken. He walked almost entirely on the fore part of his feet, and would have fallen every step if he 
had not been supported by his stick. He described the disease as having come on very gradually, and 
as being, according to his full assurance, the consequence of considerable irregularities in his mode 
of living, and particularly of indulgence in spirituous liquors. He was the inmate of a poor-house of a 
distant parish, and being fully assured of the incurable nature of his complaint, declined making any 
attempts for relief.” 
 
 
 
 
 
 
 
 
Figure 1.1: Photograph of Dr. James Parkinson (1755 – 1825). Taken from: 
http://www.allaboutparkinsons.com/james-parkinson.html  
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Half a century later, Dr. Jean-Martin Charcot named the disorder in honour of Dr. Parkinson. Today, 
PD is characterised as the degeneration or loss of neuromelanin-containing dopaminergic neurons in 
the substantia nigra pars compacta (SNc), a portion of the midbrain (Figure 1.2). There are four 
cardinal motor symptoms which are observed in the majority of PD patients, namely resting tremor 
(trembling usually of the hands and feet that occurs only when not in motion), bradykinesia 
(slowness of movement), rigidity (stiffness of the muscles) and postural instability (loss of balance 
and difficulty with walking), but there are also many other non-motor symptoms including loss of 
smell, depression, constipation, sleep disturbances and psychosis. There are currently no proven 
neuroprotective or neurorestorative therapies for PD, and progression of the disease is irreversible 
(Dawson & Dawson, 2002) 
 
 
 
 
 
 
 
 
Figure 1.2: Cross-sectional cut of the mid-section of the brain showing the location of the 
substantia nigra pars compacta (SNc), the site of dopaminergic neurons. The SNc is the black 
pigmented area, indicated by the arrow (Taken from: http://health.allrefer.com/health/parkinsons-
disease-substantia-nigra-and-parkinsons-disease.html). 
 
1.1. Prevalence of Parkinson’s disease (PD) 
 
It has been observed that PD affects approximately 1-2% of the global population over the age of 65 
years, and 4% over the age of 80 years (de Lau & Breteler, 2006). In a study on Western Europe’s five 
Substantia nigra 
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most and the world’s ten most populous countries (including Germany, France, Nigeria and Japan) 
the number of PD-affected individuals was estimated to be between 4.1 and 4.6 million in 2005, and 
this number is expected to double by 2030 (Dorsey et al., 2007).  
 
The most recent study recording incidence rates of PD across age, gender and ethnicity (Van Den 
Eeden et al., 2003) showed an overall annual incidence rate of 12.3 per 100 000, whereas individuals 
with an age of over 50 years had an incidence of 44.0 per 100 000, showing that the incidence of PD 
increases with age. Noticeably different incidence rates were observed between different ethnic 
groups – Hispanics had the highest age- and gender-matched incidence rate of 16.6 per 100 000, 
non-Hispanic Whites at 13.6 per 100 000, Asians at 11.3 per 100 000, and Blacks at 0.2 per 100 000. 
The reason for this difference could be due to either genetic or environmental diversity; however it 
may also be due to a lack of facilities and services (in underdeveloped countries) needed to diagnose 
the disease. Gender-specific incidence rates showed 19.0 per 100 000 in males, and 9.9 per 100 000 
in females, with a male: female ratio of 1.9 (Van Den Eeden et al., 2003). Although similar ratios have 
been seen in other studies (Twelves et al., 2003), this is not a consistent finding and further studies 
are needed. 
 
1.2. Clinical characteristics 
 
1.2.1. Age at onset 
 
The age at onset (AAO) in PD patients ranges from 20 years of age to over 70 years, and is 
categorised into three sub-groups, namely juvenile onset PD, early onset PD (EOPD) and late onset 
PD (LOPD). Juvenile onset PD (AAO <20 yrs.) is uncommon, and is caused by rare mutations in the 
genes that cause PD (Section 1.3.2). EOPD (≤40-50 yrs.) is also relatively rare with predominantly 
genetic causative factors. Patients with an AAO over the age of 50 fall into the LOPD category, and 
this is thought to be caused by a combination of genetic and environmental factors. PD is an age-
related disorder, and it has been found that an increase in age is one of the strongest risk factors. 
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1.2.2. Neuropathology of PD 
 
PD is characterized pathologically by the loss of 70 – 80% of the dopaminergic neurons which results 
in depigmentation of the SNc (Figure 1.3 A) as dopaminergic neurons also produce melanin that is 
responsible for the pigmentation of the SNc. This neuronal loss causes a substantial decrease in 
dopamine production, thus leading to the movement problems seen in PD patients. A second 
pathological characteristic of PD is the presence of Lewy bodies (LB) in the SNc and several other 
regions of the brain (Figure 1.3 B). LBs are cytoplasmic protein inclusions composed predominantly 
of alpha-synuclein, neurofilament proteins and ubiquitin (Figure 1.4; Spillantini et al., 1997; Wooten, 
1997). It is hypothesized that the formation of LBs occurs prior to PD diagnosis in the dorsal motor 
nucleus, and progressively moves through the brainstem into the SNc and towards the cerebral 
cortex (Braak et al., 2003). Patients with EOPD caused by mutations in the parkin gene generally 
have an absence of LBs in post mortem analyses, suggesting that parkin may play a role in the 
formation and ubiquitylation of these inclusions. 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The pathology of the substantia nigra pars compacta (SNc). A. Unaffected (top) and PD-
affected (bottom) SNc showing de-pigmentation of the neurons as a result of a loss of melanin-
containing cells. B. The presence of a Lewy body (arrow) in the SNc. Taken from: Stacy et al., 2009 
A B 
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Figure 1.4: Immunohistochemical analysis of sections from the substantia nigra pars compacta 
(SNc) of a patient with sporadic PD. A. Lewy body stained with an antibody against ubiquitin (green 
dye). B. Lewy body stained with an antibody against α- synuclein (red dye). Taken from: Guttmacher 
et al., 2003 
 
1.2.3. Symptoms of PD 
 
Traditionally, it was believed that PD was only a motor system disorder, with little or no symptoms 
affecting other bodily functions. However, clinical data now show a far more complex and systemic 
condition with not only motor symptoms, but also neuropsychiatric and other non-motor symptoms 
playing a role in the early diagnosis of PD. 
 
1.2.3.1. Motor symptoms 
As previously mentioned, there are four cardinal motor symptoms found in the majority of PD 
patients, namely resting tremor, bradykinesia, rigidity and postural instability, and these are 
depicted in Figure 1.5. 
 
A B 
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Figure 1.5: Illustration indicating the motor symptoms of Parkinson’s disease. Taken from: 
http://schoolworkhelper.net/2011/02/parkinson.  
 
A resting tremor is usually the first sign of the onset of PD. It can appear in the hands, feet, face or 
jaw and the exact cause is not known. It has been speculated that a loss of dopamine disrupts the 
operations of the thalamus, leading to a lack of control of movement. 
 
Bradykinesia is defined as the slowing of movement. It is thought to result from ‘a failure of basal 
ganglia output to reinforce the cortical mechanisms that prepare and execute the commands to 
move’ (Berardelli et al., 2001).Other factors such as muscle weakness, rigidity, tremor, movement 
variability and slowing of thought can all contribute to the development of bradykinesia. 
 
Rigidity is described as an increased resistance to passive movement about a joint. Patients suffering 
from PD often complain of stiffness and pain, which is the result of rigidity of the joints.  
 
Tremor 
Tremor 
Masklike faces 
Arms flexed at 
elbows and wrists 
Short shuffling steps 
Stooped 
posture 
Rigidity 
Hips and knees 
slightly flexed 
Stellenbosch University  http://scholar.sun.ac.za
10 
 
Postural instability is a symptom that causes a lack of balance or stability. It leads to a higher risk of 
falling in PD patients, due to a loss of ‘righting reflexes’ or the occurrence of freezing (Gelb et al., 
1999) 
 
1.2.3.2. Non-motor symptoms 
Several non-motor symptoms, such as loss of smell, constipation and depression, can occur up to ten 
years before the onset of motor symptoms. These symptoms remain under-recognized as an 
indication of PD, and as a result, are under-treated. Other non-motor symptoms include sleep 
disorders, apathy and cognitive impairment, hallucinations, dementia and psychosis (Chaudhuri et 
al., 2006). It has been suggested that these non-motor symptoms may be markers of a pre-clinical 
stage of PD. Some patients list non-motor symptoms as even more disabling than the motor 
symptoms (Gulati et al., 2004). A study by Whetten-Goldstein et al interviewed over one hundred 
people suffering from PD to determine the burden of the disease (Whetten-Goldstein et al., 1997). A 
substantial number of these patients listed non-motor symptoms such as depression and fatigue as 
some of the greater burdens of PD, particularly in the earlier stages of the disease. Studies such as 
these suggest that more effort should be made in recognizing these symptoms prior to the onset of 
motor symptoms, and treating them in a unified and integrated manner. 
 
1.2.4. Treatment strategies 
 
Currently, there are several drug treatment options available to treat for PD. Levodopa (precursor to 
dopamine) and dopamine agonists can both manipulate the dopaminergic system, however, these 
strategies only alleviate the symptoms and each drug has a wide-range of side effects that need to 
be carefully monitored and controlled.  
 
Levodopa is a large aromatic amino acid which acts as a precursor to dopamine (Figure 1.6). It is 
absorbed from the small bowel, via amino acid transporters into the blood. It is able to cross the 
blood-brain barrier, where it is converted into dopamine via a chemical reaction involving the 
enzyme aromatic L-amino acid decarboxylase (AAD), thus increasing the concentrations of dopamine 
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in the central nervous system. Levodopa has a particularly short half-life (about 90 minutes); 
therefore sustained antiparkinsonian response is dependent on continuous delivery of Levodopa 
(Nutt 2010). Side effects include involuntary movements and mental status changes such as anxiety, 
panic and depression, specifically towards the end of a dose cycle.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: The conversion of Levodopa into dopamine via the enzyme aromatic L-amino acid 
decarboxylase. Taken from: www.ualberta.ca.htm 
 
Two of the dopamine agonists, pramipexole and ropinirole, are agonists at the dopamine D-2 
receptor family. These agents show antiparkinsonian effects, however not as effectively as Levodopa 
(Rascol et al., 2000), due to a limitation imposed by stimulation of only the dopamine D-2 receptor 
family (Nutt 2010). Side effects of dopamine agonists also include motor complications and 
depression, however these are to a far lesser extent than the side effects experienced by Levodopa. 
Other side effects include hallucinations and impulse control disorders.  
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Another treatment option for PD is deep brain stimulation therapy (DBS). DBS is a surgical 
procedure, whereby electrodes are implanted into a precise location in the brain (either the 
subthalamic nucleus or the globus pallidus, depending on each individual patient) within specific 
brain circuits, or neuronal loops, for modulation of the activity of those circuits. The electrodes are 
connected to an implanted pulse generator that is responsible for delivery of continuous 
stimulation, and the current produced then acts as either a suppressor or a driver of neuronal 
activity (Lozano, 2012). Risks of DBS include the small chance of a haemorrhage or stroke, 
depression, paraesthesias, dysarthria, motor contractions and infection. However, this treatment 
option is continually expanding and improving, and studies show that the clinical benefits of DBS 
outweigh the risks involved (Deuschl et al., 2006; Follett et al., 2010) 
 
 
A major drawback of all current therapies for PD is that they only treat the symptoms and do not 
cure the disorder. Therefore, more intensive research is required into the underlying cause of PD for 
the ultimate development of a cure or neuroprotective therapy. 
 
1.3. Causes of PD 
 
PD was traditionally considered to be a sporadic disease, caused by environmental factors, such as 
lifestyle and aging. However, the past fifteen years have been successful in proving the role of 
genetic factors in the cause of this condition. A positive family history is associated with a higher risk 
of PD and the aetiology of this disorder, although not fully understood, is considered to involve an 
interaction between genetic and environmental factors (Sherer et al. 2002). 
  
1.3.1. Environmental causes 
 
Several environmental factors have been found to influence the occurrence of PD. Current interest is 
focused on pesticide and neurotoxin exposure, such as rotenone, paraquat and MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine). It is thought that farming as an occupation also holds a 
significant risk for PD, possibly due to the greater risk of pesticide exposure (Gorell et al., 1998). A 
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meta-analysis examining 16 case-control studies found a positive association with rural living and the 
risk of PD in 11 of the studies, with the average duration of exposure being 40 years or longer 
(Priyadarshi et al., 2001). This could be due to a higher concentration of neurotoxins that are present 
in pesticides, well-water or spring water in these areas. The same study analysed the effect of well-
water drinking on the onset of PD, where 11 out of the 19 studies found a positive association, 
although this was not significant. Reasons for the onset of PD from well-water drinking could be due 
to chemical or bacterial contaminations of the water from the soil and surrounding areas (Butterfield 
et al., 1993).  Other possible environmental causes include head trauma, heavy metal exposure 
(manganese), as well as exposure to organic solvents, carbon monoxide and carbon disulphide; 
however studies have shown conflicting results (Seidler et al., 1996; Taylor et al., 1999). 
 
Apart from the environmental risk factors for an increased risk of developing PD, there are also 
several factors that have been associated with a decreased risk, such as coffee drinking and cigarette 
smoking. A meta-analysis performed on 48 studies that have analysed the effect of these factors on 
the onset of PD found a 60% lower risk of PD among cigarette smokers compared to those that had 
never smoked, and a 30% lower risk of PD for coffee drinkers compared to non-coffee drinkers 
(Hernán et al., 2002). They also discovered that PD risk continues to decrease as exposure to 
smoking and increased coffee intake increases.  
 
It is thought that components of cigarette smoke may decrease the activity of type B monoamine 
oxidase (MAO-B) in the brain. MAO-B is responsible for the breakdown of dopamine in the brain 
(Checkoway et al., 2002), so by decreasing the activity of MAO-B, the eventual risk of PD is 
decreased. Similarly, caffeine intake is thought to have neuroprotective properties, and has been 
shown to decrease the dopamine cell destruction in mice exposed to MPTP (Hernán et al., 2002).  
 
1.3.1.1. Rotenone 
Rotenone is a garden pesticide with a high-affinity to inhibit mitochondrial complex I. Complex I is 
one of the five enzyme complexes in the electron transport chain of the mitochondria, responsible 
for oxidative phosphorylation (Refer to Section 1.4.2). Impaired complex I activity leads to an 
increase in oxidative stress, which is defined as an imbalance between production of free radicals 
(e.g. reactive oxygen species; ROS) and the antioxidant capacity of the cell. The increase in ROS and 
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the decrease in ATP (Adenosine-5’-triphosphate) production caused by the complex I dysfunction 
will ultimately lead to cell death via apoptosis. Exposure to rotenone in rat models showed a defect 
in complex I that led to behavioural, anatomical, neurochemical and neuropathological features of 
PD (Betarbet et al., 2000). 
 
1.3.1.2. MPTP 
MPTP is a neurotoxin capable of crossing the blood-brain barrier, resulting in its conversion to MPP⁺ 
(1-methyl-4-phenylpyridinium). MPP⁺ then enters the mitochondria of the dopamine-producing 
neurons and prevents the binding of complex I to electron transport particles such as electrons and 
hydrogen ions, thus impairing mitochondrial respiration (Tipton & Singer, 1993; Przedborski et al., 
2004). This leads to cell death due to a decrease in ATP production and an increase in the production 
of ROS. 
 
 In America in the early 1980’s, a number of heroin users presented at emergency rooms with 
symptoms indistinguishable to that of PD (Burns et al., 1985). It was discovered that the heroin used 
was from a synthetic batch that was contaminated with MPTP, causing the addicts to become mute 
and rigid and present with symptoms similar to PD, as the MPTP acted on the nerve cells in the 
substantia nigra. These patients were described by Dr. JW Langston in his paper “The Case of the 
Tainted Heroin” (Langston, 1985). 
 
Primates treated with MPTP showed motor disturbances such as bradykinesia, rigidity and postural 
instability, almost indistinguishable to the motor symptoms seen in patients with PD (Jenner, 2003). 
Biochemically, these primate models have decreased release of dopamine and serotonin, as well as 
nerve cell loss in the SNc (Burns et al., 1985; Russ, et al., 1991).  These animal models have provided 
critical insight into the understanding of the possible pathophysiology of PD. 
 
1.3.1.3. Paraquat  
Due to the similarity in structure of paraquat (1,1’-dimethyl-4,4’-bipyridinium) and MPP⁺ 
(McCormack et al., 2002), it is hypothesized that paraquat plays a similar role in the cell. However, 
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animal models have produced contradicting results (Uversky, 2004; Ossowska et al., 2005), thus it is 
still questionable as to whether this pesticide has a significant effect on causing PD.  
 
1.3.2. Genetic causes 
 
Thus far, at least 17 loci and 11 genes have been linked to inherited forms of PD. Of these, eight 
genes (SNCA, LRRK2, parkin, PINK1, DJ1, ATP13A2, EIF4G1 and VPS35) have shown conclusive 
evidence to cause the condition (Lesage & Brice, 2009; Vilarioo-Güell et al., 2011; Chartier-Harlin et 
al., 2011). These genes can be divided into either autosomal dominant (AD) or autosomal recessive 
(AR) inheritance forms of PD. Approximately 5-10% of PD patients are thought to have a genetic 
cause of the disorder. Table 1.1 shows a summary of the genes involved in PD.  
 
1.3.2.1. Genes involved in autosomal dominant forms of PD 
To date, the dominant forms of PD arise from mutations in the α-synuclein (SNCA), and leucine-rich 
repeat kinase 2 (LRRK2) genes, and in the last year two additional genes have  been found - 
eukaryotic translation initiation factor 4-gamma (EIF4G1) and vacuolar protein sorting 35 (VPS35). 
 
SNCA 
SNCA was the first gene to be identified as a cause for AD PD (Polymeropoulos et al., 1997). The 
gene comprises six exons and encodes a 140 amino acid protein. Human α-synuclein protein is made 
up of an amphipathic region, a NAC domain (highly amyloidogenic) and an acidic tail (Appendix I). 
Seven imperfect repeats (KTKEGV) are found in the amino end of the protein. The α-synuclein 
protein is expressed abundantly throughout the brain, and is the major component of Lewy bodies, 
however little is known about its biological function. Mutations in SNCA range from missense 
mutations (PARK1-linked PD) to whole-gene multiplications (duplications and triplications; PARK4-
linked PD), and are extremely rare forms of familial PD. Three missense mutations have been 
reported, namely A53T, A30P and E46K (Polymeropoulos et al., 1996; Zarranz et al., 2004). 
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Table 1.1: Summary of Parkinson’s disease genes and loci 
 
CBS: corticobasal syndrome, FBXo7: F-box only protein 7; FTDP: frontotemporal dementia with parkinsonism; GBA: β glucocerebrosidase; GIGYF2: GRB10 interacting GYF protein 2; MAPT: 
microtubule associated protein tau; O: ocular signs; HTRA2: HtrA serine peptidase 2; SCA2: spinocerebellar ataxia type 2; UCHL1: ubiquitin carboxyl-terminal esterase L1. Adapted from: 
Lesage & Brice, 2009
PARK Loci Gene Map position Inheritance Disease onset AAO (yrs.) Mutations 
PD-associated loci and genes with conclusive evidence 
PARK1/PARK4 SNCA 4q21 AD EOPD 20-85 A30P, E46K, A53T, genomic duplications/triplications 
PARK2 Parkin 6q25 – q27 AR Juvenile, EOPD 16-72 Point mutations, exonic rearrangements 
PARK6 PINK1 1p35-p36 AR EOPD 20-40 Point mutations, rare large deletions 
PARK7 DJ-1 1p36 AR EOPD 20-40 Point mutations, large deletions 
PARK8 LRRK2 12q12 AD LOPD 32-79 80 missense variants, 7 of them pathogenic, including the 
common G2019S 
PARK9 ATP13A2 1p36 AR EOPD, Juvenile Kufor-Rakeb syndrome 
(KRS) 
11-16 Point mutations 
PARK18 EIF4G1 3q26-q28 AD LOPD 57-80 R1025H, A502V, 8 coding variants, 4 missense mutations 
Not assigned VPS35 16p12.1-q12.1 AD LOPD 37-72 D620N, P316S 
PD-associated loci and genes with unknown relevance 
PARK3 unknown 2p13 AD LOPD 60-69 Not identified 
PARK5 UCHL1 4p14 AD LOPD 55-58 One mutation in a single PD sibling pair 
PARK10 unknown 1p32 unclear LOPD 50-60 Not identified 
PARK11 GIGYF2 2q36-q37 AD LOPD 33-68 Seven missense variants 
PARK12 unknown Xq21-q25 unclear unclear - Not identifies 
PARK13 Omi/HTRA2 2p13 unclear LOPD 49-77 Two missense variants 
PARK14 PLA2G6 22q12-q13 AR Juvenile levodopa-responsive dystonia-
parkinsonism 
18-26 Two missense variants 
PARK15 FBXO7 22q12-q13 AR Early-onset parkinsonism-pyramidal 
syndrome 
10-19 Three point mutations 
PARK16 unknown 1q32 unclear unclear - Not identified 
Not assigned SNCAIP 5q23 Unclear LOPD 63-69 R621C, various SNPs with association 
Not assigned MAPT 17q21 AD FTDP, O, CBS 25-76 Haplotype H1, various SNPs with association 
Not assigned SCA2 12q24.1 AD EOPD 45-59 Low-range interrupted CAG expression in SCA2 
Not assigned GBA 1q21 AR EOPD 40-50 Point mutations 
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Duplications and triplications of the PARK4 locus are more common than missense mutations, and 
result in an increase in the amount of protein produced, leading to a more rapid progression of PD. 
Early onset, marked dementia and frequent dysautonomia (disorder of the autonomic nervous 
system) are found in patients expressing triplications of the gene (Ross et al., 2008). 
 
LRRK2 
LRRK2 mutations (PARK8-linked PD) present with LOPD at a mean age at onset of 60 years, and are 
present in up to 10% of AD familial PD cases (Paisán‐Ruíz et al., 2008). The majority of mutations in 
the LRRK2 gene are missense variants, of which seven mutations thus far are considered pathogenic. 
The most common of these is the G2019S mutation, which occurs in three to six percent of familial 
cases of PD in persons from European descent (Di Fonzo et al., 2005). This mutation is 
predominantly prevalent in North African Arabs, where 7 of 17 familial cases were observed (Lesage 
et al., 2005) . The frequency of mutations among Arabs was found to be 37 percent in familial cases 
and more surprisingly, 41 percent in sporadic cases (Lesage et al., 2006). Similarly, this frequency is 
also high in the Ashkenazi Jewish population, reaching 29.7 percent in familial cases and 13.3 
percent in sporadic cases (Ozelius et al., 2006) due to founder effects. 
 
LRRK2 has 2527 amino acids and contains a combination of motifs and several conserved domains 
(Appendix I). The function of LRRK2 is unknown, although it is thought to play a role in kinase activity 
and protein-protein interactions due to the functional domains of the protein (Dächsel et al., 2007). 
It is suggested that the kinase activities of LRRK2 are increased by the PD-associated mutations, 
hence the hypothesis of a gain-of-function pathogenic mechanism. LRRK2 is considered to interact 
with α-synuclein however little is known regarding the mechanism of this occurrence (Lin et al., 
2009). 
 
EIF4G1 
A genome-wide linkage analysis of a French family with a positive family history of AD PD discovered 
a missense mutation R1025H in the EIF4G1 gene (Chartier-Harlin et al., 2011). Further analysis found 
the mutation present in families from Ireland, Italy and the US. It is suggested that the mutation 
originates from a common ancestral founder (Sundal et al., 2012). A second novel missense 
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mutation – A502V - has also been found in 3 PD individuals (Tucci et al., 2012). PD caused by the 
R1025H mutation presents at a relatively late AAO, between 57 and 80 years of age. EIF4G1 encodes 
for a scaffold protein eIF4G1, which plays a role in the regulation of translation in response to 
development or environmental stressors in the cell.  
 
VPS35 
Whole exome sequencing of a Swiss family with 11 affected members with AD LOPD was performed 
(Vilarioo-Güell et al., 2011). The D620N mutation in the VPS35 gene was discovered; and an 
independent study done on a family from the US and Tunisia confirmed the presence of the PD-
causing D620N mutation (Zimprich et al., 2011). The gene encodes for the VPS35 protein, which is a 
critical component of the retromer cargo-recognition complex. The role of this complex is recycling 
membrane proteins between endosomes and the trans-Golgi network. 
 
1.3.2.2. Genes involved in autosomal recessive forms of PD 
The recessive forms of PD arise from mutations in four genes – namely parkin, PTEN-induced kinase 
(PINK1), oncogene DJ-1 (DJ-1) and ATPase type 13A2 (ATP13A2). The pathogenic mechanism of 
recessive forms of PD is a loss-of-function, due to the resulting absence or inactivation of protein. 
 
Parkin 
Parkin (PARK2-linked PD) mutations range from missense and nonsense mutations, to exonic 
deletions (most common), rearrangements and duplications. PARK2-linked PD is a common cause of 
juvenile and EOPD, although there are cases where LOPD occurs. It is estimated that parkin 
mutations are responsible for up to 50% of recessive familial cases of PD in some studies (Lucking et 
al., 2000). Parkin encodes a 465 amino acid ubiquitin E3 ligase protein. The protein is comprised of a 
C-terminal ‘ring between ring fingers’ (RBR) domain consisting of 2 RING fingers (R1 and R2) linked 
by a cysteine-rich ‘in-between-RING” (IBR) motif. The N-terminal is an ubiquitin-like domain (Ubl) 
(Appendix I).  
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The role of parkin in the cell is the targeting of other cellular proteins for degradation via the 
ubiquitin-proteasome system (UPS). This is performed by the RBR domain and several ubiquitin 
enzymes (e.g. E1 and E2), catalysing the attachment of ubiquitin to proteins (ubiquitylation), thus 
tagging these proteins for destruction (Further discussed in Section 1.4.5). Parkin possibly links 
ubiquitylation with mitophagy (autophagy which is selective for degradation of mitochondria). 
Parkin knockout studies in the fruit fly Drosophila melanogaster and mice have resulted in 
mitochondrial abnormalities (Greene et al., 2003; Palacino et al., 2004), suggesting possible 
mitochondrial dysfunction in patients with PD (Further discussed in Section 1.4.5).  
 
PINK1 
PINK1 (PARK6-linked PD) is a form of early onset AR PD. The protein has been shown to localize in 
the matrix and intermembrane space of the mitochondrion. Mutations in the PINK1 gene include 
missense and nonsense mutations (most common), frameshifts and truncating mutants. PINK1 
encodes for a 581 amino acid protein which has a protein kinase domain; a mitochondrial-targeting 
domain (MTS) and a transmembrane domain (TM; Appendix I; Corti et al., 2011). Although the 
function of PINK1 is unknown, it is thought to play a neuroprotective role against mitochondrial 
dysfunction. Studies on human cells with PINK1 mutations have shown that a deficiency of PINK1 
can lead to swelling of the mitochondria and loss of mitochondrial complex I activity (Section 1.4.5; 
Exner et al., 2007; Grünewald et al., 2009). 
 
Interestingly, PINK1 and parkin appear to work in the same pathway to prevent oxidative stress and 
regulate mitochondrial morphology. In Drosophila, parkin overexpression supresses PINK1 mutant 
phenotypes tested, whereas PINK1 overexpression does not compensate for loss of function in 
parkin mutant phenotypes (Clark et al., 2006; Park et al., 2006). Therefore PINK1’s role in the 
pathway is thought to be situated upstream of parkin, as parkin can rescue PINK1 but the inverse 
does not occur (Dagda et al., 2009; Park et al., 2006). Both genes affect the same pathway, so the 
interactions are thought to occur in the mitochondria (Shimura et al., 1999; Silvestri et al., 2005). 
Interaction of these proteins has been speculated to occur via three mechanisms – i) by direct 
binding and phosphorylation of PINK1 to parkin; ii) by phosphorylation of an intermediate protein by 
PINK1, which would then form a signal to alter the activity of parkin or iii) both proteins act on the 
same target. Parkin and PINK1 also seem to play roles in mitochondrial quality control and disposal 
(Narendra et al., 2010), which will be further discussed in sections 1.4.4 and 1.4.5. 
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DJ-1 
DJ-1 mutations constitute an extremely rare early onset AR EOPD, and consist of missense 
mutations, frameshift and splice-site mutations, and exonic deletions. The protein is made up of 189 
amino acids (Appendix I) and expressed in most mammalian tissues. DJ-1 is a cytoplasmic protein 
and part of a family of molecular chaperones, and can act as an anti-oxidant as well as a ROS 
scavenger in high levels of oxidative stress. Studies have shown a deficiency of DJ-1 results in 
increased apoptosis due to oxidative stress levels, whereas DJ-1 overexpression has protective 
effects on the cell under oxidative conditions (Abeliovich & Flint Beal, 2006). Currently, the 
mechanism of these effects is unknown. 
 
ATP13A2 
ATP13A2 is a large protein, made up of 1180 amino acids and 10 transmembrane domains (Appendix 
I). The protein is a lysosymal membrane protein, and although the function is relatively unknown, it 
is thought to be involved in the transport of inorganic cations and other substrates. High levels of 
ATP13A2 are found in the SNc. ATP13A2 (PARK9-linked PD) mutations were first recognized in 
Jordanian and Chilean families (Ramirez et al., 2006) with Kufor-Rakeb syndrome (KRS), which is a 
form of recessively inherited atypical parkinsonism, characterized by very early or juvenile AAO (11 – 
16 yrs.). The mutations found in these families are thought to induce degradation of ATP13A2 in the 
endoplasmic reticulum (ER; Ramirez et al., 2006) 
 
1.3.2.3. Heterozygous mutations in recessive genes 
In AR EOPD, mutations that cause PD are either homozygous or compound heterozygous 
(heterozygous for two different mutations). It has been reported in several studies that individuals 
who are heterozygous carriers of mutations (have only one mutation) in parkin and PINK1 can also 
present with PD (West et al., 2002; Bonifati et al., 2005; Hedrich et al., 2006). However there is much 
debate as to whether these individuals have mild signs of parkinsonism but not PD per se. 
Parkinsonism is the term for nervous disorders similar to PD, marked by muscular rigidity, tremor 
and impaired motor control. However, not all studies have shown that heterozygous individuals 
present with parkinsonism features and symptoms (Chien et al., 2006; Chishti et al., 2006), 
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suggesting that further research is essential in deciphering the role of heterozygous mutations in 
causing PD. 
 
Identification of the PD-causing genes have shed light on a number of pathways thought to be 
underlying the disorder, which include oxidative damage, abnormal protein accumulation, defective 
protein phosphorylation, defective cell signalling and mitochondrial dysfunction (Cookson & 
Bandmann, 2010). The next section will elaborate on the mitochondrial dysfunction hypothesis as 
this has received much attention over the last three years (Grünewald et al., 2009; Grünewald et al., 
2010; Zheng et al., 2010; Pacelli et al., 2011) 
 
1.4. Mitochondrial dysfunction and PD 
 
As stated in previous sections, mitochondrial dysfunction has been implicated in the development of 
PD through studies on pesticides and neurotoxins that disrupt complex I (e.g. MPTP, rotenone) and 
various genes that play a role in mitochondrial function (parkin, PINK1 and DJ-1). The following 
section will briefly discuss the structure, function, genome and dynamics of this organelle and will 
also focus on parkin and PINK1’s possible roles in the maintenance of healthy mitochondria. 
 
The mitochondrion is a vital intracellular organelle found in all tissue types and it is responsible for 
one of the cell’s key survival functions – the production of energy in the form of ATP. Mitochondria 
are also responsible for several other secondary functions, including regulation of cellular 
metabolism and respiration, signalling, cellular differentiation, cell death, control of the cell cycle 
and cell growth, and storage of calcium ions.  
 
1.4.1. Structure of the mitochondria 
 
Mitochondria are approximately 0.5-1µm in diameter, and are elongated, cigar-shaped organelles. 
The structure of the mitochondria is divided into the outer membrane, the intermembrane space, 
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the inner membrane, and the matrix (Figure 1.7). The mitochondrial structure facilitates efficient 
functional capacity of the organelle. If there is swelling of the mitochondria or fragmentation of the 
mitochondrial network, this generally leads to mitochondrial dysfunction and a decrease in the ATP 
levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Images to show the structure of the mitochondria. A. Schematic diagram and B. Electron 
micrograph of a mitochondrion. Taken from: http://www.tutorvista.com 
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1.4.1.1. Outer membrane 
The outer mitochondrial membrane encloses the entire organelle, and is composed of phospholipids 
and proteins. Large channels called porins allow for the diffusion of larger proteins from one side of 
the membrane to the other.  
 
1.4.1.2. Intermembrane space 
Separating the outer membrane from the inner membrane is a space known as the intermembrane 
space (IMS). The IMS is made up of the same composition of the cytosol of the cell, and houses 
enzymes such as cytochrome c, which is important for oxidative phosphorylation and cell apoptosis 
(Finsterer, 2004) 
 
1.4.1.3. Inner membrane 
The inner membrane is less permeable than the outer membrane, but far more complex. Situated 
here are all four respiratory chain complexes and the ATP synthase (also known as complex V) of the 
electron transport chain, which is the site of oxidative phosphorylation in mitochondrial respiration. 
Cristae (Figure 1.7) are folds formed by the inner membrane in order to increase the surface area, 
and are vital for rapid and efficient energy production. Other membrane proteins situated in the 
inner membrane include metabolites and ion carriers that aid in linking the metabolism of the 
cytoplasm with the IMS (Sherwood, 2012). 
 
1.4.1.4. Matrix 
The matrix is situated inside the inner membrane and is the site of the Krebs cycle. It is a gel-like 
solution, composed of enzymes involved in other processes such as the urea cycle and fatty acid 
oxidation. Also found in the matrix are ribosomes, messenger RNAs (mRNAs), transfer RNAs (tRNAs) 
and multiple copies of the mitochondrial genome. 
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1.4.2. Function of the mitochondria 
 
The mitochondrion is involved in a variety of functions but for the purpose of the present study, the 
focus will be on the production of energy via mitochondrial respiration. 
 
1.4.2.1. Mitochondrial respiration and ATP production 
Mitochondrial respiration is defined as the series of metabolic processes by which all living cells 
produce energy through the oxidation of organic substances. Glycolysis is the first step of the 
process and occurs in the cytosol of all cells. It involves the breakdown of one molecule of glucose 
into two three-carbon molecules of pyruvate via a series of enzyme-controlled reactions. In 
glycolysis, a net yield of two ATP molecules for one molecule of glucose is produced (Figure 1.8). In 
comparison, oxidative phosphorylation produces 36 ATP molecules per molecule of glucose 
(assuming that for each molecule of NADH three ATP is produced, and each molecule of FADH2 
produces two ATP). This is notably higher than the amount produced during glycolysis, signifying 
that glycolysis is less efficient in energy production than oxidative phosphorylation. Should oxidative 
phosphorylation be dysfunctional, then glycolysis assumes the role of the primary source for ATP. An 
example of when this occurs is in the absence of oxygen (when the cells are undergoing anaerobic 
respiration), oxidative phosphorylation cannot proceed, and glycolysis is then responsible for ATP 
production. 
 
 
 
 
 
 
Figure 1.8: Equation of cellular glycolysis producing a net yield of two ATP molecules 
 
C₆H₁₂O₆ + 2HPO₄²¯ + 2ADP³¯ + 2NAD+  
  
2Pyruvate + 2NADH + 2H+ + 2H₂O + 2ATP  
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The two pyruvate molecules produced by glycolysis are transported into the matrix of the 
mitochondria and converted to acetic acid, which combines with coenzyme A to form a compound, 
acetyl coenzyme A (acetyl CoA). Acetyl CoA then enters the eight-step Krebs cycle (also known as the 
Citric Acid Cycle), resulting in the production of electron donors NADH (reduced nicotinamide 
adenine dinucleotide) and FADH₂ (reduced flavin adenine dinucleotide) as well as two ATP 
molecules.  
 
The final step of mitochondrial respiration is that of oxidative phosphorylation, which is the 
synthesis of ATP from adenosine diphosphate (ADP) and inorganic phosphate (Pi). This process 
occurs on the inner membrane of the mitochondria via five enzyme complexes (complex I, complex 
II, complex III, complex IV and ATP synthase/complex V; Figure 1.9). NADH and FADH₂ act as carrier 
molecules, transporting hydrogen ions from the matrix to the inner membrane. NADH releases the 
hydrogen protons at complex I, whereas FADH₂ releases the protons at complex II. Once the protons 
are released, high energy electrons are extracted from the hydrogen. The hydrogen ions then move 
through the complexes and into the IMS, whilst the electrons move through the electron transport 
chain via ubiquinone and cytochrome c and other specific electron carriers. When the electrons 
reach complex IV, they are passed to O₂, the final acceptor, and H₂O is formed. 
 
As the electrons move, energy is released which aids in the movement of more hydrogen ions into 
the IMS. The high concentration of hydrogen ions in the IMS then leads to a density gradient from 
the IMS to the matrix, forcing the hydrogen ions to move from the IMS into the matrix through the 
ATP synthase complex. This leads to the activation of ATP synthase, which drives the conversion of 
ADP and Pi into ATP (Figure 1.9). 
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Figure 1.9: Oxidative phosphorylation at the mitochondrial inner membrane, shown in steps 1-9. This process involves the movement of electrons from the electron 
donors NADH and FADH₂ through a series of complexes, resulting in the movement of proton’s to the IMS. This creates a high proton gradient, which in turn forces the 
hydrogen ions to move from the IMS into the matrix through the ATP synthase complex which drives the conversion of ADP and Pi into ATP 
e¯, electron; NADH, reduced nicotinamide adenine dinucleotide; FADH₂, reduced flavin adenine dinucleotide; IMS, Intermembrane space; H
+
, proton; ADP, adenosine 
diphosphate; Pi, inorganic phosphate; ATP, adenosine triphosphate 
Taken from: Sherwood, 2012
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Figure 1.10 represents the final equation of mitochondrial respiration, whereby the substrates 
glucose and oxygen are converted into carbon dioxide, water and energy in the form of ATP. 
 
 
 
Figure 1.10: Equation of mitochondrial respiration producing a net yield of 38 ATP molecules 
 
1.4.2.2. Mitochondrial ROS 
 
Mitochondria are the main producers of ROS in the cell as a by-product of respiration. ROS are part 
of the free radical family, which are molecules that have a shortage of electrons in their outer 
orbital. An example of such a molecule is oxygen, because it has two unpaired electrons in its outer 
orbital. ROS are scavengers, because in order to find stability they need to extract electrons from 
neighbouring molecules to complete their own outer orbital (Beal, 2003). This leads to oxidation of 
neighbouring molecules.  
 
For example, when oxygen adds an extra electron, it becomes the superoxide anion (O₂˙¯), which is 
also a free radical. When there is a complex I deficiency or any other deficiency in the respiratory 
chain, the amount of electrons lost to oxygen significantly increases, resulting in an increase in the 
levels of ROS. A cell undergoes oxidative stress when there is an imbalance between the production 
of ROS and the cells ability to detoxify or neutralize the changes with antioxidants. Excessive ROS 
production, and oxidative stress, is toxic to the cell as they cause protein, lipid and DNA damage. For 
example guanosine can be oxidized to form 8-hydroxy-deoxyguanine which can lead to the incorrect 
pairing of these bases in the DNA molecule. Concentrations of 8-hydroxy-deoxyguanine have been 
shown to be significantly increased in the substantia nigra of patients with PD (Sanchez-Ramos et al., 
1994; Alam et al., 1997).  
 
 
C₆H₁₂O₆ + 6O₂  6CO₂ + 6H₂O + ENERGY (38ATP)  
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1.4.3. Mitochondrial genome 
 
The mitochondrial genome is a small, circular double-stranded DNA molecule consisting of 16 569 
base pairs (Figure 1.11), far smaller than the nuclear genome. Each human cell contains hundreds of 
mitochondria and thousands of copies of the mitochondrial genome. It is also more compact than 
the nuclear genome, as there are no introns present. It encodes for 37 genes – specifically 13 
polypeptides, 22 tRNAs and 2 rRNAs (Figure 1.11). The 13 polypeptides are all involved in the 
respiratory chain, and make up subunits of the five enzyme complexes. Mutations in the 
mitochondrial DNA (mtDNA), such as point mutations and rearrangements, can cause several 
diseases that typically affect the organs with high-energy requirements such as the brain, eyes and 
liver. These disorders include diabetes mellitus and deafness (DAD), myoclonic epilepsy with ragged 
red fibres (MERRF), and Leber’s hereditary optic neuropathy (LHON). 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: A map of the human mitochondrial genome. The legend indicates the mtDNA genes 
encoding each specific complex, as well as the position of the rRNAs and tRNAs. The D-loop, also 
known as the displacement loop, is a non-coding region with sequences vital for the initiation of 
mtDNA replication and transcription. The origin of the heavy stand is indicated as OH and the origin 
of light-strand replication is shown as OL. Taken from: Taylor & Turnbull, 2005 
 
 
 
 
 
Genes that encode the subunits 
of complex I (ND1-ND6, ND4L) 
Cytochrome c oxidase (COI-
COIII) 
Cytochrome b of complex III  
Subunits of ATP synthase 
(ATPase 6 and 8)  
Two ribosomal RNAs (rRNAs; 
12S and 16S)  
22 tRNAs denoted by their 
single letter code  
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Several studies have been done to investigate whether mutations in mtDNA may cause PD through a 
complex I defect. This is difficult to determine due to the fact that as one ages, large mtDNA 
deletions accumulate, causing complex I activity to decrease (Beal, 1995). Therefore, as PD is also 
associated with old age, distinguishing between the two causes has proven to be difficult. One study 
showed that although there was a high proportion of deleted mtDNA in age matched controls, there 
was a higher proportion of deleted mitochondria in parkinsonian cases (Bender et al., 2006).  
Furthermore, although specific mitochondrial sequence variants have been found in patients with 
PD there has not been a common finding in all studies (Kösel et al., 2000; Shoffner et al., 1993; Vives-
Bauza et al., 2002). 
 
The definition of a mitochondrial haplogroup is ‘an individual group characterized by the presence of 
a particular set of polymorphisms’ (Domínguez-Garrido et al., 2009). Human mitochondria can be 
subdivided into 36 different haplogroups which are all labelled by a letter of the alphabet, ranging 
from haplogroup A – N, P – Z, and subgroups of several of these haplogroups, such as HV, JT and L0 – 
L6. A study done by van der Walt and colleagues analysed 609 unrelated PD patients of European 
ancestry and compared them to age-matched controls (Van der Walt et al., 2003). It was found that 
the frequencies of haplogroup J and haplogroup K were lower in the PD cases compared to the 
control cases. This was due to single nucleotide polymorphism (SNP) 10398G in the NADH 
dehydrogenase 3 (ND3) gene in both haplogroups. It is thought that this SNP protects against 
development of PD compared to haplogroup H due to a possible increase in the performance of 
complex I in the brain and other tissues (Van der Walt et al., 2003). It has also been suggested that 
SNP 4216C which defines the haplogroup cluster JT is more frequent among Irish patients with PD 
than controls (Ross et al., 2003). This was also observed by Autere and colleagues when analysing 
the JTIWX supercluster (Autere et al., 2004) . However, it is currently unknown as to whether the 
decreased or increased risk of PD is due to a single polymorphism or a combination of 
polymorphisms.   
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1.4.4. Mitochondrial dynamics 
 
Recent studies have shown that mitochondria are not only static organelles with primary and 
secondary functions, but are highly dynamic, and are involved in processes such as movement, 
fusion, fission and mitophagy (Detmer & Chan, 2007). In most tissues, but especially in neuronal 
tissue, healthy mitochondria are transported towards areas with a high energy demand. In contrast, 
damaged or dysfunctional mitochondria move away from these areas into less demanding spaces of 
the cell. Movement can also promote morphological transitions in the mitochondria depending on 
the cell type. This is controlled by fusion and fission. Fusion and fission play major roles in 
maintaining the mitochondria, which is done by controlling the integrity of the mitochondria, the 
electrical and biochemical connectivity, the turnover of the mitochondria, and the protection of 
mtDNA (Berman et al., 2008) 
 
Fusion is the merging of the double membranes of two mitochondria, resulting in a larger single 
organelle (Figure 1.12). Subsequently, fission may occur, which is the division of one mitochondrion 
into two smaller mitochondria, a healthy one and an ‘impoverished one’, which is tagged for 
degradation whilst the healthy mitochondrion remains in the cell. The balance of both of these 
processes is vital in the maintenance of functional mitochondria and cellular requirements (Burbulla 
et al., 2010) and an imbalance can lead to autophagy and cellular apoptosis. Any type of 
disequilibrium of this system results in increased fission for fragmentation and removal of damaged 
mitochondria. 
 
There is tight regulation of these process via the action of the GTPases – namely Mitofusin 1 (Mfn1) 
and Mitofusin2 (Mfn2) which are situated in the mitochondrial outer membrane, and Opa1 which 
resides in the intermembrane space. These three GTPases are responsible for the process of 
mitochondrial fusion (Figure 1.12), and it is thought that the carboxy-terminal coils secure the two 
organelles undergoing fusion (McBride et al., 2006). Mitochondrial fission is controlled by a large 
GTPase called dynamin-related protein 1 (Drp1), with the aid of mitochondrial protein Fis1 and 
cytoplasmic endophilin B1/Bif-1 (Santel & Frank, 2008). Drp1 is recruited to the surface of the 
mitochondria (Figure 1.12); however the exact mechanism of fission remains unclear.  
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Figure 1.12: Mitochondrial fusion and fission mechanisms. Taken from: Mattson et al., 2008 
 
Detection of mitochondrial fusion or fission in cells is done via analysis of the mitochondrial network. 
These organelles form tubular networks (Legros et al., 2002) and when they are predominantly 
undergoing fusion, they appear joined together, resulting in a highly connected network. Conversely, 
when the majority of the mitochondria are undergoing fission to rid the cell of damaged 
mitochondria, the network appears fragmented and broken up. Defects in both processes are shown 
in Figure 1.13. The mitochondria are stained using fluorescent probes in order to observe the 
networks within the cells. 
 
 
Figure 1.13: Diagram illustrating defects in mitochondrial fusion and fission.  
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A study performed on Drosophila models used RNA interference (RNAi) to knockdown and over 
express the genes involved in fusion (Mfn1/2 and Opa1) and fission (Drp1 and Fis1; Ziviani et al., 
2010). They found that the knockdown of Opa1 and Mfn resulted in fragmented mitochondria, as no 
fusion was occurring (Figure 1.14A). In contrast, knockdown of Fis1 and Drp1 caused a highly 
connected mitochondrial network, as no fission was occurring. The opposite was seen to occur when 
Opa1 and Mfn were overexpressed – resulting in a high level of mitochondrial connectivity. When 
over expressing Fis1 and Drp1, a fragmented network was observed, similar to the knockdown of 
Mfn and Opa1 (Figure 1.14B). The normal state of the cells should show a balance of both fusion and 
fission. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14: Under- and over-expression of the genes responsible for fusion (Opa1 and Mfn) and 
fission (Fis1 and Drp1). A. Control cells exhibit a balanced network, knockdown of Opa1 and Mfn 
show fragmented mitochondria, whereas knockdown cells of Fis1 and Drp1 show a high connectivity 
of mitochondria. B. Control cells indicate a healthy mitochondrial network, over-expression of Opa1 
and Mfn show fused mitochondria, whereas over-expressed Fis1 and Drp1 have a fragmented 
network. Taken from: Ziviani et al., 2010 
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Damaged mitochondria are thought to be degraded via the process of mitophagy, which is defined 
as autophagy specifically selected for degradation of mitochondria. Mitochondria are especially 
susceptible to damage due to the relatively high levels of ROS produced during oxidative 
phosphorylation. Increased ROS can lead to ATP depletion, a higher mutation rate of mtDNA (Yakes 
& Van Houten, 1997) and ultimately cell death (Lemasters et al., 1998). Mitophagy is therefore 
essential in removing dysfunctional mitochondria to prevent cell death (Kim et al. 2007). 
 
1.4.5. Mitochondrial-associated PD genes 
 
The three PD genes known to be associated with mitochondrial function are parkin, PINK 1 and DJ-1. 
The autosomal dominant gene LRRK2 has also been associated with mitochondrial membranes. 
However, since most of the work has been done on parkin and PINK1, these genes will be the focus 
of the next section. Both genes have been implicated in causing mitochondrial structural defects 
such as an alteration in mitochondrial morphology (Grunewald et al., 2009; Pacelli et al., 2011), as 
well as functional defects such as an increase in ROS production, a decrease in the levels of ATP and 
a decrease in respiratory complex activity (Piccoli et al., 2008; Grunewald et al., 2009; Grunewald et 
al., 2010; Pacelli et al., 2011). Mitochondrial function can also be affected by changes in the 
expression levels of genes within the mitochondrial energy metabolism pathway.  
 
1.4.5.1. Parkin 
 
Parkin forms part of the UPS system whereby cystolic, secretory and membrane proteins undergo 
degradation (Dawson & Dawson, 2003). It is specifically involved in the removal of degraded, 
unwanted or short-lived proteins in the cell. The process is initiated by the activation of the carboxyl 
group of ubiquitin, resulting in its transfer to specific E2 ubiquitin-conjugating enzymes. This then 
causes conjugation of ubiquitin to the ε-amino group of lysine residues of the protein substrate (Ye 
& Rape, 2009). This process is aided and catalysed by three specific enzymes – E1 ubiquitin-
activating enzyme, E2 ubiquitin-conjugating enzyme and E3 ubiquitin-protein ligases. The 
attachment of ubiquitin to the lysine residue of the substrate leads to the formation of a 
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polyubiquitin chain, and thus the protein is ‘tagged’ for degradation. Parkin acts as an E3-ubiquitin-
protein ligase, and absence or inactivation of parkin is thought to lead to abnormal accumulation of 
the proteins selected for degradation (Kahle & Haass, 2004). Also, due to the presence of LBs 
(partially made up of ubiquitin) in PD patients, failure of the UPS might also play an important role in 
the pathology of the disease. 
 
Animal studies 
Animal knockout models of parkin show several changes in the mitochondria in comparison to the 
wild-type controls. A study on a Drosophila knockout model revealed that mitochondrial defects 
were a common characteristic of pathology (Greene et al., 2003). They found severe morphological 
differences in the knockout models – such irregular & dispersed myofibrillar arrangements and 
swollen and malformed mitochondria with disintegration of cristae (Figure 1.15). In mice knockout 
models, a decrease in the number of proteins involved in mitochondrial function or oxidative stress, 
a decrease in respiratory capacity of striatal mitochondria, as well as decreased serum antioxidant 
capacity were found (Palacino et al., 2004). In contrast to the Drosophila model however, the 
mitochondrial morphology in the mouse model was similar between the knockouts and the control. 
 
 
 
 
 
 
 
Figure 1.15: Sections through parkin wild-type (parkin +) and parkin knockout (parkin -) Drosophila 
muscle fibres.  A & B. Regular and compact myofibril arrangement (white arrow) with electron 
dense areas (red arrow) in parkin + cells. C & D. Irregular and dispersed myofibrillar arrangement 
(white arrows) with swollen mitochondria and disintegration of cristae in parkin – cells (red arrows). 
Taken from: Greene et al., 2003 
Parkin + Parkin - 
A C 
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Human studies 
In humans, loss-of-function mutations of parkin should result in no parkin protein being produced 
(Mortiboys et al., 2008; Pacelli et al., 2011). This is thought to lead to the accumulation of critical 
substrates, resulting in the initiatory events that induce changes in mitochondrial structure and 
function. Studies done on mitochondrial morphology in fibroblasts from patients with parkin 
mutations show an increase in mitochondrial mass (Grünewald et al., 2010) which is suggestive of 
swollen mitochondria. This is supported by analysis of ultrastructural changes in the mitochondria 
from fibroblasts of patients with parkin mutations where irregular shaped, swollen mitochondria 
with few remaining cristae were observed (Figure 1.16). It has been shown that impaired 
mitochondrial fusion is common in parkin-null mutants (Deng et al., 2008;  Poole et al., 2008) and 
this is indicated by a fragmented mitochondrial network (Figure 1.17; Pacelli et al., 2011), although 
this particular finding has not been observed in other studies (Grünewald et al., 2010; Mortiboys et 
al., 2008). Further morphological studies need to be conducted on parkin-null fibroblasts, as the 
current findings are contradictory. 
 
 
 
 
 
 
 
Figure 1.16: Electron microscopy analysis of fibroblasts obtained from PD patients with parkin 
mutations. Swollen mitochondria with disorganized membrane compartments and few remaining 
cristae (indicated by arrow heads in A and B), electron dense vacuoles (arrow in A), and enlarged 
rough endoplasmic reticulum (RER) cisternae (asterisk in A) were found. Taken from: Pacelli et al., 
2011  
A B 
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Figure 1.17: Mitochondrial network analysis of A. control and B & C. two parkin-mutant patients. 
The red dye indicates the mitochondrial network and the green dye shows the nucleus. Note the 
highly fragmented network in the patients compared to the control, indicating dysfunctional 
mitochondria. Taken from: Pacelli et al., 2011 
 
Further evidence of a dysfunctional mitochondrion is via analysis of the respiratory capacity in the 
electron transport chain complexes of the inner membrane of the mitochondria. The majority of 
studies performed on fibroblasts to detect complex I activity in patients with parkin mutations have 
found a significant decrease in activity in comparison to age-matched controls (Mortiboys et al., 
2008; Pacelli et al., 2011; Winkler-Stuck et al., 2004) . Muftuoglu and colleagues analysed complex I 
activity in leukocytes from parkin-null patients and also found a significant decrease (Müftüoglu et 
al., 2004). However, the activities of the other respiratory enzyme complexes remain unchanged in 
parkin mutant patients compared to controls (Grünewald et al., 2010). In some studies, complex IV 
activity has been found to be decreased in patients with parkin mutations, but this is not a 
consistent finding (Mortiboys et al., 2008; Müftüoglu et al., 2004; Pacelli et al., 2011), suggesting 
that further analysis needs to be done in order to determine which complexes are affected by 
parkin-null mutations and the mechanisms involved. Another indication of mitochondrial 
dysfunction in a cell is the amount of ROS present. An increased amount of cellular ROS levels is 
indicative of faulty oxidative phosphorylation, as more electrons are lost to oxygen than should be. 
Various studies on parkin-null patients have shown significantly increased concentrations of 
intracellular ROS (Grünewald et al., 2010; Pacelli et al., 2011), although to date no studies have 
analysed generic and mitochondrial ROS as separate entities. 
 
A B C 
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1.4.5.2. PINK1 
 
Animal studies 
Several animal knockout models of PINK1, specifically in Drosophila, have shown mitochondrial 
dysfunction, as well as muscle and dopamine-producing neuron degeneration. Studies on Drosophila 
are important, as the structure and localisation of PINK1 in flies is similar to that of humans (Park et 
al., 2006). Results from loss-of-function PINK1 mutant flies showed locomotion defects in flight 
ability and climbing speed. Furthermore, abnormal muscle structure was observed. When analysing 
mitochondrial morphology, mutant flies had swollen, enlarged mitochondria with a loss of the 
mitochondrial outer membrane and fragmented cristae (Figure 1.18). The number of dopaminergic 
neurons was also notably decreased. Functionally, energy depletion was noted due to a decrease in 
ATP levels of mutant flies. In all cases, phenotypes were rescued by PINK1 expression, suggesting 
that PINK1 is a critical factor in the normal functioning of the mitochondria (Clark et al., 2006; Park et 
al., 2006; Yang et al., 2006). In Drosophila models, mitochondrial dynamics such as the fusion and 
fission machinery play a large role in cell survival and overall plasticity of neurons. When PINK1 is 
over-expressed, fission appears to be promoted, however when under-expressed fusion appears to 
take over (Yang et al., 2006). 
 
 
 
 
 
 
 
 
Figure 1.18: Transverse and longitudinal sections of the flight muscle in two PINK1 knockout 
Drosophila models - RV and B9. Irregular arrangement of myofibrils (red arrow) and swollen 
mitochondria lacking an outer membrane (blue arrow) are observed. Taken from: Park et al., 2006 
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Human studies 
A study was performed on human HeLa cells transfected with small interfering RNA (siRNA) to cause 
PINK1 silencing and thus create a PINK1 knockout model (Exner et al., 2007). This down-regulation of 
PINK1 expression resulted in an increase in the number of cells with swollen, ruptured mitochondrial 
morphology with altered degraded cristae compared to the control cells. The same study also looked 
at mitochondrial network analysis and found that exposure to PINK1 siRNA caused more cells to 
have a fragmented mitochondrial network (Figure 1.19; Exner et al., 2007). Grunewald and 
colleagues also noted swollen mitochondria with enlarged cristae in fibroblasts of patients with 
missense PINK1 mutations, whereas no structural changes were observed in patients with nonsense 
mutations (Grünewald et al., 2009).  
 
 
Figure 1.19: Representative examples of normal or altered (truncated or fragmented) 
mitochondrial morphologies in HeLa cells following down-regulation of PINK1 using siRNA. Taken 
from: Exner et al., 2007 
 
As ROS generation is thought to underlie the degeneration of neurons with dopaminergic 
neurotransmission, it is vital to detect levels of ROS in patients, as well as levels of antioxidants, to 
determine the extent of the damage as well as the degree of activation of the defence mechanisms. 
Analysis of mitochondrial dysfunction in PINK1 null mutant patients shows accumulation of 
hydrogen peroxide (H₂O₂) in the mitochondria (Piccoli et al., 2008). H₂O₂ is a ROS formed by the 
addition of one electron to the outer orbital of the superoxide anion. This is thought to occur due to 
the decrease in the content of cytochrome c, which is a scavenger of ROS.   
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A second study on fibroblasts of mutant PINK1 patients showed an increase in the levels of 
malondialdehyde (MAD), which is a marker for oxidative stress and is formed by the degradation of 
polyunsaturated lipids by ROS (Hoepken et al., 2007). This indicates an increase in the levels of ROS. 
Levels of 8-oxo-2’deoxyguanosine (indicates DNA damage) and protein carbonyls (indicate protein 
damage) remained unchanged, suggesting that mutant PINK1 results in a peroxidation effect on 
lipids, but has no effect on DNA and proteins (Petit et al., 2005). The levels of the antioxidant 
manganese superoxide dismutase (MnSOD) were increased in the patients, implying that oxidative 
stress induces significant damage which results in the activation of the cellular defence mechanisms.  
 
Analysis of respiratory activity on mutant PINK1 fibroblasts has shown varied results in both 
complexes I and IV which is dependent on the type of mutation present in the patients – either 
nonsense or missense. In terms of complex I activity, results showed a significant decrease in activity 
in patients with a G309D missense mutation (Grünewald et al., 2009; Hoepken et al., 2007), but 
unchanged levels of activity in patients with a W437X nonsense mutation (Piccoli et al., 2008; 
Grünewald et al., 2009) Investigation of complex IV activity showed a decrease in the activity of 
patients with missense mutations, and no changes in the activity of patients with nonsense 
mutations (Grünewald et al., 2009).  
 
1.5. Gene and protein expression analysis 
 
Altered gene or protein levels may be an important contributory factor in the pathobiology of a 
disorder. In contrast to studying one gene at a time, analysis of all mRNA transcripts or proteins in a 
cell can potentially identify the global biological pathways that are causally, reactively or 
independently involved with the disorder. This data could be used to generate hypotheses about 
disease mechanisms and analyses of the transcriptomes and proteomes of PD patients could 
potentially also provide insights into the processes underlying other forms of neurodegeneration 
such as Alzheimer’s disease and Huntington’s disease. 
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Gene expression levels can be analysed from tissue from an individual using a technique known as 
quantitative real-time PCR (qRT-PCR). qRT- PCR is a gene expression tool used to quantitate the 
target gene, and involves the production of identical copies of parts of cDNA that are fluorescently 
measured after each cycle of PCR to produce a threshold cycle (Ct) number once a certain amount of 
product has been formed. It requires the analysis of the change in levels of PCR product over time in 
both patient and control samples. Quantification allows one to detect the signals on a response 
curve graph. As the amount of product increases, the signal of the fluorescence increases 
exponentially and this is known as the exponential growth phase. When the reaction has completed, 
a plateau is reached called the plateau phase (Figure 1.20). A response curve enables one to 
distinguish between a positive sample (e.g. cDNA) where visible exponential growth and plateau 
phases are present, and a negative sample (e.g. gDNA or dH₂O) where no product is amplified and 
thus no curve is produced. 
 
 
 
 
 
 
 
 
 
Figure 1.20: RT-PCR response curve of fluorescence vs. cycle number indicating the growth phase 
and the plateau phase, the threshold line and the point where the number of cycles to reach 
threshold is registered (Ct). Taken from: Kubista et al., 2006 
 
The Ct value is the number of amplification cycles required to obtain a particular amount of DNA, or 
in other words, to reach the threshold (Kubista et al., 2006). The threshold value is subject to 
change, and can be done so to allow the response curves to be parallel in the growth phase (Kubista 
et al., 2006). Therefore, although the individual Ct values are changed by an increase or decrease in 
 Ct   Ct 
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the threshold value, the overall differences in the product of each samples will remain the same. The 
more copies of cDNA there are in a sample, the fewer cycles of amplification are required to 
generate the number of amplicons that can be detected reliably, and thus the Ct number will be 
lower (Bustin et al., 2005).  
 
It is essential to normalize the expression level of a target gene to the expression level of a reference 
or housekeeping gene (HKG; Bower et al., 2007), such as glyceraldeyde-3-phosphate dehydrogenase 
(GAPDH) or β-actin. Normalisation accounts for differences in quality and quantity of the starting 
RNA and efficiencies of the reverse transcription reaction, as well as controls for errors between 
samples. Due to the lack of knowledge that there is one reference gene that is expressed in all tissue 
types (Dheda et al., 2004) it is vital that more than one HKG is used in expression studies. In order to 
ensure that normalization has occurred, expression levels of the HKGs should differ by no more than 
one Ct value between patient and control samples.  
 
Data obtained from qRT-PCR is commonly analysed by relative quantification, which describes the 
change in expression of the gene of interest relative to a reference group such as an untreated 
control (Livak & Schmittgen, 2001). Relative quantification enables one to determine the fold 
increase or decrease of expression levels of a particular gene. The method used to determine this 
fold change number is known as the Delta-Delta Ct method (or 2¯ΔΔCt).  This is calculated by the 
change in Ct values of the target gene for the control and the target gene for the patient, subtracted 
from the change in Ct values of the reference gene for the control and the reference gene for the 
patient. The value obtained is the relative up – or down-expression of the gene of interest in the 
patient compared to the control. 
 
1.5.1. Gene expression studies in PD 
 
When using microarrays in expression studies on PD patients, the genes involved in mitochondrial 
energy metabolism and cell quality control have shown expression changes in tissue from the SNc 
(Mandel et al., 2005; Moran et al., 2006). Simunovic and colleagues found down-regulation of a large 
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number of genes involved in mitochondrial function when analysing data from microarrays of SNc 
tissue from patients and controls (Simunovic et al., 2009).  
 
Sherzer and colleagues isolated RNA from the blood of 50 PD patients and 55 age-matched controls, 
and performed a real-time PCR on specific genes of interest (Scherzer et al., 2007). This study 
showed 22 differentially expressed genes in PD patients, including genes involved in the UPS (e.g. 
ST13), apoptosis-related genes (e.g. BCL11B) as well as mitochondrial genes (e.g. LRPPRC). Also, qRT-
PCR analysis performed on two parkin-mutant PD patients found significant down-regulation of the 
genes involved in mitochondrial biogenesis (NRF-1, NRF-2, TFAM) and fatty acid metabolism (MCAD) 
(Pacelli et al., 2011). 
 
As individual studies with small sample sizes often produce contrasting results, genome-wide 
expression meta-analysis studies are essential in creating a greater understanding of PD 
pathobiology. A meta-analysis was performed on the data sets of 17 independent genome-wide 
expression studies (Zheng et al., 2010). Nine studies had been conducted on laser-captured 
dopamine neuron and SNc post-mortem tissues, one on blood, one on a lymphoblastoid cell line and 
the remainder on various brain tissue. This analysis revealed significant defects in mitochondrial 
electron transport, as well as defects in glucose utilization and glucose sensing. Notably, this was 
found in the brain tissues as well as in the blood and lymphoblastoid cells. The majority of nuclear-
encoded electron transport chain genes showed under expression in PD patients (Figure 1.21). 
Zheng and colleagues also specifically analysed the expression of peroxisome proliferator-activated 
receptor-γ coactivator (PGC-1α) – responsive genes. PGC-1α is a transcriptional coactivator and a 
master regulator of mitochondrial biogenesis and oxidative metabolism. They found under-
expression of PGC-1α – responsive genes in patients with PD (Figure 1.21). Activation of PGC-1α 
resulted in up-regulation of nuclear subunits of all complexes in the mitochondrial respiratory chain. 
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Figure 1.21: qPCR analysis shows under-expression of specific electron transport chain (ETC) genes 
in SNc of patients with PD. Taken from: Zheng et al., 2010 
 
1.5.2. Proteome analysis in PD 
 
Proteome analysis involves the identification and measurements of levels of the entire protein 
complement of a cell or tissue in order to give insights into alterations associated with specific 
protein pathways. Due to the high level of complexity and vast number of proteins in a single cell, 
the detection and analysis of proteins has proven to be a complicated and intricate process. Several 
methods have been developed for detection of protein complexes, protein-protein interactions, and 
protein levels in the cells as well as identification of post-translationally modified proteins.   
 
Mass spectrometry (MS) is the most widely used technique to study proteomics, and involves the 
measurement of a mass-to-charge ratio of charged particles as they are eluted through a system. 
However, due to the surge in the reports of genomics, metabolomics and proteomics over the past 
decade, high performance instruments are vital in the understanding of these ‘omic’ studies. One 
such instrument known as the LTQ Orbitrap Velos spectrometer (ThermoFisher Scientific Inc., USA) 
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uses quantitative mass spectrometric analysis to capture and measure ion frequencies which can, 
through intricate physics calculations, determine the mass/charge ratios of each individual amino 
acid in the sample (Hu et al., 2005). 
 
A study performed on healthy human fibroblasts analysed the proteome of the mitochondria to 
detect the protein levels responsible for mitochondrial stress response and unbalanced metabolism 
(Palmfeldt et al., 2009). They cultivated the cells in both glucose and galactose – which is a medium 
that induces cellular stress. Using the Orbitrap, they found an increased level of respiratory chain 
proteins when cells were grown in the galactose medium. By using the Mascot database, they 
grouped all the proteins detected into different mitochondrial pathways, such as citric acid cycle, 
fatty acid oxidation, respiratory chain and apoptosis and mitochondrial morphology, and were able 
to determine the specific mechanisms occurring in the cells. This study is just one example of many 
that show the impact of the results of quantitative proteomics.  
 
To date, only a handful of studies on proteomic analysis on PD patients have been performed, 
typically using mass spectrometry techniques such as 2D electrophoresis and matrix assisted laser 
desorption/ionisation time of flight (MALDI-TOF). One study identified 44 proteins using these 
techniques, of which nine were differentially expressed in PD SNc tissue (Basso et al., 2004). A 
second study focusing on large scale protein detection used MALDI-TOF and detected 16 
differentially expressed proteins involved in ion and redox regulation as well as novel metabolic and 
structural functions (Werner et al., 2008). However, despite the success of these techniques, 
detection of hundreds of proteins is only possible when making use of a mass spectrometer such as 
the Orbitrap.  
 
In knockout parkin mice models, 2D electrophoresis was performed to separate the proteins and 
thereafter MALDI-TOF was used as a mass spectrometer procedure (Palacino et al., 2004). This 
revealed a decrease in the abundance of a number of proteins involved in mitochondrial function 
and oxidative stress. In a second study using parkin-expressing HeLa S3 cells, the proteome changes 
in response to parkin activity were analysed after a 2 hour treatment with carbonyl cyanide m-
chlorophenylhydrazone (CCCP), which aids in the recruitment of parkin to the mitochondria (Chan et 
al., 2011). A total of 2979 unique proteins were quantified, of which 766 were mapped in the 
MitoCarta inventory, which is a database of 1013 human genes encoding proteins specifically 
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localized to the mitochondria. K48-linked proteins were detected, which targets proteins for 
degradation via the UPS. The study also observed degradation of mitochondrial outer membrane 
proteins which is thought to precede mitophagy. This result suggests that the UPS and mitophagy 
are functionally linked, and stresses the importance of proteome studies in determining disease 
mechanisms for PD. 
 
1.6. The present study 
 
Increasing evidence has linked PD with mitochondrial dysfunction, but there is still much debate on 
the exact mechanisms leading to dopaminergic cell death, and whether mitochondrial dysfunction is 
a cause or an effect. It is therefore important to conduct further comprehensive and conclusive 
studies to investigate the pathophysiology of this disorder. Ultimately, this may lead to the 
development of improved treatment modalities and neuroprotective strategies for individuals with 
PD and their at-risk family members. 
 
In the present study we investigated South African PD patients with parkin-null mutations using a 
number of different approaches to determine whether these individuals exhibit evidence of 
mitochondrial dysfunction. There have been a limited number of studies on parkin-null patients and 
these have shown conflicting results. Previous studies also have limitations such as (1) not including 
heterozygous carriers to compare with the patients and wild-type controls (Müftüoglu et al., 2004; 
Mortiboys, et al., 2008; Grünewald et al., 2010); (2) not including analysis of muscle tissue from 
patients; and (3) not including analysis of the proteome. The present study was based on previous 
work but attempted to overcome these various shortcomings. 
 
1.6.1. Hypothesis 
 
It is hypothesized that mitochondrial dysfunction plays a major role in the development of PD in 
South African patients with null alleles of parkin.  We would expect to detect a down-regulation in 
mitochondrial gene expression and also differences in the proteome between patients and controls. 
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In addition, it is hypothesized that these patients would exhibit mitochondrial structural defects and 
functionally show an increased mitochondrial ROS production.  
 
1.6.2. Aims & Objectives 
 
The aim of the present study was to determine whether mitochondrial dysfunction plays a role in 
the development of PD in specific South African patients who harbour two null alleles in the parkin 
gene (and therefore produce no functional parkin).  
There are three South African families who harbour mutations in the parkin gene, and these were all 
recruited for this study. Also, family members who have a heterozygous parkin mutation (carriers) 
were included, and this will enable a comparison to be made between the carriers, the patients and 
the wild-type controls.  
 
The objectives of this study were as follows: 
1. To obtain peripheral blood samples, muscle biopsies and skin biopsies for culturing of 
fibroblasts from patients and carriers of three PD families with null mutations in parkin. 
2. To analyse mitochondrial morphology in fibroblasts and muscle tissue. 
3. To determine ROS levels in fibroblasts. 
4. To analyse mitochondrial gene expression levels in peripheral blood samples. 
5. To investigate expression of parkin protein in fibroblasts. 
6. To investigate the proteome in fibroblasts. 
*Initially, we had wanted to include patients with PINK1-null mutations for comparison with the 
parkin-null patients. However, we were unable to recruit the PINK1-null patients for this study. 
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2.1. Summary of methodology 
 
Four PD patients with parkin-null mutations from three families were recruited for this study. Three 
tissue types were obtained from the patients – a peripheral blood sample, a skin biopsy and a 
muscle biopsy (Figure 2.1). Family members (unaffected carriers) and wild-type controls were 
recruited and from these skin biopsies and blood samples were obtained. 
 
A muscle biopsy was performed on the probands for histological and transmission electron 
microscopy (TEM) mitochondrial morphology analysis. Muscle is the best tissue to observe 
mitochondrial morphological defects but the muscle biopsies were performed only on the three 
probands as part of their clinical work up. Due to the invasiveness of this procedure and the risks 
associated with it, muscle biopsies were not performed on the other study participants. 
A skin biopsy was performed and fibroblasts were cultured which were then used in both structural 
experiments via TEM and mitochondrial network analysis, and functional (ROS measurement) 
experiments. A western blot was performed to confirm the absence of parkin in patient fibroblasts 
and proteome analysis was conducted in order to assess the effect that the lack of parkin has on 
fibroblast protein content, thus elucidating alterations in specific protein pathways associated with 
mitochondrial function. 
A blood sample was obtained from each patient, and RNA was extracted for use in the two gene 
expression qRT-PCR studies – the PCR Array and the Primer Assay. Due to the high cost of the PCR 
Arrays only the three probands and a wild-type control were analysed using this technique. 
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Figure 2.1: Summary of Methodology 
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2.2. Ethical approval 
 
This study was approved by the Committee for Human Research at Stellenbosch University (Protocol 
number: 2002/C059). The approval is renewed annually. All study participants were recruited with 
informed written consent.  
 
2.3. Patient and control selection  
 
Over the past six years, patients suffering from PD have been recruited from the Movement Disorder 
clinic at Tygerberg Hospital, as well as the Parkinson’s Association of South Africa. The patients were 
examined by a movement disorder specialist, Professor Jonathan Carr, and met the UK Parkinson’s 
Disease Society Brain Bank Research criteria for diagnosis of PD (Gibb & Lees, 1988).  Four patients 
that each have two null parkin mutations were selected for the study (designated P1, P2, P3.1 and 
P3.2, Table 2.1). Inclusion criteria were individuals with two parkin mutations, with familial PD and 
who had provided consent for a blood sample as well as muscle and skin biopsies. The mutations 
had been identified in previous studies using multiplex ligation-dependent probe amplification 
(MLPA) and DNA sequencing (Bardien et al., 2009; Keyser et al., 2010). Patient P1 has a 40bp 
deletion in exon 3 of one allele of parkin, and a whole exon 3 deletion on the other allele and patient 
P2 is homozygous for exon 3 and exon 4 deletions. Patients P3.1 and P3.2 are siblings, and are both 
homozygous for an exon 4 deletion. In effect, all these patients resemble ‘knock out’ models of 
parkin. For each patient recruited, a heterozygous carrier from the patient’s family was also included 
(Table 2.1). Incorporated in the analysis, were two wild-type controls, WTC1 and WTC2. The control 
for the muscle biopsy was supplied by National Health Laboratory Service (NHLS) Histopathology 
Laboratory at Red Cross Children’s Hospital.   
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Table 2.1: List of patients, family members and controls included in the study.  
 
*AAO, age at onset; het, heterozygous; homo, homozygous; del, deletion 
 
2.4. RNA extraction 
 
After obtaining patient consent, 20ml blood was drawn into two PAXgene Blood RNA tubes 
(PreAnalytix, Qiagen, Germany). The PAXgene Blood RNA Kit (PreAnalytix, Qiagen, Germany) was 
used for isolation and purification of intracellular RNA from whole blood. The first step of 
centrifugation (Centrifuge 5810 R, eppendorf, Germany) was performed to pellet nucleic acids. 
Family 
Patient/
control 
Status 
Age and 
Gender 
AAO 
Length of 
disease  
Parkin mutations 
1 
P1 PD patient – proband 
38 years 
Male 
25 years 13 years 
 Het 40bp exon 3  del 
 Het exon 3  del 
P1het 
Heterozygous mutation 
carrier - unaffected 
71 years 
Female 
- -  Het exon 3 del 
2 
P2 PD patient - proband 
37 years 
Female 
27 years 10 years 
 Homo exon 3 and ex 4 
del 
P2het 
Heterozygous mutation 
carrier - unaffected 
65 years 
Female 
- -  Het exon 3 and ex 4 del 
3 
P3.1 PD patient - proband 
50 years 
Female 
27 years 23 years  Homo exon 4 del 
P3.2 PD patient 
52 years 
Female 
27 years 25 years  Homo exon 4 del 
P3het 
Heterozygous mutation 
carrier - unaffected 
54 years 
Female 
- -  Het exon 4 del 
 
WT C1 Wild-type control 
39 years 
Male 
- - - 
 
WT C2 Wild-type control 
36 years 
Male 
- - - 
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Thereafter, the pellet was washed and resuspended, followed by manual RNA purification according 
to the manufacturer’s instructions. 
 
2.4.1. RNA Quality determination 
2.4.1.1. NanoDrop® N1000-UV-Vis Spectrophotometer (NanoDrop 
Technologies Inc., USA) 
 
The RNA quality was determined using the NanoDrop® N1000-UV-Vis Spectrophotometer 
(NanoDrop Technologies Inc., USA) and verified by the Experion StdSens Analysis Kit (BioRad, USA). 
The NanoDrop is made up of a spectrophotometer and linked to computer-based software. To blank 
the machine, 1.5µl of sterile water (EuroMed Inc., Denmark) was pipetted onto the sensor and read 
by the software. Thereafter, the sensor was wiped clean and 1.5µl of the RNA sample was pipetted 
onto it. The software then reads the concentration of the RNA. As efficient as the NanoDrop may be, 
it is not accurate enough for RNA studies. Thus, the Experion StdSens Analysis Kit was used to verify 
the results of the NanoDrop. 
 
2.4.1.2. Experion StdSens Analysis Kit (BioRad, USA) 
 
This kit involves the use of a 16-well chip and equipment whereby a virtual gel is run using the 
Experion machine. The reagents used were an RNA gel, RNA StdSens stain, RNA StdSens loading 
buffer and RNA ladder. All the equipment was calibrated and run according to the manufacturer’s 
specifications. The Experion automatically measures the total RNA concentration, ratio of 28S/18S 
rRNA and the RQI (RNA Quality Indicator) value. The ratio 28S/18S is the ratio of two rRNA species 
that are derived from the same precursor molecule. Figure 2.2 indicates an example of the 
difference between a good quality RNA sample and a bad quality sample, based on the individual 
28S/18S ratio. This ratio serves as an indication of RNA integrity. The RQI values are the equivalent 
to RIN (RNA Integrity Number) values, whereby a result out of ten is given that rates the quality of 
the RNA. The higher the result, the better the quality of the RNA. RNA with a value of 8 and above 
was used for all RNA-based experiments.  
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Figure 2.2: Total RNA separation using Experion StdSens Analysis. A. Example of a high quality RNA 
sample with a high 28S/18S ratio. B. Example of a low quality RNA sample with a lower 28S/18S 
ratio. 
 
2.4.2. cDNA synthesis 
 
RNA conversion into cDNA was carried out using the Quantitect Reverse Transcription Kit (Qiagen, 
Germany) in a two-step process. This kit provides a convenient procedure for effective reverse 
transcription as well as effective genomic DNA (gDNA) elimination. The first reaction involves the 
removal of gDNA by the gDNA wipeout buffer, and the second step is a reverse transcription 
reaction prepared by the addition of reverse transcriptase (Qiagen, Germany), RT buffer (Qiagen, 
Germany) and RT primer mix (Qiagen, Germany). The result is high yields of cDNA template for use 
in subsequent real-time PCR reactions. 
 
 
A 
B 
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2.5. Polymerase Chain Reaction (PCR) 
 
2.5.1.  Using cDNA as a template 
 
All PCR primers (Table 2.2, Figure 2.3) were designed using Primer 3 software (Rozen & Skaletsky, 
2000) and the sequences available from the GenBank database 
(http://www.ncbi.nlm.nih.gov/Entrez). The accession number used for PARK2 was NT_007422. 
Integrated DNA Technologies (IDT, USA) synthesized all primers. Calculation of the melting 
temperature was conducted using the following formula: 
Tm = 4(G + C) + 2(A + T) 
 
Table 2.2: PCR primers used for amplification of the PARK2 cDNA between exons 2 and 5  
*Tm, melting temperature; Ta, annealing temperature 
 
GCAGCCGCCACCTACCCAGTGACCATGATAGTGTTTGTCAGGTTCAACTCCAGCCATGGTTTCCCAGT
GGAGGTCGATTCTGACACCAGCATCTTCCAGCTCAAGGAGGTGGTTGCTAAGCGACAGGGGGTTCCGG
CTGACCAGTTGCGTGTGATTTT 
 
        PARK2 2i FORWARD primer 
       
CGCAGGGAAGGAGCTGAGGAATGACTGGACTGTGCAGAATTGTGACCTGGATCAGCAGAGCATTGTTC
ACATTGTGCAGAGACCGTGGAGAAAAGGTCAAGAAATGAATGCAACTGGAGGCGACGACCCCAGAAAC
GCGGCGGGAGGCTGTGAGCGGGAGCCCCAGAGCTTGACTCGGGTGGACCTCAGCAGCTCAGTCCTCCC
AGGAGACTCTGTGGGGCTGGCTGTCATTCTGCACACTGACAGCAGGAAGGACTCACCACCAGCTGGAA
GTCCAGCAGGTAGATCAATCTACAACAGCTTTTATGTGTATTGCAAAGGCCCCTGTCAAAGAGTGCAG
CCGGGAAAACTCAGGGTACAGTGCAGCACCTGCAGGCAGGCAACGCTCACCTTGA 
 
     PARK2 5i REVERSE primer 
 
CCCAGGGTCCATCTTGCTGGGATGATGTTTTAATTCCAAACCGGATGAGTGGTGAATGCCAATCCCCA
CACTGCCCTGGGACTAGTGCAGAATTTTTCTTTAAATGTGGAGCACACCCCACCTCTGACAAGGAAAC
ATCAGTAGCTTTGCACCTGATCGCAACAAATAGTCGGAACATCACTTGCATTACGTGCACAGACGTCA
PCR primer 
orientation 
Primer name Primer Sequence %GC 
Primer Tm 
(°C) 
Ta (°C) 
Product 
size 
Forward PARK2 2i 5'-GGA GCT GAG GAA TGA CTG GA-3' 55% 56.4 
60 555bp 
Reverse PARK2 5i 5'-ATC ATC CCA GCA AGA TGG AC-3'   50% 54.7 
Exon 2 
Exon 3 
Exon 4 
Exon 5 
Exon 6 
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GGAGCCCCGTCCTGGTTTTCCAGTGCAACTCCCGCCACGTGATTTGCTTAGACTGTTTCCACTTATAC
TGTGTGACAAGACTCAATGATCGGCAGTTTGTTCACGACCCTCAACTTGGCTACTCCCTGCCTTGTGT
GGCTGGCTGTCCCAACTCCTTGATTAAAGAGCTCCATCACTTCAGGATTCTGGGAGAAGAGCAGTACA
ACCGGTACCAGCAGTATGGTGCAGAGGAGTGTGTCCTGCAGATGGGGGGCGTGTTATGCCCCCGCCCT
GGCTGTGGAGCGGGGCTGCTGCCGGAGCCTGACCAGAGGAAAGTCACCTGCGAAGGGGGCAATGGCCT
GGGCTGTGGGTTTGCCTTCTGCCGGGAATGTAAAGAAGCGTACCATGAAGGGGAGTGCAGTGCCGTAT
TTGAAGCCTCAGGAACAACTACTCAGGCCTACAGAGTCGATGAAAGAGCCGCCGAGCAGGCTCGTTGG
GAAGCAGCCTCCAAAGAAACCATCAAGAAAACCACCAAGCCCTGTCCCCGCTGCCATGTACCAGTGGA
AAAAAATGGAGGCTGCATGCACATGAAGTGTCCGCAGCCCCAGTGCAGGCTCGAGTGGTGCTGGAACT
GTGGCTGCGAGTGGAACCGCGTCTGCATGGGGGACCACTGGTTCGACGTGTAGCCAGGGCGGCCGGGC
GCCCCATCGCCACATCCTGGGGGAGCATACCCAGTGTCTACCTTCATTTTCTAATTCTCTTTTCAAAC
ACACACACACACGCGCGCGCGCGCACACACACTCTTCAAGTTTT  
 
 
Figure 2.3: Representation of the 555kb fragment of parkin generated by PCR-amplification. The 
blue and black font separates each exon in the 12 exon PARK2 gene 
 
 
 
The cDNA synthesised from patient RNA was used as a template for PCR amplifications. PCR 
reactions were all performed on the GeneAmp® PCR system 2720 Thermal Cycler (Applied 
Biosystems, USA). The PCR reagents added included 20pmol of the forward and the reverse primers 
(Table 2.2), 75µM dinucleotide triphosphates (dATP, dGTP, dCTP, dTTP; Bioline Ltd., UK), 0.5 Units 
BIOTAQ™ DNA Polymerase (Bioline Ltd., UK), 1 X NH4 Buffer (Bioline Ltd., UK), 1.5mM MgCl2 (Bioline 
Ltd., UK) and ddH₂O (Euro Med, Denmark) to a final volume of 25µl. 
 
PCR cycling conditions comprised of an initial denaturation step of 94°C for 5 min, followed by 30 
cycles of denaturation at 94°C for 30s, annealing at 60°C for 1 min, extension at 72°C for 2 min 30 s 
and a final extension step of 72°C for 10 min. The PCR products were then run on a 2% Agarose 
(SeaKem®, USA) or PAGE gels (Section 2.6). After amplification, all PCR products were stored at -4°C 
until further use. 
 
2.5.2. Using genomic DNA (gDNA) as a template 
 
Total gDNA was isolated from blood samples by Mrs. Ina le Roux using an in-house method 
(Appendix III). The gDNA of two samples used as wild-type controls in this study (WTC1 and WTC2) 
underwent PCR amplification to screen for pathogenic mutations in each of the 12 exons of PARK2. 
PCR primers had been designed previously and Table 2.3 shows the PCR conditions and primer 
Exon 8 
Exon 10 
Exon 11 
Exon 7 
Exon 9 
Exon 12 
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sequence for each exon. PCR reactions and cycling conditions were as described in section 2.5.1. The 
PCR amplicons were electrophoresed on agarose gels (to determine whether they were the correct 
size) and then sequenced. 
 
Table 2.3: Primers designed to amplify the exonic regions of the PARK2 gene 
Region Primer Sequence (number of bps) Tm %GC PCR Ta bp 
PCR 
conditions 
Exon 1 
For: gaa cta cga ctc cca gca g (19) 60°C 58 
55 300 
5% 
Formamide Rev: ccc gtc att gac agt tgg (18) 56°C 56 
Exon 2 
For: cac cat tta agg gct tcg ag (20) 60°C 50 
55 313 
5% 
Formamide Rev: tca ggc atg aat gtc aga ttg (21) 60°C 43 
Exon 3 
For: tct cgc att tca tgt ttg aca (21) 58°C 39 
55 364 
No 
additives Rev: gca gac tgc act aaa caa aca (21) 62°C 43 
Exon 4 
For: gct ttt aaa gag ttt ctt gtc (21) 56°C 33 
55 299 
No 
additives Rev: ttt ctt ttc aaa gac ggg tga (21) 58°C 38 
Exon 5 
For: gga aac atg tct taa gga gt (20) 56°C 40 
55 223 
No 
additives Rev: ttc ctg gca aac agt gaa ga (20) 58°C 45 
Exon 6 
For: cca aag aga ttg ttt act gtg (21) 58°C 38 
55 276 
No 
additives Rev: ggg gga gtg atg cta ttt tt (20) 58°C 45 
Exon 7 
For: cct cca gga tta cag aaa ttg (21) 60°C 43 
55 280 
No 
additives Rev: gtt ctt ctg ttc ttc att agc (21) 58°C 38 
Exon 8 
For: ggc aac act ggc agt tga ta (20) 60°C 50 
55 232 
No 
additives Rev: ggg gag ccc aaa ctg tct (18) 58°C 61 
Exon 9 
For: tcc cat gca ctg tag ctc ct (20) 62°C 55 
55 297 
No 
additives Rev: cca gcc cat gtg caa aag c (19) 60°C 58 
Exon 10 
For: caa gcc aga gga atg aat at (20) 56°C 40 
53 272 
No 
additives Rev: gga act ctc cat gac ctc ca (20) 62°C 55 
Exon 11 
For: ccg acg tac agg gaa cat aaa (21) 62°C 48 
55 300 
No 
additives Rev: ggc acc ttc aca cag ct (20) 62°C 55 
Exon 12 
For: tct agg cta gcg tgc tgg tt (20) 62°C 55 
55 296 
No 
additives Rev: gcg tgt gtg tgt gtg ttt ga (20) 60°C 50 
*bp, base pair; Tm, melting temperature 
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2.6. Gel electrophoresis 
 
2.6.1. Agarose gel electrophoresis 
 
PCR products were run on a 2% agarose (SeaKem®, USA) gel. For a 100ml gel plate, 2grams of 
agarose was weighed out and dissolved in 100ml sodium borate (SB) buffer (Appendix II) in an 
Erlenmeyer flask. This was placed in the microwave and heated for approximately 2 min until the 
agarose was completely dissolved. It was then cooled down and 7µl of 1µg/µl ethidium bromide 
(EtBr) was added to the gel solution, which enables visualisation of the DNA fragments under a UV 
light. The gel solution was then poured into a gel tray and a well-forming comb was firmly placed in 
the gel. 
 
Once the gel was set (15 min), the comb was removed and the samples were loaded. Approximately 
2µl of Bromophenol Blue (Appendix II) loading dye was mixed with 8µl of the PCR product, and this 
was loaded into the first well of the gel. Each product was then loaded into separate wells of the gel, 
and 1.5µl of the 100bp or 200bp DNA ladder (Promega, USA) was loaded as a size marker to 
determine the size of the PCR fragments. The gel plate was attached to two electrodes, covered with 
SB buffer and electrophoresis was run at 240 volts for approximately 20 min. The gel was analysed 
under a UV light in the gel documentation (gel doc) system using the G: Box (Syngene, UK). The gel 
was placed under the Transilluminator and a live image was captured by the software (GeneSnap 
Image Acquisition Software).  
 
2.6.2. Polyacrylamide gel electrophoresis (PAGE) 
 
PAGE gels were used in order to detect PCR fragments that could not be resolved on an agarose gel, 
specifically fragments that had a small size difference (<50bp) between them.  
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Two 100mm x 80mm plates and two 80mm x 10mm x 1mm spacers were cleaned with 70% ethanol 
sprayed onto the surface and wiped with a paper towel. The spacers were placed on either side of 
the two plates in order to make room for the comb once the gel had been poured. The two plates 
were then sealed together at the bottom and the sides with gel-sealing tape (Sigma, Germany) and 
then clamped tight on both sides and the bottom. This is done to ensure that none of the gel 
solution will leak out whilst setting.  
 
A 12% gel solution was then prepared with the following reagents: 6ml 40% acrylamide (Promega, 
USA), 120µl 10% APS (Ammonium-Perox-Disulphate), 45µl TEMED (Tertramethylethylenediamine; 
(Sigma, Germany), 1.5ml 10x TBE buffer (Appendix II) and 7.5µl ddH₂O. Immediately after the 
solution was made, it was poured between the two plates and the well-forming comb was placed in 
the gel between the two plates. This was then left to set for approximately 45 minutes.   
 
Once the gel had set, the tape was removed from each side of the gel, and the comb was extracted 
using a spatula to avoid disrupting the wells. The plates were then added to an electrophoresis 
apparatus ensuring the plates were tightly clipped on using clamps. A dilution of 1 X TBE buffer 
(Appendix II) was then poured into the buffer chambers of the apparatus. Thereafter, 1.5µl of the 
20bp, 100bp, 200bp or 500bp DNA ladder (Promega, USA) was loaded into the first well of the gel, 
depending on the size of the PCR fragment. A second size marker, Pst1-digested lambda DNA 
(Promega, USA), was loaded as a secondary DNA ladder so that a more accurate reading of the size 
fragments could be made. A minimum of 6µl of the PCR products was then mixed with 3µl 
Bromophenol Blue and loaded into the remaining wells. The cables were then connected to the 
voltage power and the gel underwent electrophoresis for approximately 1 hour to at 150V at room 
temperature. 
 
Once the gel had run, it was removed from the plates and placed in a clean plastic trasdy. A solution 
of 50ml SB buffer and 5µl EtBr was made up and poured over the gel. This was placed on the orbital 
shaker SSL1 (Stuart®, UK) for 20 minutes. The solution was removed and ddH₂O was poured over the 
gel and left to shake for an additional 5 minutes. The gel was then visualised using the 6: Box gel doc 
system.   
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2.7. DNA Sequencing  
 
2.7.1. Purification of PCR products 
 
Sequencing was performed to verify the DNA sequence of the PCR fragments. A volume of 8µl of 
each PCR product was pipetted into a 0.2ml microcentrifuge PCR tube (Sigma-Aldrich, USA), and this 
was purified with 5U of both Exonuclease I (USN Corporation, USA) and SAP (Shrimp Alkaline 
Phosphatase; Promega, USA). The samples were mixed and spun in the Hermle Z100M 
microcentrifuge (Labnet, USA) and then incubated at 37°C for 15 minutes followed by 80°C for 10 
minutes to deactivate the enzymes. The concentration of each sample (ng/µl) was then read by the 
NanoDrop® ND1000-UV-Vis spectrophotometer (NanoDrop Technologies Inc., USA; Section 2.4.1). 
Each product was diluted down to 30ng/µl for the sequencing reaction.  
 
2.7.2. Automated sequencing analysis 
 
The primers used for sequencing were the same primers used during the PCR amplification and 
these were diluted to 1.1µM. All automated sequencing reactions of the PCR products were 
performed at the Central Analytical Facility of the Department of Genetics, Stellenbosch University 
using the BigDye terminator V3.1 Ready reaction kit on the ABI 3130xl ® Genetic analyser (Applied 
Biosystems, USA). Analysis of sequencing data was performed using the BioEdit Sequence Alignment 
Editor version 7.0.5 software (Hall, 1999). 
 
2.8. Culturing of skin fibroblasts 
 
Skin biopsies were performed by Dr. Willie Visser (Department of Dermatology, Tygerberg Hospital) 
and these were taken from the inside of the upper arm. The 2mm x 2mm skin piece was suspended 
in a solution of DMEM with 10% fetal calf serum and 1% penicillin streptomycin and immediately 
transported to the Unistel Medical Laboratories (Pty) Ltd. at Tygerberg, Stellenbosch University for 
the culturing of skin fibroblasts (Appendix III).  
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2.8.1. Culture conditions 
 
The fibroblasts cultured at Unistel Medical Laboratories used collagenase treatment in Chang D. and 
Amniochrome II media (1:1 ratio) at 37°C (Appendix III). Once the cells had reached confluency, they 
were used in various experiments for mitochondrial morphology analysis (TEM and mitochondrial 
network analysis), ROS measurement, Western blots and proteome analysis on the LTQ Orbitrap 
Velos spectrometer. Aliquots of fibroblast cells were frozen down in liquid nitrogen by Mrs. Ina le 
Roux (Appendix III) for use when needed. 
 
2.9. Mitochondrial morphology analysis from both muscle and skin 
biopsies 
 
2.9.1. Analysis of mitochondrial morphology on muscle cells 
 
A muscle biopsy was performed on patients P1, P2 and P3.1 by Dr. Franclo Henning at the Division of 
Neurology, Tygerberg Hospital. The biopsies were analysed by Dr. Komala Pillay at the NHLS 
Histopathology Laboratory at Red Cross Children’s Hospital using histopathological and TEM analysis. 
This is a diagnostic service; therefore all patient samples were compared to the standard muscle 
pathology. Data was obtained in the form of reports and this was analysed and summarised.  
 
2.9.2. Analysis of mitochondrial morphology on fibroblasts 
 
After skin fibroblasts were cultured, the morphology of the fibroblasts was analysed using TEM by 
Dr. Nolan Muller from the NHLS, Electron Microscopy laboratory in the Division of Anatomical 
Pathology at Tygerberg Hospital. Images were loaded onto a CD-ROM and studied for morphological 
changes. 
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In addition, mitochondrial network analysis was performed by Dr. Ben Loos (Department of 
Physiological Sciences, Stellenbosch University) using fluorescence microscopy. Fibroblasts were 
stained using Mitotracker Red (Invitrogen, Life Technologies, USA) for the mitochondrial network 
and Hoeschst 3343 (Thermo Scientific, Pierce Biotechnology, USA) for the nucleus. They were plated 
on chambered coverglass (Nunc™, Denmark) and observed on an Olympus Cell^R system attached to 
an IX-81 inverted fluorescence microscope equipped with an F-view-II cooled CCD camera (Soft 
Imaging Systems). Using a Xenon-Arc burner (Olympus Biosystems GMBH, Germany) as light source, 
images were excited with the 360nm, 492nm or 572nm excitation filters. Emission was collected 
using a UBG triple-bandpass emission filter cube. For the image frame acquisition, an Olympus Plan 
Apo N 60x/1.4 oil objective and the Cell^R imaging software was used. Images were processed and 
background-subtracted using the Cell^R software. 
 
2.10. Reactive oxygen species measurements using flow cytometry 
 
In collaboration with Dr. Ben Loos (Department of Physiological Sciences, Stellenbosch University) 
ROS analysis was performed on the cultured fibroblasts.  
 
All flow cytometric analyses were performed on a FACSAria flow cytometer (Becton Dickinson 
Biosciences, USA) equipped with a 488nm Coherent Sapphire solid state laser (13-20mW), 633nm 
JDS Uniphase HeNe air-cooled laser (10-20mW) and 407nm Point Source Violet solid state laser (10-
25mW). Generic and mitochondrial ROS was assessed by using DCF and mitoSOX Red mitochondrial 
superoxide indicator respectively, according to manufacturer’s protocol. In brief, relative ROS 
generation was evaluated with the aid of 6-carboxy-2’7’-dichlorodihydrofluoresce in diacetate, 
diacetoxymethyl ester (DCF, Molecular Probes, D399) and MitoSOX (M36008). Unfixed cells were 
incubated with 50μmol/l DCF in PBS for 20 min at 37°C, and then washed in PBS and immediately 
analysed at room temperature. Similarly, cells were incubated for 10 min at 37°C with 5 µM MitoSox 
reagent, and gently washed with warm buffer. A concentration of 100μmol/l H₂O₂ was used as a 
positive control. Samples were analysed on the flow cytometer (BD FACSAria I, BD Biosciences, USA) 
and a minimum of 50 000 events were collected. Fluorescence intensity signal was measured using 
the geometric mean on the intensity histogram. 
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2.11. Quantitative PCR using PCR Arrays and Primer Assays 
 
2.11.1. RT² Profiler PCR Array (SABiosciences, USA) 
 
The RT² Profiler PCR Array (SABiosciences, USA) was used to determine whether the expression 
levels of the genes involved in mitochondrial respiration are significantly different between PD 
patients and wild-type controls. A catalogued, 96-well plate for Mitochondrial Energy Metabolism 
(PHS-008) was chosen (Figure 2.4). In 84 wells of this plate (A1 – G12) are preloaded validated real- 
time PCR primers, each coding for a different gene in the mitochondrial energy metabolism 
pathway. Genes in this array include ATP synthases, cytochrome c oxidases and NADH 
dehydrogenases (Appendix IV). Five HKGs are also included on the PCR array as controls, namely 
GAPDH, actin-β, B2M, HPRT1 and RPL13A in wells H1 – H5. The plate also includes controls for gDNA 
contamination (H6), RNA quality/Reverse Transcription Control (RTC, H7 - H9) and general PCR 
performance/Positive PCR Control (PPC, H10 – H12).  
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Standard PCR Array layout for a 96-well plate 
 
A 
B 
C 
D 
E 
F 
G 
H 
1     2      3     4      5     6      7     8      9    10   11    12 
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Using the RT² First Strand Kit (SABiosciences, USA), 5µg patient and control RNA was separately 
converted to cDNA according to the manufacturer’s user guidelines. A total of 102µl of the cDNA 
reaction was added to 1350µl RT² qPCR Master Mix (SABiosciences, USA) and RNase-free H₂O to a 
final volume of 2700µl. The master mix formulation enables the PCR Array to amplify 96 different 
gene-specific products simultaneously under uniform cycling conditions. This combination provides 
the PCR Array with the specificity and the high amplification efficiencies required for accurate real-
time SYBR Green results.  
 
Once the cocktail was made, 25µl was then added to each well of the 96-well plate by the EpiMotion 
(eppendorf, Germany). This was performed on patient and control samples. After centrifugation of 
each plate for 1 min at 1000xg on the Centrifuge 5810R (eppendorf, Germany), the ‘patient’ plate 
was placed in the ABI 7900HT (Applied Biosystems, USA), a fast real time PCR system, situated at the 
Central Analytical Facility’s satellite laboratory at Tygerberg. The ‘control’ plate remained in the 
freezer for the duration of the first plates run. The system was run for 1 cycle at 95°C for 10 min, and 
40 cycles at 95°C for 15s and 60°C for 1 min, and a dissociation melting curve was included at 1 cycle 
at 95°C for 15s, 60°C for 15s and 90°C for 15s. The ‘patient’ plate was then removed, covered in 
aluminium foil and stored at -20°C. The real time PCR conditions were repeated for the ‘control’ 
plate. After both plates were run, the threshold value was manually set so that the Ct values in the 
PPC wells were 20 ± 2, as per manufacturer’s instructions. Automatic ΔΔCt based fold-change 
calculations were then performed using the raw threshold cycle data via the software provided 
(http://sabiosciences.com/pcrarraydataanalysis.php). 
 
2.11.2.  RT² Primer Assay (SABiosciences, USA) 
 
The RT² Primer Assay (SABiosciences, USA) was utilized as a confirmation for the results obtained 
from the RT² Profiler PCR Array (SABiosciences, USA).  
 
The first step in the RT² Primer Assay gene expression protocol is the elimination of gDNA and 
subsequent reverse transcription of RNA to produce cDNA. This was performed by the RT² First 
Strand Kit (SABiosciences, USA). The cDNA was then added to the RT² qPCR mastermix, the RT² qPCR 
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Primer assay and RNase-free H₂O. The gene of interest selected was CYC1, and the two house-
keeping genes chosen were HPRT1 and RPL13A. A standard curve was conducted for each gene so as 
to determine the efficiency value (should be approximately 1) which was calculated by REST-2009© 
gene quantification software (http://www.gene-quantification.de/rest.html). All reactions were 
performed in triplicate and gDNA was included as a negative control. The final volume was pipetted 
into each well in a 96-well plate (Lasec, SA). The run was performed on an ABI 7900HT (Applied 
Biosystems, USA)  for 1 cycle at 95°C for 10 minutes, and 40 cycles at 95°C for 15 seconds and 60°C 
for 1 minute. A dissociation melting curve was added for 1 cycle at 95°C for 15s, 60°C for 15s and 
90°C for 15s. Data was analysed using REST (relative expression software tool) gene-quantification 
software. 
 
2.12. Protein analysis 
 
2.12.1. Cell lysis procedure 
 
Prior to cell lysis, a cell lysis buffer was made (Appendix II).This was stored on ice until future use. 
Once the fibroblast cells in the culture flasks were trypsinized and concentrated in a 50ml tube, the 
supernatant was removed and the pellet was suspended in 200µl PBS (Appendix II). This solution 
was added to 2ml tubes and centrifuged at 7000rpm for 30s in the PRISM microcentrifuge (Labnet, 
USA). The supernatant was removed and an additional 500µl PBS was added to the pellet. This 
solution was then mixed in order to disrupt the pellet and re-centrifuged under the above 
conditions. Thereafter, 200µl of cell lysis buffer was added to the newly formed pellet, and this was 
kept on ice for 30min. The tubes were then centrifuged (UEC13, United Scientific, USA) for a further 
10 minutes at 120rpm at -20°C. The supernatant was removed and stored in 2ml tubes at -20°C for 
future use. 
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2.12.2. Bradford protein concentration determination 
 
In order to calculate a standard curve of protein concentrations, 10µl of a dilution range of bovine 
serum albumin (BSA) standards ranging from 0 - 1000µg/µl was loaded into the wells of a 
luminometer plate (Nunc™, Denmark) in duplicate. A volume of 1µl of cell lysate samples were also 
added to the plate in duplicate. Thereafter, 200µl of Bradford reagent (Appendix II) was added to 
each standard and lysate sample. The protein concentration of each well was determined by a 
Synergy HT luminometer (BioTek Instruments Inc., USA). Using the KC4™ v 3.4 software (BioTek 
Instruments Inc., USA), a standard curve was set up and each sample’s protein concentration was 
calculated. 
 
2.12.3. Western Blot 
 
The Western Blot technique is a procedure for the identification and measurement of the amount of 
a specific protein in a cell. Proteins isolated from fibroblasts are separated by gel electrophoresis 
(SDS-PAGE) and then transferred to a nitrocellulose membrane which in turn is subject to 
immunodetection. A primary and secondary antibody is then added for detection and labelling of a 
specific protein, which in this case was parkin. All equipment and apparatus used in the Western blot 
procedure were supplied by BioRad, USA. 
 
2.12.3.1. Gel casting 
Two 100mm x 74mm glass plates were sprayed with 70% ethanol and wiped down using a paper 
towel. Once the plates were clipped together, an Agarose (SeaKem®, USA) solution was heated up in 
the microwave and pipetted onto the bottom of the plates using a Pasteur pipette. This is done to 
avoid leakage out of the plates when the gel solution is left to set. A 12% resolving gel solution 
(Appendix II) was first prepared and poured between the two plates, leaving about a 20mm space 
from the top of the plates. One layer of Isopropanol was then added to the top of the resolving gel 
solution. This was left to set for 20 minutes.  
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Once the resolving gel had set, the stacking gel solution (Appendix II) was made up. Prior to addition 
of the stacking gel, the isopropanol was poured out and absorbed by filter paper. The stacking gel 
was then added to the top of the plates, and a well-forming comb was slid in between the plates. 
This was left for 20 minutes to set. 
 
2.12.3.2. Running gel 
Once the gel was set, the plates were placed in a holding apparatus, with the shorter plate facing 
inwards. When only one gel was being run, a second makeshift plate known as the Buffer Dam was 
added for balance. The holding apparatus was then placed in a container. A 1x SDS Running Buffer 
was made up from 10x SDS Running Buffer (Appendix II), and this was poured into the container first 
between the two plates and then filled up to the level labelled ‘2 gels’. The comb was then removed 
from the gel. 
 
Samples were denatured for 5 minutes at 95°C in the GeneE Thermal Cycler (Techne Inc., USA). After 
spinning down the samples in the Hermle Z100M microcentrifuge (Labnet, USA), the calculated 
amount of sample was mixed with 5µl SDS loading dye (Appendix II) and loaded into each well of the 
gel. A volume of 10µl of the Spectra Broad Range protein ladder (Fermentas, Lithuania) was loaded 
into a separate well. A lid was placed on the container with electrodes that attached to the voltage 
power source and the gel was run for approximately one hour at 100V. 
 
2.12.3.3. Transferring gel 
Transfer Buffer was freshly prepared (Appendix II). Six 85mm x 5mm pieces of filter paper were cut, 
as well as one 8.5mm x 5mm polyvinylidene fluoride (PVDF) nitrocellulose transfer membrane 
(Amersham Biosciences, USA). The membrane was soaked in pure methanol (Merck, Germany) for 
15 seconds and then transferred to a container with ddH₂O and placed on the orbital shaker SSL1 
(Stuart®, UK) for 5 minutes. It was then removed from the ddH₂O and placed in a container with 
Transfer Buffer and placed on the shaker for 20 minutes. The 6 pieces of filter paper and 2 sponges 
were left to soak in a container with Transfer Buffer for 20 minutes.  
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A sandwich was made with all the elements needed for the transfer. The two sponges were placed 
on the outside, 3 pieces of the filter paper on the inside of each of the sponges, and lastly the gel 
and membrane in the middle. A roller was used to ensure no bubbles were present. This was then 
placed in a transfer container (BioRad, USA) next to a block of ice, and was positioned on a magnetic 
stirrer with a magnet placed in the centre of the container. The apparatus was then filled with 
Transfer Buffer. It was connected to the voltage power and ran for 1 hour at 100V.  
 
2.12.3.4. Membrane blocking 
Following the transfer of proteins from the SDS PAGE gel onto the PVDF membrane, the membrane 
was removed from the transfer apparatus and rinsed with ddH₂O for 5 minutes on the shaker. The 
membrane was then either blocked with 5% fat free milk (Elite, Weigh-Less) dissolved in TBST 
(Appendix II) or in BSA in order to determine optimal blocking medium for the antibodies used. This 
was placed in the shaker for 1 hour to eliminate non-specific binding of the antibodies. 
 
2.12.3.5. Addition of Primary antibody 
Following the membrane blocking, the PVDF membrane was briefly rinsed twice with TBST. 
Thereafter, the primary antibody was added to milk in TBST according to the optimal ratio (Table 
2.4). Initially, a polyclonal goat antibody against parkin (Abcam, UK) was used at a dilution of 1:2000, 
however due to lack of success, the primary antibody was changed to a monoclonal mouse antibody 
against parkin (Cell Signalling Technology, USA). The membrane was then incubated overnight with 
the antibody-milk mixture on the shaker (Labcon, USA) at 4°C.  
 
2.12.3.6. Addition of Secondary antibody 
Following the incubation period, the membrane was briefly rinsed twice with TBST, followed by a 20 
minute wash with TBST on the orbital shaker.  The TBST was then replaced and three additional 
wash steps of 5 minutes each ensued, with fresh changes of TBST in between. The appropriate ratio 
of secondary antibody (Santa Cruz Biotechnology, USA) to milk in TBST (Table 2.4) was then added to 
the membrane and placed on the orbital shaker at room temperature for 1 hour. Thereafter, the 
membrane was washed with the same washing protocol used after the primary antibody incubation. 
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Table 2.4: Antibodies and antibody concentrations used in the Western blot assays 
ANTIGEN 
PRIMARY Ab AND 
MANUFACTURER 
OPTIMUM 
RATIO 
SECONDARY Ab 
OPTIMUM 
RATIO 
PRODUCT 
SIZE 
Parkin 
ab7295 Goat polyclonal Ab 
to parkin (Abcam, Biocom 
Biotech) 
1:5000 Donkey anti-goat  1:5000 65kDa 
Parkin (PARK8) Mouse 
monoclonal Ab (Cell 
Signalling Technology) 
1:500 Donkey anti-mouse 1:2000 50kDa 
*Ab, Antibody 
 
2.12.3.7. Chemiluminescent visualization of membrane proteins using the 
SuperSignal® West Pico Chemiluminescent Substrate kit 
After all excess secondary antibody was removed from the PVDF membrane; all reagents needed for 
processing of the film were taken to the dark room (FISAN building, Faculty of Medicine and Health 
Sciences, Stellenbosch University). The two substrate components of the SuperSignal® West Pico 
Chemiluminescent Substrate kit (Thermo Scientific, Pierce Biotechnology, USA), viz. the SuperSignal 
West Pico Luminol/Enhancer solution and the SuperSignal West Pico Stable Peroxide solution, were 
mixed in a 1:1 ratio. The membrane was subsequently incubated in this solution for 5 minutes under 
the red light in the dark room. The excess solution was removed from the membrane by lightly 
tapping the corner of the membrane onto a dry paper towel. The membrane was then placed inside 
an autoradiography cassette and covered with a transparent plastic sheet. Two glow-in-the-dark 
stickers were placed in each top corner in the cassette to aid in orientation of the film once 
processed. Autoradiography film (Eastman Kodak Company, USA) was placed over the membrane 
and the cassette was closed. Exposure time varied from 10 seconds to 10 minutes, depending on the 
strength of the signal. The film was processed by the Hyperprocessor™ automatic autoradiography 
film processor (Amersham Pharmacia Biotech UK Ltd., UK). The size of the protein was determined 
when placing the film against the protein ladder on the membrane. Dr. Chrisna Swart from the 
Division of Molecular Biology and Human Genetics, Stellenbosch University, assisted with 
optimisation and protein detection in the western blot procedure. 
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2.12.4. Proteome analysis 
 
Proteome analysis was performed on fibroblasts from patients P3.1 and P3.2, unaffected control 
WTC2 and heterozygous carrier P3het in collaboration with Dr. Salome Smit at the Central Analytical 
Facility (Faculty of Medicine and Health Sciences, Stellenbosch University). This was performed on 
the LTQ Orbitrap Velos mass analyser (ThermoFisher Scientific Inc., USA), which is able to detect 
thousands of proteins from one tissue type. The Orbitrap (Figure 2.5) employs electric fields to 
capture and confine ions. The ions move from the linear ion trap into the C-trap, and converge on 
the entrance into the Orbitrap. Ions of each mass-to-charge ratio arrive at the entrance of the 
Orbitrap and begin coherent axial oscillation. By Fast Fourier Transformation (FFT) of the amplified 
current, the instrument obtains the frequencies of these axial oscillations and therefore mass-to-
charge ratios of the ions by calculation. Because every peptide oscillates at a different speed, the 
peptides can be fragmented and the amino acid sequence can be detected. 
 
Thermo Proteome Discoverer 1.3 software (Thermo Scientific, Germany) was used to identify 
proteins via automated database searching (Mascot, Matrix Science, UK and Sequest) of all tandem 
mass spectra against the IPI Human database (downloaded July 2011). Carbamidomethyl cysteine 
was set as fixed modification, and oxidized methionine, N-acetylation and deamidation (NQ) was 
used as variable modifications. The precursor mass tolerance was set to 10ppm, and fragment mass 
tolerance set to 0.8Da. Two missed tryptic cleavages were allowed. Proteins were considered 
positively identified when they were identified with at least two tryptic peptides per proteins, a 
Mascot or Sequest score of more that p<0.05 as determined by Proteome Discoverer 1.3. Percolator 
was also used for validation of search results. In Percolator a decoy database was searched with a 
FDR (strict) of 0.02 and FDR (relaxed) of 0.05 with validation based on the q-value. Proteins 
identified in the fibroblasts were analysed using IPA software (Ingenuity Systems, USA) to find 
pathways that are associated with various cellular networks and disorders. 
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Figure 2.5: Diagram of the LTQ Orbitrap Velos spectrometer 
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Chapter 3 
 
RESULTS 
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3.1. Sampling of PD patients and controls 
 
3.1.1. Biological samples obtained from patients and controls 
 
In the present study, we attempted to identify evidence for mitochondrial dysfunction at the 
morphological, functional, as well as gene and protein expression levels of PD patients. For these 
experiments, we needed to obtain a range of biological specimens from the patients and controls 
(Table 3.1). Four parkin-null PD patients from three separate families were recruited for this study, 
namely patients P1 (family 1), P2 (family 2), and P3.1 and P3.2 (family 3). From the wild-type control 
WTC1, only a blood sample had been obtained and this was used as a control for the gene 
expression studies whereas from wild-type control WTC2 we were able to obtain a skin biopsy, and 
this was used as a control for the morphological, functional and protein expression studies. 
 
Table 3.1: List of biological samples obtained from PD patients, heterozygotes and wild-type 
controls 
 
, sample obtained; , sample not obtained 
Patient /  carrier/ 
control 
Muscle biopsy 
Skin biopsy / 
fibroblasts cultured 
Peripheral blood 
sample for RNA studies 
P1       
P1het       
P2       
P2het       
P3.1       
P3.2       
P3het       
WTC1       
WTC2       
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The fibroblasts cultured from the skin biopsies were used for the majority of the experiments in this 
study. Biopsies of the substantia nigra would have been an ideal tissue to use, but fibroblasts have 
been used as a proxy tissue in many similar studies (Auburger et al., 2012) and parkin has previously 
been shown to be expressed in this particular cell type (Mortiboys et al., 2008;  Pacelli et al., 2011). 
Fibroblasts were successfully cultured from all the patients and carriers except for patient P1 and 
P1het. In their case, a skin biopsy had been taken from patient P1 and his spouse (intended for use 
as a wild-type control at the time); however the samples were mistakenly sent to the wrong 
laboratory and subsequently did not grow. Since patient P1 and his spouse had travelled from 
another Province down to Cape Town to donate the samples, we were unable to repeat the 
procedure. Therefore in this case, the ROS functional analysis was performed using leukocytes, or 
white blood cells (WBC), and the proteome analysis was performed on cultured lymphocytes 
obtained from these individuals. Lymphocytes are T- and B- cells that account for 25-35% of the 
WBCs. 
 
3.1.2. Confirmation of parkin deletions 
Sequencing of the cDNA from these PD patients confirmed the presence of the deletions in parkin  
(Figure 3.1). 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure 3.1: Representative results of deletions present in parkin in patients recruited for this study. 
The positions of the deletions are indicated. A. 40bp deletion in exon 3; B. Whole exon 3 deletion; C. 
Whole exons 3 & 4 deletion. Taken from: Haylett et al., 2011 
 
3.1.3. Exclusion of parkin mutations in wild-type control samples 
 
Sequencing of the parkin gene in both wild-type controls (WTC1 and WTC2) was performed to 
ensure that there are no mutations in the gDNA of these individuals. All 12 exons were screened and 
the results confirmed that both controls did not harbour any non-synonymous or nonsense 
pathogenic mutations, small indels or homozygous exonic deletions in parkin (Table 3.2). An intronic 
variant was found in both controls, with a G to A base pair change in intron 7 (IVS7 – 35G>A). A 
second intronic variant was found in WTC2, with a T to C base pair change in intron 2 (IVS2 + 25T>C). 
In addition, an exonic variant was present in exon 4 of WTC2 (S167N), causing an amino acid change 
from serine (S) to asparagine (N). The frequency of the A allele is 0.042 (n = 4550 chromosomes) 
indicating that this variant is a common polymorphism. All these variants are non-pathogenic 
polymorphisms according to dbSNP and Ensembl (http://www.ncbi.nlm.nih.gov/snp; 
www.ensembl.org)  
  
 
 
 
 
C 
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Table 3.2: Results from sequencing of parkin for WTC1 and WTC2 
Exon WTC1 WTC2 
1 No variants; wild-type No variants; wild-type 
2 No variants; wild-type IVS2 +25 T>C 
3 No variants; wild-type No variants; wild-type 
4 No variants; wild-type S167N rs1801474 
5 No variants; wild-type No variants; wild-type 
6 No variants; wild-type No variants; wild-type 
7 No variants; wild-type No variants; wild-type 
8 IVS7 -35 G>A IVS7 -35 G/G>A/A 
9 No variants; wild-type No variants; wild-type 
10 No variants; wild-type No variants; wild-type 
11 No variants; wild-type No variants; wild-type 
12 No variants; wild-type No variants; wild-type 
 
 
3.2. Analysis of mitochondrial morphological changes  
 
Mitochondria that are dysfunctional typically present with gross morphological defects including 
swollen, enlarged mitochondria, with disorganized membrane compartments and degenerating 
electron dense matrices. As parkin is thought to play a role in maintaining healthy mitochondria, we 
sought to determine whether there was any evidence for defective or misshapen mitochondria in 
the PD patients with two null mutations in parkin. 
 
 
Stellenbosch University  http://scholar.sun.ac.za
79 
 
 
3.2.1. Mitochondrial morphology in muscle biopsies 
 
The muscle biopsies of the three probands were analysed using histology and TEM to examine 
mitochondrial morphology. The findings suggested subtle changes in the morphology among all 
three patients; however the extent of mitochondrial damage differed across the three individuals. 
 
Histological analysis showed little similarity across patients, with the exception of the absence of 
ragged red fibres found in all three patients (Table 3.3). Ragged red fibres are irregular skeletal 
muscle fibres associated with mitochondrial disease. These fibres accumulate in damaged 
mitochondria, thus acting as a universal indicator of mitochondrial abnormality. However, despite 
the absence of these fibres, several other fibre-based indicators of morphological differences are 
apparent. Although patient P2 showed no indication of atrophic fibres, patient P1 presented with 
scattered atrophic fibres, and patient P3.1 exhibited scattered elongated atrophic fibres. Grouping of 
type II fibres were observed in two patients (P2 and P3.1) and a predominance of these fibres were 
observed in patient P3.1. These are fast twitch muscle fibres that utilize anaerobic metabolism to 
produce energy. They have a much faster rate of fatigue, and contain less mitochondria than type I 
fibres. The ATP generation of type II fibres is predominantly through glycolysis, not via oxidative 
phosphorylation, suggesting a noticeable metabolic change within these patient cells.  
 
Interestingly, there appeared to be a correlation between the defects and the duration of the 
disease – patient P2 had a shorter duration (10 years) than patients P1 (13 years) and P3.1 (23 
years). Both patients P1 and P3.1 exhibited scattered atrophic fibres as well as variation in muscle 
fibre size which has been associated with the ageing process (Brunner et al., 2007). Sarcolemmal 
accentuation of enzymes also correlated with the length of the disorder – from normal in patient P2, 
mild in patient P1, and extensive accentuation in patient P3.1. This could also explain why patient 
P3.1 shows the presence of cytochrome oxidase, an oxidizing enzyme that acts at the end terminal 
of the respiratory chain, with the main function of electron transport. This increased presence may 
be suggestive of a possible compensatory mechanism by the damaged mitochondria. Results from 
patient P3.1 also suggest that her muscle portrays features of a possible neurogenic aetiology, which 
is due to the large extent of focal grouping of type II fibres. However patients P1 and P2 fibre 
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analysis did not appear to suggest such a cause. This result further indicates the more severe 
morphological changes observed in patient P3.1 in comparison to patients P1 and P2. 
 
The results from the electron microscopy analysis (Table 3.3) also suggest subtle features of 
mitochondrial abnormality in both patients P1 and P3.1. All three patients’ mitochondria illustrate 
wrinkling of the sarcolemmal membrane that is indicative of muscular atrophy, sub-sarcolemmal 
aggregates of mitochondria and the absence of inclusions. Both patients P1 and P3.1 exhibit an 
increase in the glycogen and lipid content of these mitochondrial aggregates, and an increase in 
these substrates was also observed in the histological analysis of patient P2. Patient P3.1 also 
exhibits the presence of lipofuscin, which are involved in protein storage and have lipid-containing 
residue. These granules are indicative of protein degradation and mitochondrial damage, and are 
known to accumulate with age.  Most notable, however, are that in both the histological and TEM 
analysis more prominent and enlarged mitochondria were observed in patient P3.1. Although not 
grossly oversized, this is a clear indication of mitochondrial dysfunction. 
 
Table 3.3: Results from the muscle biopsy analysis of mitochondrial morphology in terms of 
histology and transmission electron microscopy in patients P1, P2 and P3.1 
 
Histological analysis of muscle cells 
Patients P1 P2 P3.1 
Muscle fibres 
No ragged red fibres No ragged red fibres No ragged red fibres 
Scattered atrophic fibres No atrophic fibres Scattered elongated 
atrophic fibres 
No predominant fibre type No predominant fibre 
type 
Predominantly type II fibres 
 Focal grouping of type II 
fibres 
Focal grouping of type II 
fibres 
Mild variation in muscle size Minimal variation in 
muscle size 
Predominantly small muscle 
fibres with mild variation in 
size and shape 
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Cell cytoplasm 
content 
  Mitochondria appear 
slightly more prominent 
Sarcoplasmic lipid mildly 
increased in static fibres 
Small amount of 
intraplasmic lipid present 
No increase in sarcoplasmic 
lipid 
Mild sarcolemmal 
accentuation of enzymes 
Normal sarcolemmal 
accentuation of enzymes 
Extensive sarcolemmal 
accentuation of enzymes 
  Cytochrome oxidase present 
Conclusions 
Focal isolated markedly 
atrophic cells present 
Muscle biopsy within 
normal limits 
Subtle features of 
neurogenic aetiology 
Subtle mitochondrial changes 
of uncertain insignificance 
 Primary or secondary subtle 
mitochondrial changes 
Transmission Electron Microscopy of muscle cells 
Muscle fibres 
Wrinkling of sarcolemmal 
membrane (indicative of 
atrophy) 
Wrinkling of 
sarcolemmal membrane 
(indicative of atrophy) 
Wrinkling of sarcolemmal 
membrane (indicative of 
atrophy) 
Cell cytoplasm 
content 
Sub-sarcolemmal aggregates 
of normal mitochondria 
Sub-sarcolemmal 
aggregates of normal 
mitochondria 
Sub-sarcolemmal and inter 
myofibrillar accumulations 
of normal mitochondria 
Aggregates associated with 
increased lipid and glycogen 
No increased lipid or 
glycogen 
Scattered lipid droplets and 
lipofuscin 
No inclusions No inclusions No inclusions 
  Slightly enlarged 
mitochondria 
Conclusions 
Features suggestive of 
primary or secondary 
mitochondrial abnormality 
Biopsy within normal 
limits 
Subtle mitochondrial 
abnormality 
Patient details 
Length of disease 13 years 10 years 23 years 
Current age 38 years old 37 years old 50 years old 
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3.2.2. Mitochondrial morphology in cultured fibroblasts from skin 
biopsies  
 
Morphological analysis was also performed on fibroblasts obtained from the patients (P2, P3.1, and 
P3.2), the heterozygous mutation carriers (P2het, P3het) and the wild-type control (WTC2). Previous 
studies on fibroblasts of parkin-mutant patients found gross morphological changes, with one 
particular study reporting on swollen mitochondria with disorganized membrane compartments as 
well as lysosomal vacuoles filled with electron dense material possibly indicative of degenerating 
mitochondria (Pacelli et al., 2011).  As the mitochondrial abnormalities observed in the muscle 
tissues had been subtle, it was necessary to determine whether the extent of the defects in the 
fibroblasts were similar to that found in the muscle tissues of these patients.  
 
 The morphology, using TEM, of the wild-type control fibroblasts is shown in Figure 3.2. The nucleus 
(Figure 3.2 B), ER (Figure 3.2 B) and round, rod-shaped mitochondria (Figure 3.2 A, B) are clearly 
visible. Analysis of the mitochondria show normally arranged cristae (Figure 3.2 B) that are very dark 
in colour, which is indicative of a highly electron dense matrix, suggesting that the mitochondria are 
healthy and undergoing constant oxidative phosphorylation. Many autophagic vacuoles 
(autophagosomes) are also present in the fibroblasts (Figure 3.2 B). The few vacuoles that are darker 
in colour (Figure 3.2 C) indicate activity and possible fusion of a lysosome with an autophagosome to 
form an autolysosome; however this activity is normal in healthy cells at a low level. Figure 3.2 C 
shows an example of mitochondrial fusion. The purpose of mitochondrial fusion is to protect 
mitochondrial function by preventing the accumulation of damaged mtDNA and to respond more 
efficiently with the metabolic demands of the cell.  
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Figure 3.2: Wild-type control (WTC2) fibroblasts analysed using transmission electron microscopy. 
A & B: nucleus (blue arrow), endoplasmic reticulum (red arrow), mitochondria (yellow arrow) and 
lysosomal vacuoles (orange arrow). C: The process of mitochondrial fusion occurring within the cell 
(green arrow); a vacuole or autophagosome in the process of lysosomal digestion (orange arrow). 
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B
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Results from the TEM performed on patient P2 and carrier P2het can be seen in Figure 3.3. In terms 
of the mitochondrial morphology, the mitochondria in the patient appear rod-shaped with intact 
membranes and cristae (Figure 3.3 A), however several mitochondria appear circular and slightly 
swollen (Figure 3.3 C). Fusion is observed in the mitochondria that appear to be joined (Figure 3.3 A, 
B). Most notable in the patient is the appearance numerous electron dense (dark) vacuoles which 
suggest that they are filled with some kind of cellular material (Figure 3.3 B, C, and D). These 
vacuoles may be lysosomes undergoing fusion with autophagosomes for the process of autophagy. It 
is not clear what the material is, but it could be speculated that it is proteins targeted for 
degradation or dysfunctional mitochondria that are in the process of mitophagy. Whatever the 
content of these vacuoles, it is obvious that due to their large number, a mechanism is occurring 
within these cells that may be trying to remove large amounts of possibly toxic material. When 
comparing these patient cells to that of the control (Figure 3.2) and P2het (Figure 3.3 E, F), these 
vacuoles appear markedly different in terms of their size, number and colour. In P2het, the 
mitochondria (Figure 3.3 E, F) are well-formed and look similar to that of the mitochondria in the 
wild-type control WTC2. There are a number of large vacuoles, but they are predominantly light in 
colour. Fusion is also visible but to a lesser degree than the control. 
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B 
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Stellenbosch University  http://scholar.sun.ac.za
85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Patient P2 and carrier P2het fibroblasts analysed using transmission electron 
microscopy. A & B show well-formed rough endoplasmic reticulum (red arrow), nucleus (blue 
arrow), mitochondria (yellow arrow) as well as the process of fusion (green arrow).  C indicates 
circular, swollen mitochondria (purple arrow) and along with D show vacuoles filled with electron 
dense material not seen in the control or P2het (orange arrow). E & F: Rod-shaped mitochondria 
(yellow arrow) with well-formed cristae in carrier P2het. Also, the majority of the vacuoles are white 
in colour indicating that they are empty (orange arrow). 
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E 
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The fibroblasts of patients P3.1 and P3.2 and the heterozygous carrier P3het are shown in Figure 3.4. 
The mitochondria (Figure 3.4 A, B, and D) of the two patients appear to be normally shaped (not 
swollen or irregular), and similar to those observed in the control cells (Figure 3.2). Pacelli and 
colleagues had observed few remaining cristae in patient cells (Pacelli et al., 2011), but this is not 
apparent in these patients. Although to a lesser degree than patient P2, a large number of electron 
dense autophagosomes or lysosomal vacuoles with noticeable inclusions were also observed in both 
patients P3.1 and P3.2 (Figure 3.4 C, D and F). Figure 3.3E from patient P3.2 shows a vacuole situated 
next to a mitochondrion and it could be speculated that the vacuole is an autophagosome in the 
process of digesting the mitochondrion. Mitochondrial fusion was also noted in the patient cells 
(Figure 3.4 C and F), and although the activity of fusion is to a lesser degree than in the control cells, 
it still suggests that some of the mitochondria are healthy and functional. 
 
TEM images of fibroblasts from P3het are shown in Figure 3.4 G and H. The nucleus and ER are 
present (Figure 3.4 H) and the mitochondria are rod-shaped and round (Figure 3.4 G), not exhibiting 
irregularity in shape. The cristae are well formed and mitochondrial fusion is visible (Figure 3.4 H), 
but the fused mitochondria appear shorter than in the control (Figure 3.2 C). The vacuoles have 
varying degrees of electron density with inclusions (Figure 3.4 G and H), although less are observed 
in the carrier than in patients P3.1 and P3.2.  
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Figure 3.4: Patients P3.1 and P3.2 and carrier P3het fibroblasts analysed using transmission 
electron microscopy. A: Mitochondrion with well-shaped cristae (yellow arrow). B & D: Well shaped 
mitochondrion (yellow arrow) and autophagosomes with inclusions (orange arrow). C & F: Electron 
dense vacuoles (orange arrow) and mitochondrial fusion (green arrow). E: Indication of possible 
mitophagy (pink arrows). G and H: Rod-shaped mitochondria with well-formed cristae in carrier 
P3het (yellow arrow) and clear vacuoles with some showing slight inclusions (orange arrow). H: 
Nucleus (blue arrow), endoplasmic reticulum (red arrow) and mitochondrial fusion (green arrow). 
 
3.2.3. Mitochondrial network analysis 
 
The mitochondrial network is highly adaptable and changeable due to the dynamic nature of this 
organelle. The branches that form this network are responsible for the connectivity of the 
mitochondria throughout the cytosol of the cell, creating communication with other vital organelles 
such as the ER and the Golgi apparatus (Anesti & Scorrano, 2006). The more networks observed 
indicate healthier mitochondria, whereas fragmented and disjointed networks indicate dysfunctional 
and damaged mitochondria. Fragmentation of these networks has been observed in several studies 
with fibroblasts from PD patients with parkin-null mutations (Grunewald et al., 2010; Pacelli et al., 
2011). 
 
G 
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The mitochondrial network analysis of patient P2 (Figure 3.5 A), carrier P2het (Figure 3.5 B) and 
WTC2 (Figure 3.5 C) shows the mitochondrial network (red) and the nucleus (blue) of the fibroblasts. 
Both patient P2 and carrier P2het’s mitochondrial network appear more fragmented compared to 
the control. The arrows on both images (Figure 3.5 A & B) indicate a dot-like and clustered 
appearance of the mitochondrial network. In contrast, the control mitochondrial network appears 
highly connected, suggesting a functional mitochondrial population.  
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Figure 3.5: Mitochondrial network analysis of A. patient P2, B. carrier P2het and C. WTC2. The 
mitochondrial network is stained in red (MitoTracker Red dye) and the nucleus in blue (Hoescht 
3343 dye). Fragmented mitochondria are indicated by the arrows in A and B. 
 
 
Mitochondrial network analysis of family 3 was also performed (Figure 3.6). Patient P3.1 (Figure 3.6 
A) shows very subtle signs of fragmentation of the mitochondrial network in her fibroblasts but not 
as severe as that of patient P2. In contrast, patient P3.2 does not exhibit these signs of mitochondrial 
fragmentation, but rather shows interconnectivity between individual mitochondria (Figure 3.6 B). 
Similarly, the fibroblasts from P3het show clear mitochondrial connection and fusion (Figure 3.6 C). 
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Figure 3.6: Mitochondrial network analysis in fibroblasts from A. patient P3.1, B. patient 3.2, C. 
heterozygous P3het and D. WTC2. Fragmented mitochondria are indicated by the arrow in A. 
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3.3. Analysis of mitochondrial function 
 
3.3.1. ROS analysis  
 
One of the main functions of mitochondria is the production of energy in the form of ATP via 
oxidative phosphorylation. During this process, ROS is released as a by-product and therefore 
measurement of mitochondrial ROS levels in a cell is an indication of mitochondrial function. In 
addition to mitochondrial ROS, generic ROS is released from all parts of the cell such as metabolic 
ROS produced by oxidation and reduction reactions in response to stress within the cell. Generic ROS 
can also enter the cells from the environment from sources such as radiation, UV light exposure, 
pesticide use and infection. Further examples of generic ROS sources include peroxisomal oxidases, 
cytochrome P-450 enzymes and NADPH oxidases (Kregel & Zhang, 2007). In comparison, 
mitochondrial ROS is produced only from the mitochondria.  
 
The mitochondrial ROS is either produced in normal non-toxic amounts via oxidative 
phosphorylation, or through a defect in complex I of the electron transport chain, in which case 
higher levels of ROS are produced, thus resulting in oxidative stress of the cells. It was hypothesized 
that PD patients release a higher level of mitochondrial ROS compared to the wild-type control. 
Generic and mitochondrial ROS levels were measured separately in all study participants. For patient 
P1 and his spouse, the ROS analysis was performed on cultured WBCs, whereas for P2, P2het, P3.1, 
P3.2, P3het and WTC2 the experiments were performed on fibroblasts. Intensity histograms 
(example shown in Figure 3.7) were calculated after analysis on the flow cytometer, and the 
resulting fluorescence intensity signal was measured in terms of the PE and FITC geometric means, 
respectively.  
 
 
 
 
A 
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Figure 3.7: Example of the intensity histograms produced after flow cytometry to measure A. 
generic ROS measured via the PE geometric mean and B. mitochondrial ROS measured via the FITC 
geometric mean. 
 
The raw data for the generic and mitochondrial ROS are shown in Table 3.4. Each run was performed 
on a separate date; therefore the data cannot be compared across runs as these are independent 
events. The normalized values are indicated in Table 3.5. Represented graphically, it is apparent that 
there is no trend in the generic ROS level across the study participants (Figure 3.8 A). Both patients 
P1 (153.5%) and P3.1 (145.8%) exhibit increased generic ROS compared to the wild-type control 
WTC2. In contrast, patients P2 (40.6%) and P3.2 (83.8%) have decreased generic ROS levels. 
Moreover, one heterozygote has decreased levels (P2het; 59.6%) and the other has increased levels 
(P3het; 115.8%). 
 
Interestingly, for the mitochondrial ROS there is a trend with patients P1 (121.6%), P2 (163.6%) and 
P3.1 (125.3%) all exhibiting increased levels relative to the wild-type control WTC2. The only 
exception is patient P3.2 (85.2%) which showed decreased mitochondrial ROS levels. The reason for 
the different result in this patient is currently unclear, although it is thought that this patient may 
have a compensatory mechanism at play that alleviates the ROS levels. The findings in the other 
three patients fit with our hypothesis of increased mitochondrial ROS as a result of dysfunctional 
mitochondrial in PD patients. Both heterozygotes also exhibited increased mitochondrial ROS 
(P2het; 104.0% and P3het; 121.3%), although P2het was only marginally higher than the wild-type 
control WTC2.  
 
 
B 
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Table 3.4: Values of the PE geometric mean measuring generic ROS and the FITC geometric mean 
measuring mitochondrial ROS in the WBCs of patient P1 and the fibroblasts in patients P2, P3.1 
and P3.2, heterozygotes P2het and P3het, and WTC2. 
 
 
Table 3.5: Analysis of generic and mitochondrial ROS measurements in patients and carriers as a 
percentage of the wild-type control. 
 
Patient 
Generic ROS 
(PE geometric mean ) 
 Mitochondrial ROS 
(FITC geometric mean) 
Cells 
Date of 
experiment 
P1 2586 180 WBCs 
01/03/2011 P1 Spouse 
(wild-type) 
1685 148 WBCs 
P2 167 162 Fibroblasts 
25/07/2012 P2het 245 103 Fibroblasts 
WTC2 411 99 Fibroblasts 
P3.1 1051 1747 Fibroblasts 
15/03/2012 
P3.2 604 1188 Fibroblasts 
P3het 835 1691 Fibroblasts 
WTC2 721 1394 Fibroblasts 
 Generic ROS (%) 
(Normalized to WTC2) 
Mitochondrial ROS (%) 
(Normalized to WTC2) 
P1 153.5 121.6 
P2 40.6 163.6 
P3.1 145.8 125.3 
P3.2 83.8 85.2 
P2het 59.6 104.0 
P3het 115.8 121.3 
*WBCs, white blood cells 
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Figure 3.8: Graphical representation of the reactive oxygen species (ROS) in patients and carriers. 
A. generic and B. mitochondrial ROS.  
A 
B 
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3.4. Analysis of mitochondrial gene expression 
 
Mitochondrial function may also be affected by the expression levels of the mitochondrial genes. 
Previous studies have shown down-regulation of the genes involved in mitochondrial electron 
transport in both brain tissues and blood from PD patients (Zheng et al., 2010). In the present study, 
peripheral blood samples were used for the gene expression studies due to the fact that expression 
studies on cultured cells do not produce reproducible results as a result of artifacts induced during 
the culturing process (Dr. Suzanne Lesage, personal communication). 
 
3.4.1. Determination of quality of extracted RNA 
 
RNA was extracted from peripheral blood samples obtained from patients P1, P2, P3.1, and P3.2 as 
well as the respective heterozygote family member of each patient, and the wild-type control used 
in gene expression experiments (WTC1). It is essential to ensure that the isolated RNA is of the 
highest quality, in other words that there are no contaminants in the sample (a measure of RNA 
purity), and that the RNA has not been degraded (a measure of RNA integrity). If the RNA is not of a 
sufficiently high quality, this will result in inhibition of the qRT-PCR process, and may lead to biased 
data (Taylor et al., 2010). Directly after the extraction, the RNA was pipetted onto the NanoDrop® 
N1000-UV-Vis Spectrophotometer and the concentration of the RNA was determined using the 
Beer-Lambert law, which predicts a linear change in absorbance with concentration. A ratio of 
260:280 primarily represents the purity of the RNA, and a ratio value of ±2 is accepted as ‘pure’ RNA. 
A much lower value may be indicative of possible contamination. The 260:230 ratio is generally 
accepted at around 1.8 – 2.2 for ‘pure’ RNA. A lower ratio may also indicate sample contaminants of 
salts, phenol or protein in the sample.  
 
The concentration of the extracted RNA was within an acceptable range and the samples were 
relatively pure (Table 3.6). The 260:280 ratio was approximately 2 for all samples, but the 260:230 
ratio was <1 for all except P2het, which suggests possible contamination. It could be speculated that 
column-based extraction methods, such as the one used, may lead to contamination with particles 
from the column which absorb at 230nm. Both purity and integrity need to be assessed before the 
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RNA can be used for qRT-PCR experiments, and it is not possible for spectrophotometric readings to 
produce data on RNA integrity. Therefore a more accurate method of RNA quality determination 
was performed using the Experion StdSens Analysis Kit (BioRad, USA), which is a microfluidics 
electrophoresis based system.   
 
Table 3.6: RNA concentration and quality determination using the NanoDrop® N1000-UV-Vis 
Spectrophotometer  
 
 
 
 
 
 
 
 
 
 
The parameters measured in an Experion run include RNA concentration, RNA area, 28S/18S RNA 
ratio and the RNA Quality Indicator (RQI) value. The RQI value standardizes and quantifies RNA 
integrity, and is able to show the extent of degradation of each RNA sample loaded onto the chip. It 
is ranked from a value of 1, which indicates highly degraded RNA, to a value of 10, which indicates 
intact RNA (Drug, Discovery & Development magazine, 
http://www.dddmag.com/products/2008/12/rna-quality-indicator). The cut-off RQI value used for 
RNA experiments was taken as 8 or above. With the exception of P1het, all the RNA samples met 
this standard (Table 3.7) and were thus used in the subsequent gene expression studies. A second 
quality determining factor is the 28S/18S ratio, which is calculated during the run for each sample. 
The higher the ratio, the greater the level of intact RNA in the sample, and this will produce a 
Patient Concentration (ng/µl) 260/280 260/230 
P1 77 1.93 0.69 
P1het 67 2.1 0.45 
P2 98 2.08 0.56 
P2het 82 2.06 1.99 
P3.1 117 2.04 0.62 
P3.2 78 2.16 0.21 
P3het 64 2.09 0.39 
WTC1 134 2.14 0.74 
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subsequent higher RQI value. A 28S/18S ratio between 1 and 2 is accepted as good quality RNA. 
Based on the run and the run images (an example is shown in Figure 3.9), the 28S/18S ratio was 
indicative of good quality RNA in each of the samples, as two distinct bands were seen that 
represent 28S and 18S rRNA respectively. The RNA extracted from heterozygous P1het yielded an 
RQI value of 6.5 and the concentration and 28S/18S ratio were also relatively low in comparison to 
the RNA values of all other individuals (Table 3.7). Therefore that sample was not used in 
subsequent experiments. Reasons for the production of a poor quality sample may be contamination 
of the sample during the RNA extraction procedure, or a degraded blood sample due to a faulty 
blood collection tube.  
 
 
 
 
 
 
Figure 3.9: Gel picture of an Experion run. Lane L represents the RNA ladder, lanes 1 and 2 
represent bad quality RNA (as no 28S and 18S bands are seen) and lanes 3-12 represent good quality 
RNA (with distinct 28S and 18S bands). 
L 1       2       3        4       5        6       7        8       9      10      11    12 
18S 
28S 
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2000 
1500 
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50.0 
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4000 
3000 
2000 
1500 
1000 
500.0 
250.0 
50.0 
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Table 3.7: RNA concentration and quality determination using the Experion StdSens Analysis Kit 
 
 
The RNA extracted from patients P1, P2, P3.1 and the wild-type control WTC1 was converted to 
cDNA and this was used in qRT-PCR gene expression experiments – namely the RT² Profiler PCR 
Array (SABiosciences, USA) and the RT² Primer Assay (SABiosciences, USA).  
 
The RT² Profiler PCR Array allows for simultaneous analysis of 84 genes involved in mitochondrial 
energy metabolism. Up- or down-regulated genes were determined as genes with a fold regulation 
value of 2 or more compared to WTC1. Thereafter, one of the genes found to be down-regulated 
genes across all three patients was chosen for independent verification using the Primer Assay, and 
analysed using REST software. The Primer Assay PCR reactions were performed in triplicate so as to 
ensure the validity of the results.  
 
 
Patient Concentration (ng/µl) RNA Area 28S/18S RQI 
P1 64.31 315 0.96 8.4 
P1het 51.68 253.12 0.63 6.5 
P2 111.41 330.67 1.28 9.3 
P2het 69.71 206.91 1.4 9.4 
P3.1 89.62 221.23 1.59 9.5 
P3.2 77.82 214.87 1.51 9.2 
P3het 63.37 156.42 1.5 9.3 
WTC1 103.41 506.51 1.09 8.8 
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3.4.2. RT² Profiler PCR Array and RT² Primer Assay 
 
Table 3.8 summarizes the list of down-regulated genes found across two or more of the patients. 
The fold difference number shows the fold change for each gene, which was chosen at a minimum 
value of 2. Each gene is part of one of the five complexes of the mitochondrial electron transport 
chain, responsible for the production of cellular ATP. Of the 14 down-regulated genes that were 
found in at least two patients, five form part of complex I, four from complex III, two from complex 
IV and three from complex V. Notably, no genes from complex II were found to be down-regulated. 
Of the 14 down-regulated genes, four were found to be down-regulated across all three patients 
(NDUFS2, BCS1L, CYC1 and LHPP). Only six genes were found to be up-regulated in two or more 
patients (Table 3.9). Of these, one forms part of complex I, three from complex IV, and two from 
complex V. No gene was found to be up-regulated across all three patients. 
 
Table 3.8: List of down-regulated genes common in two or more patients, and resulting fold 
regulation (i.e. under-expression relative to the control). 
P1 
Fold 
regulation 
P2 
Fold 
regulation 
P3.1 
Fold 
regulation 
Mitochondrial 
complex 
  NDUFA11 -11.01 NDUFA11 -3.46 I 
  NDUFB7 -6.30 NDUFB7 -3.04 I 
NDUFS1 -2.09 NDUFS1 -18.13   I 
NDUFS2* -2.47 NDUFS2 -65.63 NDUFS2 -2.41 I 
  NDUFS7 -27.03 NDUFS7 -5.85 I 
BCS1L* -3.68 BCS1L -9.93 BCS1L -2.62 III 
CYC1* -2.74 CYC1 -8.89 CYC1 -9.42 III 
  UQCRC1 -25.78 UQCRC1 -3.22 III 
UQCRCQ -2.48 UQCRCQ -2.32   III 
  COX6B1 -6.77 COX6B1 -4.12 IV 
  COX8A -11.03 COX8A -2.12 IV 
  ATP5G1 -8.18 ATP5G1 -2.07 V 
ATP5J2 -2.91   ATP5J2 -2.01 V 
LHPP* -2.75 LHPP -6.36 LHPP -2.12 V 
*Genes down-regulated across all three patients 
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Table 3.9: List of up-regulated genes common in two or more patients, and resulting fold 
regulation (i.e. over-expression relative to the control). 
 
 
It was hypothesized that the majority of the 84 genes analysed would be down-regulated in patients 
P1, P2 and P3.1. This was, however, not observed in the patients. Also different profiles were 
observed across these three individuals (Figure 3.10 A-C). Figure 3.10A indicates all genes up- and 
down-regulated in patient P1. A total of 24 genes showed differences and of these only 30% (8/24) 
were found to be down-regulated. In comparison, patient P2 had a total of 57 genes with a change 
in gene expression, of which a 74% majority were down-regulated (42/57; Figure 3.10 B). Patient 
P3.1 had the least amount of genes with differences in expression (15 genes), however similarly to 
patient P2, the majority of these genes, 87%, were also down-regulated (13/15; Figure 3.10 C).  
 
 
P1 
Fold 
regulation 
P2 
Fold 
regulation 
P3.1 
Fold 
regulation 
Mitochondrial 
complex 
NDUFA4 +9.54 NDUFA4 +2.35   I 
COX7B +9.46 COX7B +3.05   IV 
COX6C +5.98 COX6C +2.52   IV 
COX7A2 +3.87 COX7A2 +2.81   IV 
  ATP6VOD2 +3.27 ATP6VOD2 +2.56 V 
ATP50 +3.19 ATP50 +2.11   V 
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Up- and down-regulated genes in P3.1 
Figure 3.10: Graphs showing all up-and down-regulated genes found in A. patient P1; B. patient P2; C. patient P3.1
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The PCR Primer Assay was performed as a validation step for the results observed in the PCR Array. 
A gene of interest that was down-regulated across all three patients (CYC1) was chosen for the 
Primer Assay and two housekeeping genes were chosen for normalisation of results – HPRT1 and 
RPL13A. The CYC1 gene was chosen as it correlated with down-regulation observed in a previous 
study (Zheng et al., 2010). The standard curve results for each of the three genes are shown in 
Appendix V. After normalisation the results indicated that although an increased expression is 
observed (5.693), CYC1 expression levels is unchanged in the patient blood samples compared to the 
wild-type control (p = 0.065; Table 3.10). This contradicts the results observed in the PCR Array, in 
which down-regulation of CYC1 was seen for all three patients.   
 
Table 3.10: Relative expression values of the target (TRG) gene CYC1 normalized to the two 
housekeeping (REF) genes HPRT1 and RPL13A.  
 
 
3.5. Analysis of protein expression 
 
Studies have failed to provide a correlation between differences in the levels of mRNA transcripts 
and levels of protein expression for protein-coding genes (Nie et al., 2007). It is therefore important 
to also examine the differences between patients and controls at the level of the proteome, as gene 
expression studies can only provide limited insight into post-transcriptional regulation. 
 
In the present study, we wanted to ensure that no parkin protein was produced in the parkin-null 
patients. In addition, we performed a pilot study to determine whether a sufficient number of 
Gene Type 
Reaction 
Efficiency 
Expression Std. Error 95% C.I P(H1) 
HPRT1 REF 0.9353 0.937    
RPL13A REF 0.8521 1.067    
CYC1 TRG 0.9818 5.693 1.959 – 34.845 1.461 – 69.694 0.065 
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proteins could be extracted from cell lysates of fibroblasts and also to determine whether there 
were any differences between the proteomes of PD patients and the wild-type control. 
 
3.5.1. Determination of parkin expression in cultured fibroblasts 
using Western blotting 
 
When an antibody against an epitope of a particular protein is available, western blotting can enable 
high sensitivity detection of that specific protein in a protein mixture such as a lysate. One of the 
objectives in this research project was to show, using fibroblasts, that parkin protein is present in a 
wild-type control, absent in a patient with PD caused by two mutations in the parkin gene, and 
present in a heterozygote carrier of the parkin mutation, but to a lesser degree than in the wild-type.   
 
3.5.1.1. Polyclonal goat antibody 
 
Initially, the primary antibody used was a polyclonal goat antibody (Abcam, Biocom BioTech, SA) and 
according to the manufacturer’s protocol, a dilution of 1:5000 was recommended. Using this dilution 
of primary antibody, parkin could not be detected (Figure 3.11). Thereafter, the cell lysate was 
blotted with different dilutions of antibody – 1:5000, 1:3000 and 1:2000. However, no parkin protein 
was detected using any of these concentrations, although a possible band was observed at 110kDa 
using the 1:2000 dilution, but when the procedure was repeated, no bands were visible, suggesting 
that the 110kDa band was a contaminant.  
 
 
 
 
 
Figure 3.11: Western blot with no parkin band detected when using a 1:5000 dilution of the 
primary antibody 
72kDa 
52kDa 
WT 
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3.5.1.2. Monoclonal mouse antibody 
 
After several more unsuccessful blots using the polyclonal goat antibody, it was decided that a 
monoclonal mouse antibody for parkin should be used (Cell Signalling Technology, USA). A 
monoclonal antibody is formed due to a single cell fusion that is grown up into a clonal population, 
recognizing only one epitope of the antigen. In contrast, a polyclonal antibody is a mix of different 
antibodies that recognize multiple different epitopes on an antigen (Lipman et al., 2005). The 
advantage of using a monoclonal antibody is the specificity with which this antibody interacts with 
only one target epitope; this could markedly reduce excessive background and non-specific target 
binding. The new monoclonal mouse antibody was first tested using lysates of rat hypothalamus 
GT17 cells as a positive control. The concentration of the GT17 cells was notably higher (7.3µg/µl) 
than that of the fibroblasts (4.3µg/µl). Figure 3.12 indicates the parkin band detected when the GT17 
cells and a band of 50kD was seen, which is the expected size according to the manufacturer’s 
specifications.  
 
 
 
 
 
 
Figure 3.12: Western blot showing a 50kDa band which represents parkin protein using rat 
hypothalamus GT17 cell lysates. 
 
Thereafter, control, patient and heterozygote fibroblasts were analysed on a western blot using the 
monoclonal antibody. After increasing the concentration of the cell lysate (Control = 7.3µg/µl; 
patient and carrier = 7.2µg/µl), changing the primary antibody dilution from 1:1000 to 1:500, and 
making the gel in a 10% resolving gel solution rather than a 12% solution, the blots were successful 
in showing the presence of parkin protein in wild-type control fibroblasts, and the absence in patient 
52kDa 
72kDa 
50kDa 
GT17 
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fibroblasts (Figure 3.13). Unexpectedly, no parkin was observed in the carrier, but this may be due to 
half the amount of parkin protein which was not visible on this blot. Future studies are needed to 
determine if a band of half the intensity is visible in the carrier. 
 
 
 
 
 
 
 
Figure 3.13: Western blot showing a 50kDa band which represents parkin protein in wild-type 
fibroblasts. No band was observed in patient P2 and carrier P2het. 
 
3.5.2. Investigation of the proteome of cultured fibroblasts 
 
The cell lysates of fibroblasts from the PD patients, a carrier and a control sample were analysed on 
a mass spectrometer as part of a pilot study to analyse the proteome. To date, this type of study has 
not been done on parkin-null patients, and the ultimate goal is to identify possible biomarkers for 
the disease.  
 
Patients P3.1 and P3.2, carrier P3het and WTC2 were used for this analysis. Approximately 1000 
proteins were identified in each individual: Patient P3.1 – 998 proteins; patient P3.2 – 1023 proteins; 
carrier P3het – 1143 proteins and WTC2 – 985 proteins. Firstly, the protein products of the eight 
known PD genes were screened for in these lists and notably parkin was not present in any of the 
samples (Table 3.11). DJ-1 was present in all except patient P3.1 and EIF4G1 was only present in 
P3het.  
 
WT P2 P2het 
72kDa 
52kDa 
50kDa 
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Table 3.11: List of known PD proteins screened for in the fibroblasts 
 
 
Moreover, none of the protein products of the down- or up-regulated genes from the PCR Array 
experiments (Table 3.8 and 3.9) were present in these samples. Possible reasons for this could be 
the differences in the proteomes between blood samples and fibroblasts or that the method used 
did not capture the complete fibroblast proteome. Of the 84 genes screened for in the PCR Array, 15 
of these protein products were present in the fibroblast proteomes. 
 
Thereafter, we determined which proteins were present in both of the patients and not in the wild-
type control, and also which proteins were absent in the patients and present in the control. This 
revealed a total of 152 proteins that were only in the patients and 688 proteins that were only in the 
control. The 688 proteins detected in the control (assumed to be absent in the patients) were 
analysed using IPA software (Ingenuity, USA). Interestingly, the results indicated that some of these 
proteins belong to the pathway associated with mitochondrial dysfunction in PD, Alzheimers disease 
and breast cancer (Figure 3.14).  Further analysis indicated 14 proteins from this pathway were 
present in the wild-type control and absent in the combined patient group. These proteins form part 
of smaller pathways involved in mitochondrial dysfunction such as: apoptosis (CASP3), amyloid β 
accumulation (NCSTN), complex I (NDUFA9, NDUFS1), complex II (SDHA), complex III (UQCRB), 
complex IV (COX7A2), complex V (ATP5J), protection of FES cluster containing mitochondrial 
enzymes (SOD2), oxidative stress (OGDH,  PARK7/DJ-1), ageing (CAT) and ROS accumulation (PRDX3, 
PRDX5). These results should be interpreted with caution as only 1000 proteins were identified.
Patients P3.1 P3.2 P3het WTC2 
Parkin         
DJ-1         
EIF4G1         
PINK1         
SNCA         
LRRK2         
ATP13A2         
VPS35         
 , positive detection; , no detection 
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Figure 3.14: Pathway implicated in mitochondrial dysfunction in PD, Alzheimer’s disease and breast cancer. The 14 proteins found only in the wild-type control and 
not in the two PD patients are highlighted in orange. 
Stellenbosch University  http://scholar.sun.ac.za
112 
 
 
 
 
 
 
 
 
Chapter 4 
 
DISCUSSION 
  
Stellenbosch University  http://scholar.sun.ac.za
113 
 
PAGE 
4.1. Changes in the mitochondrial morphology and network of the  
Patients               114 
 
4.2. Increase in mitochondrial ROS levels in three patients        120 
 
4.3. Down-regulation of genes involved in mitochondrial electron  
transport                122 
4.4. Proteome of fibroblasts              125 
 
4.5. Limitations of study             126 
 
4.6. Future work              127
   
4.7. Concluding remarks             132 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
114 
 
In the present study we had hypothesized that mitochondrial dysfunction plays a critical role in our 
South African PD patients with parkin mutations. Using western blots we verified that parkin protein 
was absent in the patient fibroblasts. We investigated whether there was evidence for mitochondrial 
dysfunction in these patients using a range of different experimental procedures. The TEM analysis 
of fibroblasts noted in one patient (patient P2) high levels of electron dense cellular vacuoles 
surrounding the mitochondria, suggestive of possible mitophagy. Also, the mitochondrial network 
appeared extensively damaged and fragmented in that particular patient.  In muscle cells, subtle 
defects (accumulation of lipids, wrinkling of the sarcoplasmic membrane, presence of type II fibres 
and the presence of atrophic fibres) were observed in all three patients but particularly in the oldest 
patient (patient P3.1). This patient also had slightly more prominent and enlarged mitochondria. 
 
Three of the four patients exhibited increased mitochondrial ROS levels compared to the control. 
Furthermore, a number of electron transport chain genes were down-regulated, in particular CYC1, 
BCS1L, NDUFS2 and LHPP which were found to be down-regulated in all three probands. Lastly, in 
the pilot study performed on the proteome of fibroblasts a total of 688 proteins were present in the 
control and not in the patients. IPA analysis revealed that 14 of these proteins were part of the 
‘mitochondrial dysfunction’ pathway which further implicates this process in the pathogenesis of PD. 
 
4.1. Changes in the mitochondrial morphology and network of the 
patients 
 
 
Structural analysis of the mitochondrion allows one to identify defects which could impair 
mitochondrial function, and this could ultimately affect the overall cellular function. Mitochondrial 
structure assessment should include several parameters, such as the overall size and shape of the 
mitochondria, the appearance of the cristae and the mitochondrial membrane, the electron density 
which provides a basic impression of the level of oxidative phosphorylation occurring within the 
organelle, and the presence of glycogen or lipids in the matrix of the mitochondria. Analysis of the 
cellular structure can also provide an indication of dysfunctional mitochondria, such as the presence 
of certain enzymes and lysosomal vacuoles, the fibre type when focusing on muscle cells, as well as 
the occurrence of mitochondrial fusion and/or fission through analysis of the cellular mitochondrial 
network. 
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Animal models are used to investigate a number of aspects of PD, such as cause, treatment or gene 
expression. Studies on mitochondrial morphology in animal models of parkin knockouts have yielded 
contradicting results – Drosophila parkin knockout models show mitochondrial pathology as the 
earliest manifestation of muscle degeneration (Greene et al., 2003; Pesah et al., 2004), observing an 
increase in vacuole number, cellular debris, with irregular myofibrillar arrangement of the muscle 
cells and swollen mitochondria with disintegrated cristae. In comparison, no mitochondrial 
morphological defects were seen in parkin knockout mice models (Palacino et al., 2004), with both 
knockouts and controls exhibiting well-formed mitochondrial membranes and intact, discernible 
cristae. A possible reason for the differences observed in these two animal models may be due to 
the differences in the genome of each species. Approximately 60 percent of genes are conserved 
between the Drosophila and humans (Adams et al., 2000). Comparatively, the mice genome shares 
approximately 85 percent of the human genome, although there is a high level of variation from 
gene to gene. Although these models are advantageous in investigating PD, these conflicting findings 
suggest that human studies are essential in determining the precise mechanisms involved in the 
disorder. In humans, relatively few morphological studies have been performed to date on tissues 
obtained from parkin patients (who are in essence ‘parkin knockouts’). Although these human 
studies have provided interesting insights, the findings have also been conflicting (Grünewald et al., 
2010; Hanagasi et al. 2009; Mortiboys et al., 2008; Pacelli et al., 2011). 
 
In the present study the results from the analysis of mitochondrial morphology in the muscle 
biopsies varied between the three patients (Table 3.3) but most obvious were the lack of ragged red 
fibres (RRFs). RRFs have been observed in various mitochondrial diseases such as MERRF (Berkovic et 
al., 1989), and are one of the strongest indicators of severe mitochondrial dysfunction in muscle 
cells. The generation of these fibres indicates abnormal proliferation and sub-sarcolemmal 
accumulations of mitochondria. Other reports on muscle biopsies of parkin patients are rare. One 
study done on a 53 year old male with a homozygous parkin deletion at the exon9/intron9 boundary 
observed a few ragged red fibres and an abundance of cytochrome oxidase negative fibres (Hanagasi 
et al. 2009). Although no RRFs were observed in our patients, sub-sarcolemmal aggregates of normal 
mitochondria associated with increased lipid content were noted. This could suggest that 
mitochondrial dysfunction is at an initial phase of accumulation, and that RRFs may present in the 
future in these patients. 
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Despite the lack of RRFs in the patients’ muscle cells, an abundance of type II muscle fibres were 
observed in patient P3.1, as well as grouping of these fibres in patients P2 and P3.1. Type II fibres are 
fast twitch muscle fibres that utilize anaerobic metabolism (i.e. glycolysis) to produce energy .The 
increased presence and grouping of type II fibres suggests that the majority of the ATP produced in 
these cells is via glycolysis (which occurs outside the mitochondria in the cytoplasm of the cell) and 
not via oxidative phosphorylation. This could indicate that there is a possible defect in the 
mitochondrial electron transport chain in these cells and the grouping of the type II fibres may be a 
compensatory mechanism to produce ATP. Although no work has been published regarding the 
presence of type II fibres in the muscle of PD patients, previous studies done on fibre type and 
ageing show increased grouping of type II fibres as the age of the individuals increases (Brunner et 
al., 2007; Fayet et al., 2001) as well as an increase in lipid droplets in the muscle fibres (Poggi et al., 
1987). All studies observed these changes in individuals over the age of 50 years. The patients 
recruited for this study are 50 years and younger (Table 2.1), so the fibre grouping observed appears 
to indicate premature ageing possibly due to the parkin mutation.   
 
Muscle biopsies that were performed on 13 healthy elderly individuals (66 – 77 years of age) and 15 
healthy younger individuals (23-37 years of age) revealed scattered atrophic fibres, collections of 
lipofuscin, and wrinkling of the sarcolemmal membranes only in the elderly group of patients 
(Jakobsson et al., 1990). The observation of sarcolemmal membrane wrinkling in patients P1, P2 and 
P3.1, as well as scattered atrophic fibres in patients P1 and P3.1 and lipofuscin in patient P3.1 is 
additional evidence of premature ageing of the muscle cells, as all three individuals are aged 38 
years, 37 years and 50 years respectively, and show similar muscle morphology to individuals over 
the age of 66. It would be interesting to examine muscle cells of pre-symptomatic parkin-null 
patients to see whether these individuals also show evidence of premature ageing. 
 
In addition, lipid droplets were also observed in two of our patients (patient P1 and P3.1). The 
presence of increased lipids in the mitochondria may lead to the process of lipid peroxidation – 
whereby free radicals such as ROS degrade excess lipids in order to scavenge the electrons from 
these fatty deposits. Excessive lipid peroxidation could result in cell membrane damage and cell 
death if toxic end products are produced, possibly contributing to neuronal cell death found in PD. 
Lipid accumulation and peroxidation have been observed in the brains of patients with PD (Dexter et 
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al., 1989), however the presence of lipids in cells other than neurons is unreported, and there have 
been no studies to show the presence of lipids in muscle cells of parkin-positive PD patients. 
Therefore, at this stage it is not certain that lipid peroxidation is occurring in the muscle cells of 
these patients, although it could be speculated that the subtle mitochondrial structural changes 
observed may cause altered metabolic reactions that could lead to eventual cellular death.  
 
In the present study, we also investigated mitochondrial morphology and function in fibroblasts 
cultured from skin biopsies of our patients. Ideally, neurons from the SNc should be chosen as the 
main cell type for studies on PD; however these cells can only be obtained post mortem. 
Morphological and functional studies have been performed on skin fibroblasts of PD patients and 
have noted similar results to that observed in post mortem brain tissue (Wiedemann et al., 1999; 
Hoepken et al., 2007;  Mortiboys et al., 2008; Grünewald et al., 2010; Pacelli et al., 2011). Recently, it 
has been stated that fibroblasts serve as a useful primary PD cell model (Auburger et al., 2012). 
Expression levels of both parkin and PINK1 genes are at relevant levels in fibroblasts. Several 
advantages of using skin fibroblasts as a cell model include the following (Auburger et al., 2012): 
 
 Relative ease of availability (fibroblasts can be easily isolated from a skin biopsy) 
 Robustness in culture, storage and transport 
 Reflect cumulative cellular damage according to the age of the patient 
 Expression of most of the PD genes are at relatively high expression levels  
 Fibroblasts can be immortalized (i.e. they avoid apoptosis) and can therefore proliferate faster 
than primary cells, producing far more cells than any other cell line would in the same amount 
of time 
 
Disadvantages of fibroblasts use may be the length of culture time (can only culture after passage 3) 
specifically in older cells, contaminations are frequent, and fibroblasts are resistant to stressors 
(Auburger et al., 2012). However a study performed on parkin-null fibroblasts used paraquat as a 
stressor and observed relative changes in both control and patient cells (Grünewald et al., 2010).  
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The TEM results of fibroblasts obtained from patients P3.1 and P3.2 show rod-shaped and round 
mitochondria with normally arranged cristae. In comparison, several cells from patient P2 exhibited 
a mixture of rod-shaped and circular mitochondria that appeared swollen. A recent study on parkin-
null fibroblasts showed swollen mitochondria of an irregular shape, with few remaining cristae 
(Pacelli et al., 2011). Except for their study, no other studies to date have been performed using TEM 
to analyse the mitochondrial morphology in parkin-null patient fibroblasts. 
 
Interestingly, in patient P2 cells there were numerous autophagic vacuoles filled with dark material 
of an unknown source. Cellular vacuoles are generally filled with water containing enzymes in 
solution, and function as exporters of waste in the cell. It can be speculated that these vacuoles (or 
autophagosomes) are filled with cellular material such as accumulated proteins or damaged 
mitochondria which are accumulating due to the absence of parkin. An alternative hypothesis is that 
filled autophagic vacuoles are present as a precursor for cellular apoptosis. The accumulation of 
these vacuoles is dependent on a receptor-interacting protein that is associated with a death 
receptor and caspase 8 – which initiate apoptosis (Codogno & Meijer, 2005). Electron dense 
vacuoles had previously been observed in PD parkin-positive patient fibroblasts (Pacelli et al., 2011), 
similar to that found in patient P2 and P3.1. Pacelli and colleagues speculated that this material 
degraded mitochondria that have been engorged via the process of mitophagy. However, it cannot 
be stated unequivocally that mitophagy is occurring in these cells as the electron dense vacuoles 
observed may also be due to lysosomal digestion of cellular debris, and thus increased autophagy. 
Further analysis of the material inside these vacuoles is needed before conclusions can be formed. 
 
Subsequent to the observation of mitochondrial fusion in the TEM of the fibroblasts, the cellular 
mitochondria were stained in order to investigate the mitochondrial network. Tubular networks are 
formed by the mitochondria in order to promote cell survival and maintain healthy mitochondria. 
This network is developed through the processes of fusion and fission. Although both processes are 
vital in maintenance of mitochondrial function, fusion protects function whereas fission isolates 
damaged mitochondria for autophagy (Chen & Chan, 2009). Therefore, in cells where fission is 
prominent, damaged mitochondria are in the majority. A study on fibroblasts of two siblings with 
PD, both with homozygous parkin mutations, showed fragmented mitochondria in both patients, 
which indicates fission and damaged mitochondria (Pacelli et al., 2011). In the present study, patient 
P2, and to a lesser degree patient P3.1, exhibited a mitochondrial network showing dot-like staining 
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indicating fission and extensive fragmentation. It could be speculated that the electron dense 
material observed in this patients autophagosomes are these damaged mitochondria that have been 
tagged for degradation during fission. 
 
No studies to date have been reported on mitochondrial morphology of unaffected parkin 
heterozygous family members of PD patients. In our study, individual P2het showed high degrees of 
fragmentation in the mitochondrial network, whereas P3het exhibited a normal mitochondrial 
network.  In recent years, it has been discovered that mitochondrial fragmentation, along with 
cristae remodelling, plays an important role in the initiation and execution of the death cascade that 
results in cellular apoptosis (Chang & Blackstone, 2010; Heath-Engel & Shore, 2006; Perfettini et al., 
2005). It has also been observed that fragmented mitochondria are removed by mitophagy before 
apoptosis is induced (Kim et al., 2007). Mitochondrial dysfunction has also been linked to ageing (Lin 
& Beal, 2006) through various functional aspects such as a decrease in ATP production or an increase 
in ROS production. It is now thought that control of apoptosis by mitochondria (through 
mitochondrial fragmentation) can also contribute to the decline in function of long-lived cells, 
resulting in ageing. We therefore speculate that the fragmentation observed in carrier P2het could 
be due to her increased age (65 years) compared to P3het (54 years; Table 2.1). 
 
Taken together, our findings suggest that patients with parkin –null mutations have an accumulation 
of damaged mitochondria similar to that seen in the cells of aged individuals. Parkin is known to tag 
damaged and dysfunctional proteins in the cells for degradation, and therefore a lack of parkin 
results in accumulation of these proteins. It is possible that parkin acts in the same way on 
mitochondria, and without parkin, these damaged mitochondria accumulate and result in an 
increased cellular toxicity possibly through a higher level of ROS production, eventually leading to 
apoptosis.  
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4.2. Increase in mitochondrial ROS levels in three patients 
 
We investigated whether the subtle changes observed in the mitochondrial structure would 
influence the bioenergetics metabolism. Functional analysis was determined by the measurement of 
ROS from i) the mitochondria and ii) the cytosol in patient fibroblasts and compared to that of the 
carriers and the wild-type control. Ideally, mitochondrial complex activity and ATP production should 
also be measured, however due to unavailability of equipment in our laboratory and the lack of 
suitable collaborators in the country, only ROS analysis was performed to analyse the mitochondrial 
function. By staining the mitochondrial ROS and generic ROS with two different fluorochromes these 
could be distinguished from each other. 
 
The results were inconclusive regarding generic ROS, with patient P3.1 exhibiting levels higher than 
the control and heterozygote, whereas patients P2 and P3.2 had lower levels compared to the 
control. Although lymphocytes were used instead of fibroblasts for patient P1, results from generic 
ROS studies on this patient found higher levels in the patient compared to the control. Therefore in 
summary, two patients exhibited higher generic ROS levels, and two patients exhibited lower generic 
ROS levels compared to the wild-type control. Although mitochondrial generation of ROS is one the 
cell’s primary sources of ROS, oxidation and reduction reactions that produce ROS continuously 
occur in the cytoplasm. There are also various external environmental ROS sources such as exposure 
to radiation and infections that can also increase the levels of generic ROS (Kregel & Zhang, 2007). 
This may be a reason why conflicting results were obtained as generic ROS levels are influenced by a 
number of external factors such as a different genetic make-up, environment and lifestyle. It is 
therefore more important to specifically analyse mitochondrial ROS levels to assess mitochondrial 
function. 
 
The results from the mitochondrial ROS analysis showed that three of the patients exhibited higher 
levels than the control and heterozygotes. This fits in with our hypothesis that the cells are 
experiencing oxidative stress. Notably, the patient (P2) with the highest level of mitochondrial ROS 
also exhibited highly electron dense vacuoles and a fragmented mitochondrial network. Previous 
studies performed on PINK1 knockout mice and PINK1-mutant PD patients have found an increased 
level of oxidative stress compared to controls (Gautier et al., 2008; Grünewald et al., 2009). Another 
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study analysing LRRK2 mutant fibroblasts found a significant increase in intracellular ROS levels in 
the patients (Wang et al., 2012), although these results have been contradicting (Papkovskaia et al., 
2012). Similarly, parkin-mutant PD patient fibroblasts have also shown to have a higher level of 
oxidative stress under basal conditions (Grünewald et al., 2010) when analysing the cells with an 
OxyBlot. Pacelli and colleagues found a significant increase in generic ROS production in two PD 
patients with parkin mutations by analysing the fluorescence intensity of DCF, the oxidation-
sensitive staining dye used to measure generic ROS (Pacelli et al., 2011). Our study was unique in the 
fact that we measured both generic ROS as well as mitochondrial ROS. 
 
One of our patients P3.2 showed decreased levels of mitochondrial ROS. Interestingly patient P3.2 
was also the only patient that did not exhibit any features of mitochondrial network fragmentation. 
A possible reason for this may be that this patient has an underlying compensatory mechanism that 
is able to protect the mitochondria in fibroblasts tissue. Further tests need to be performed 
regarding mitochondrial function, such as determining complex activity and levels of ATP 
production, before conclusions can be drawn regarding the mitochondrial function in parkin-null PD 
patients. Also, these analyses should be performed in triplicate, as technical repeats as well as 
biological repeats are necessary for the validation of all results. 
 
In other studies on parkin-mutant patients, alterations in mitochondrial function in several 
categories were detected – namely complex activity, respiration rates, ATP production and cellular 
content, mitochondrial membrane potential and levels of antioxidants e.g. glutathione reductase, 
glutathione peroxidase and catalase. Significantly decreased complex I activity and respiration rates, 
lower mitochondrial membrane potential, and lower antioxidant levels were observed in some 
patients from previous studies(Mortiboys et al., 2008;  Pacelli et al., 2011).  However, results were 
contradictory with regard to ATP cellular levels, with some studies revealing a decrease in ATP 
synthesis rates and ATP levels (Grünewald et al., 2010; Mortiboys et al., 2008)and others revealing a 
significantly higher ATP content in patient cells, due to possible compensation by the glycolytic 
pathway (Pacelli et al., 2011).  
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4.3. Down-regulation of genes involved in  mitochondrial electron 
transport 
 
Analysis of gene expression in mRNA allows for the identification of changes in pathways that may 
provide clues to the pathogenesis of a disease. In PD, the majority of gene expression studies have 
used dopaminergic neurons or substantia nigra (SNc) post mortem tissue (Grünblatt et al., 2004; 
Hauser et al., 2005; Simunovic et al., 2009; Zhang et al., 2005). Due to almost selective loss of 
dopaminergic neurons in the SNc of patients with PD, obtaining brain tissue is essential in assessing 
the physiological events that cause the disease. Marked expression changes in genes involved in 
energy metabolism were observed in these studies. Analysis of gene expression levels has also been 
done in other tissues, including whole blood (Scherzer et al., 2007) and fibroblasts (Pacelli et al., 
2011). These two tissue types are far easier to obtain due to the non-invasive procedures of 
specimen retrieval, however whole blood is preferable as artifacts in gene expression can be induced 
during cell culturing (Whitney et al., 2003). In the present study, we therefore used whole blood for 
the gene expression experiments.  
 
For any analysis of gene expression levels, the highest possible quality of RNA is necessary for 
reproducible results. RNA quality can be measured through two parameters – the purification of the 
sample and the integrity (or degradation status) of the RNA (Bustin & Nolan, 2009). Based on several 
analyses of RNA quality determination methods, the spectrophotometric measurement is not a 
reliable measure of sample quality as it does not reveal a degradation state. Alternatively, the use of 
an electropherogram (such as the Experion Std Sense Analyser) allows for a more objective measure 
of RNA quality by the measure of several characteristics which determine the RQI value (Denisov et 
al., 2008). A RQI value of 8 or higher has been deemed as acceptable for use in gene expression 
studies (Fleige & Pfaffl, 2006). The RNA samples that were used in the present study all had RQI 
values of >8. Possible reasons for low RQI values may be due to the presence of inhibitors or 
contaminants in the sample.  
 
For these experiments we selected a pathway-based gene expression PCR Array (SABiosciences, 
USA) that included genes which code for parts of each of the five complexes in the electron 
transport chain. A previous study performed on the same PCR Array on human embryonic stem cells 
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and induced pluripotent stem cells found similar expression in both cell types, but proved that this 
array is useful, precise and efficient when analysing gene expression (Prigione & Adjaye, 2010). 
 
Results from our analysis showed that the expression of the majority of genes (76.2%) remained 
unchanged in the patients. Also, twice the number of genes were down-regulated (16.7%) in 
patients compared to the number of up-regulated genes (7.1%). The majority of these down-
regulated genes code for part of complexes I and III. Six of the 14 down-regulated genes from our 
PCR Array gene expression analysis correlated with the findings observed in a previous meta-analysis 
(Zheng et al., 2010) – namely ATP5G1, ATP5J2, CYC1, NDUFB7, NDUFS1 and UQCRC1. Interestingly, 
two of the 14 genes that our study found to be down-regulated were up-regulated in the meta-
analysis (NDUFS2 and NDUFS7), although only slightly (by a fold change of +0.01 and +0.02 
respectively). Similarly, the genes that our study found up-regulated in the PD patients were all 
down-regulated in the meta-analysis. A possible reason for the differences may be that whilst our 
three patients all had parkin mutations, the tissues used in the previous studies were taken from 
sporadic PD cases.  
 
The Primer Assay (SABiosciences, USA) performed on CYC1 to validate the PCR Array results showed 
no change in expression levels across all four patients. This result suggests that gene expression 
studies using PCR Arrays need to be validated with independent experiments. The use of both 
biological (different samples) and technical (same sample analysed multiple times) replicates in 
Primer Assays may produce more reproducible data than that obtained using PCR Arrays. The 
greater the number of biological and technical repeats, the better the implementation of robust 
statistical methods to select differentially expressed genes (Tan et al., 2003). However, it is possible 
that the results for only the CYC1 gene are not verified in the Primer Assay and analysis of the other 
down-regulated genes is warranted. 
 
A meta-analysis of 17 independent genome-wide expression studies was recently performed (Zheng 
et al., 2010). Included in this analysis were the studies that had been performed on either different 
parts of the brain, the SNc, dopaminergic neurons, and peripheral blood or lymphoblastoid cells. The 
purpose of this study was to combine the results from individual gene expression studies to increase 
the statistical power and precision of pathway associations. Across these studies, the consensus 
appears to be that genes in various processes including mitochondrial electron transport, glucose 
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utilisation and glucose sensing, were under-expressed in PD patients. This down-regulation was 
observed in both brain and blood tissue. In particular they noted PGC-1α-responsive genes were 
under-expressed. PGC-1α is a key regulator of mitochondrial biogenesis and oxidative metabolism. It 
acts as a transcription co-activator, which is a protein that increases the probability of genes to be 
transcribed by interactions with transcription factors (such as the PPARs) involved in biological 
responses (Liang & Ward, 2006). Overexpression of PGC-1α in primary cultures from the midbrain of 
rats that were overexpressing α-synuclein (a model of PD), activated expression of the genes 
encoding the mitochondrial respiratory complexes I, II, IV and V, indicating that PGC-1α expression 
can alleviate the toxic effects of α-synuclein in this cell model (Zheng et al., 2010). Secondly, they 
also found that overexpression of PGC-1α in cells exposed to rotenone activated the expression of 
genes for all five of the respiratory complexes. Interestingly PGC-1α halted dopamine neuron loss in 
both PD models. It can therefore be speculated that the mitochondrial functional loss observed in 
PD patients, such as complex I activity decrease and ROS production increase, could be due to a 
transcriptional defect involving PGC-1α. This knowledge is critical for the development of improved 
therapeutic targets and even prevention of PD. 
 
Pacelli and colleagues investigated regulation of PGC-1α expression in fibroblasts of parkin-null 
patients (Pacelli et al., 2011). Their results showed up-regulation of PGC-1α in both patients 
compared to the control, as well as an increased PGC-1α protein content in the patients. They then 
analysed target genes involved in mitochondrial biogenesis that are all situated downstream of PGC-
1α and found that the genes were generally unchanged (ATPaseβ, COX2) or down-regulated (NRF1, 
NRF2, TFAM, MCAD). This observation suggests that post-translational modifications such as 
phosphorylation, methylation and acetylation are at play that can modulate the PGC-1α activity and 
stability (Pacelli et al., 2011).  
 
PGC-1α knockout animal models have shown up to a 44% decrease in mitochondrial content in 
muscle (Adhihetty et al., 2009) as well as impaired mitochondrial function (Lin et al., 2004). Knockout 
PGC-1α models have also shown a blunted mitochondrial respiration gene expression levels (Arany 
et al., 2005). An example of the mechanism of PGC-1α is the increased transcription of nuclear 
respiratory factor 1 (NRF1) and NRF2, which subsequently leads to increased expression of the 
complexes in the electron transport chain (Scarpulla, 2002). These are just two examples of 
thousands of genes that are activated by PGC-1α. PGC-1α has also been observed to induce 
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antioxidants in response to oxidative stress levels in the cell (St-Pierre et al., 2006), and has also 
been implicated in playing a role in Huntington’s disease when impaired (McGill & Beal, 2006). 
Therefore, PGC-1α has been the focus of several recent studies as a possible therapeutic target in 
neurodegenerative disorders such as PD. 
 
In summary, our results and that of others suggest that some of the electron transport genes may be 
down-regulated in patients with parkin mutations. It is possible that parkin regulates, directly or 
indirectly, the levels of an activator(s) such as PGC-1α, which activates transcription of specific 
components of the electron transport chain. If these findings are verified it could be speculated that 
down-regulation of these genes may lead to impaired oxidative phosphorylation and increased 
mitochondrial ROS ultimately resulting in an accumulation of damaged mitochondria triggering 
apoptosis. 
 
4.4. Proteome of fibroblasts 
 
Western blot analysis was performed to verify the absence of parkin protein in patients with two 
parkin-null mutations. The western blot experiments required extensive optimisation in order to 
identify the correct primary antibody and dilution factor, and fibroblast concentration in these 
experiments. Eventually, the procedure was successful using a monoclonal primary antibody dilution 
of 1:500, a cell lysate concentration of 7µg/µl and a 10% resolving gel solution. Parkin was detected 
at 50kDa in control fibroblasts, but was absent in the patient (with homozygous exon 3 and 4 
deletion) and carrier fibroblasts. This observation is supported by the literature whereby an absence 
of parkin was observed in fibroblasts from patients with similar exonic deletions (Mortiboys et al., 
2008; Pacelli et al., 2011). It could be speculated that the parkin band in the carrier (only one 
functional parkin allele) is present, but the intensity is too low to be visible. However this requires 
further study. 
 
In addition, we analysed the proteome of the fibroblasts in order to answer the following questions: 
Can the gene and protein expression data in the blood and fibroblast tissue be correlated? Also, can 
analysis of the proteome identify possible biological pathways implicated in PD? 
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To answer the first question we compared the gene expression data from the PCR Arrays with the 
proteome data albeit from two different tissue types, which may be problematic. We expected to 
observe the down-regulated gene products in wild-type control but not in patient samples, and the 
up-regulated gene products were expected to be observed in patient samples but not the in control. 
This was not found possibly due to these two tissue types having different expression profiles or 
because the entire fibroblast proteome had not been captured. It is thought that the each individual 
cell contains approximately 10 000 different proteins, such as enzymes, proteins involved in cell 
maintenance, transport, synthesis and various other cellular functions. Therefore, the approximately 
1000 proteins detected in each sample in the present study are likely to be an underestimate. 
However, despite this limitation, IPA analysis of the 688 proteins that were present only in the wild-
type control and not in the two patients identified the ‘mitochondrial dysfunction’ pathway as 
possibly playing a role in the disorder. 
 
4.5. Limitations of study 
 
The current study involves a multi-faceted analysis of parkin-null PD patients regarding 
mitochondrial morphology and function, as well as gene and protein expression. The limitations 
faced in this research project included not being able to utilize all four patients in every section of 
the project due to various reasons. One of the major limitations was the inability to grow up 
fibroblasts from patient P1. This patient was the first of the four to be recruited, and unfortunately 
his skin biopsy was referred to the incorrect laboratory by the doctor who took the biopsy. This 
meant that fibroblasts of patient P1 were not available for the TEM, mitochondrial network, ROS and 
proteome studies, for comparison with the other patients. Although white blood cells from patient 
P1 were used for ROS measurements, this in itself was a limitation as results should not be 
compared across different tissue types.  
 
Financial restraints also proved to be a limitation in parts of this study. Due to the cost of the RT² 
Profiler PCR Array, only the three probands could be used for gene expression analysis. Also, we 
were unable to perform exon dosage experiments on the controls. Due to financial constraints, the 
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MLPA kits needed for this procedure were not available. Also, although wild-type controls were age-
matched to patients P1 and P2, they were not age-matched to patients P3.1 and P3.2.  
 
The mitochondrial functional studies were limited to the analysis of ROS levels in this study. A better 
assessment of mitochondrial function should have included respiratory complex activities and 
mitochondrial ATP production and levels. However, during the course of the study, attempts to find 
the necessary equipment (oxygraph) and expertise were unsuccessful.  
 
Although the proteome analysis was a pilot study as no previous studies have been reported on the 
proteome of parkin-null patients, this work has also had a number of limitations. Firstly, we did not 
include technical replicates of the runs on the Orbitrap. Secondly, we did not fractionate the samples 
on a PAGE gel before analysis on the Orbitrap. Instead we used the cell lysate solution in a single 
run, and this identified only approximately 1000 proteins, whereas if we had run a fractionated 
sample then we may have been able to detect up to 5000 proteins. And thirdly, not all four of the 
patients had been analysed using this technique. 
 
Finally, another shortcoming of this particular study was the use of fibroblasts of the patients to 
study mechanisms underlying PD. Fibroblasts have been used by numerous groups to study this 
disorder and has been shown to be a good cell model albeit with some drawbacks (Auburger et al., 
2012). This may explain why some of the defects found were not consistent across all four patients 
as the experiments were not done on the tissue affected by PD – substantia nigral neuronal tissue.    
 
4.6. Future work 
 
A summary of previous work and recommended future work in relation to the findings of the 
present study is shown in Table 4.1.  
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One of the primary aims for future work is to investigate all aspects of mitochondrial function in 
fibroblasts of all four parkin-null patients. This will involve the analysis of all five respiratory chain 
complex activities through the use of an oxygraph, via collaboration with either a laboratory within 
South Africa, or an international collaboration where this method has been utilized. In addition, the 
levels of cellular ATP content should be measured for each patient, heterozygous carrier and control. 
Subsequently, several other functional aspects can also be investigated in patient fibroblasts. These 
include: mitochondrial membrane potential, cellular membrane integrity, viability and apoptosis 
analysis as well as patient and control fibroblasts growth rate in different media e.g. glucose and 
galactose. It is vital to analysis the apoptotic pathways in greater detail, to identify possible links 
between PD patients with mitochondrial fragmentation and apoptosis. Furthermore, building on the 
work on ROS levels, it would be appropriate to perform a study on the antioxidant capacity in these 
patients. Although several of these experiments have been performed by other groups (Table 4.1), 
the findings are equivocal, indicating that future work on mitochondrial function of parkin-null 
patients including a large number of biological and technical replicates, are necessary.  
 
On a structural level, this study covered mitochondrial morphological analysis on both muscle and 
skin biopsies of parkin-null patients. Until dopaminergic neurons from SNc of these patients are 
available to us post-mortem, these TEM results are the best that we can expect to obtain with 
regards to the effect of parkin on mitochondrial structure. Future work to determine the 
compositions of the electron dense vacuoles could include ultracryomicrotomy and electron probe 
x-ray microanalysis, and to determine whether mitophagy is occurring within the cell we could label 
the mitochondria with live cell imaging. Measurement of mitochondrial length and mass should also 
be performed on patients and fibroblasts in the future. Also, future work should include quantitative 
analysis of the mitochondrial network. Other groups have analysed mitochondrial networks by the 
calculation of a ‘form factor’ (Table 4.1), whereby mitochondrial area and outline are measured. The 
form factor allows for quantification of the degree of branching of the mitochondrial network 
relative to a control.  
 
In terms of future work regarding gene expression levels, other pathway focused PCR Array options 
include catalogued arrays for Apoptosis, Autophagy, Mitochondria and Oxidative Stress 
(http://www.sabiosciences.com/ ). Also, a customized plate can be designed with genes of interest 
selected to study the effect of parkin on the mitochondria. An interesting approach would be 
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analysis of the expression level of the genes involved in mitochondrial fusion (Mfn1, Mfn2, Opa1) 
and fission (Drp1 and Fis1), as well as the expression of the genes that operate upstream from PGC-
1α, as was performed by Pacelli and colleagues (Pacelli et al., 2011; Table 4.1). More importantly, 
however, will be to perform the expression studies with a larger number of biological and technical 
repeats than were previously used. Proteome expression studies should be extended by performing 
all of the runs on the LTQ Velos Orbitrap in triplicate at the same time for more accurate results.  
 
Inclusion of stressors is another important factor that should be included in the design of future 
studies. A study performed by Grunewald and colleagues analysed fibroblasts from parkin-null 
patients and controls under two conditions: i) basal conditions and ii) oxidative stress conditions 
induced by the herbicide paraquat (Grünewald et al., 2010; Table 4.1). Future work planned should 
therefore involve the addition of a stressor (such a rotenone, paraquat or H₂O₂) to the cells, to 
observe the effect on growth rate, cell viability, mitochondrial structure and function and gene and 
protein expression.  
 
As parkin and PINK1 have been shown to function in a common pathway (Dagda et al., 2009; Park et 
al., 2006; Silvestri et al., 2005), we had initially planned to include a PINK1-null patient in the present 
study but that had proven unsuccessful as this patient was too ill to travel to Cape Town. For future 
studies we will attempt to obtain a muscle biopsy, skin biopsy and peripheral blood sample from this 
patient and her two siblings, who also have PINK1-null mutations. With this we can then repeat the 
experimental approach taken in this study (Table 4.1), and compare the results between these two 
genes, to gain a better understanding of the disease process. Ideally, the effect of all the PD genes 
on the mitochondria should be assessed.  Continued patient recruitment and mutation screening is 
necessary to identify PD patients with mutations in a range of different genes. This will facilitate a 
comprehensive and systematic well-designed study on the pathobiology of PD.  
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STRUCTURAL ANALYSIS 
 Previous work The present study Recommended future work 
Mitochondrial morphology in 
muscle 
Hanagasi et al. 2009: 
 Ragged red fibres 
 Cytochrome oxidase negative fibres 
 No ragged red fibres 
 Increased lipid content 
 Wrinkling of sarcoplasmic membrane 
 Atrophic fibres 
 Type II fibre grouping 
 Subtle mitochondrial abnormalities 
 Measurement of mitochondrial 
length and mass 
 PINK1-null patients muscle biopsy 
for histological and TEM analysis  
Mitochondrial morphology in 
fibroblasts 
Pacelli et al. 2011: 
 Swollen mitochondria 
 Electron dense lysosomal vacuoles 
 Few remaining cristae 
 Decreased electron dense mitochondrial 
matrix 
 Normal rod-like shaped mitochondria 
 Slightly swollen, circular mitochondria in 
one patient 
 Electron dense autophagosomes 
 Measurement of mitochondrial 
length and mass 
 PINK1-null patients skin biopsy for 
TEM analysis 
Mitochondrial network analysis 
Mortiboys et al. 2008: 
 Fragmented mitochondria in control, not 
patients 
 Analysed by form factor 
Grunewald et al. 2010: 
 No change at basal conditions 
 Fragmentation of patients after induction 
of oxidative stress 
 Analysed by form factor 
Pacelli et al. 2011: 
 Fragmented mitochondria in patients 
 Studied patients and heterozygotes  
 Fragmented network in two out of three 
patients 
 Fragmented network in one out of two 
heterozygotes 
 Analyse network results via 
calculation of form factor 
 Perform network analysis and form 
factor calculations on PINK1-null 
patient fibroblasts 
FUNCTIONAL ANALYSIS 
 Previous work The present study Recommended future work 
ROS measurements 
Grunewald et al. 2010: 
 Higher level of oxidative stress in patient 
cells under basal conditions 
Pacelli et al. 2011: 
 Increased generic ROS in patients 
 Lower antioxidant levels in patients 
 Higher mitochondrial ROS levels in three 
out of four patients 
 No correlation with generic ROS levels 
 Analyse antioxidant capacity in 
patient fibroblasts 
 Perform ROS and antioxidant 
studies on PINK1-null fibroblasts 
Table 4.1: A comparison of previous, current and recommended future work on parkin-null PD patients to investigate mitochondrial                   
dysfunction. Recommended future work on PINK1-positive patients in pink font 
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Complex activity 
Mortiboys et al. 2008: 
 Decrease in complex I in patients 
 No change in other complexes 
Grunewald et al. 2010: 
 No change in complex activity 
Pacelli et al. 2011: 
 Decrease in complex’s I & IV in patients 
Not done  Analyse activity levels of all five 
complexes in parkin-positive and 
PINK1-null patients using an 
oxygraph 
 
ATP levels 
Mortiboys et al. 2008: 
 Decrease in ATP synthesis rates & ATP 
levels in patients 
Grunewald et al. 2010: 
 Decrease in ATP synthesis rates & ATP 
levels in patients 
Pacelli et al. 2011: 
 Decrease in ATP content in patients 
Not done  Analyse ATP synthesis rates and ATP 
content in parkin-positive and 
PINK1-null patients 
Mitochondrial membrane 
potential 
Mortiboys et al. 2008: 
 Decrease in patients 
Grunewald et al. 2010: 
 Decrease in patients AFTER oxidative stress 
insult 
Not done  Analyse mitochondrial membrane 
potential in parkin-positive and 
PINK1-null patients 
EXPRESSION STUDIES 
 Previous work The present study Recommended future work 
Gene expression analysis 
Zheng et al. 2010: 
 Down-regulation of electron transport 
genes 
Pacelli et al. 2011: 
 Up-regulation of PGC-1α 
 Down-regulation of  genes situated 
upstream of  PGC-1α 
 Up – and Down-regulation of 
mitochondrial energy metabolism genes in 
three patients 
 More genes down-regulated than up-
regulated 
 Analysis of expression levels in 
genes associated with 
mitochondria, oxidative stress, 
apoptosis and autophagy 
 Analysis of mitochondrial energy 
metabolism genes in PINK1-
nullpatients 
Proteome analysis 
Not done  A total of 688 proteins found only in 
control and not in two PD patients 
 Mitochondrial dysfunction pathway 
implicated 
 Analyse proteome of PINK1-null 
patients 
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4.7. Concluding remarks 
 
In conclusion, the present study has elucidated on possible disease mechanisms in parkin-null PD 
patients. Increased levels of mitochondrial-produced ROS, as well as subtle changes in the 
mitochondrial structure such as type II fibre grouping, indicate a dysfunctional oxidative 
phosphorylation system, and a possible compensation for ATP production via glycolysis. This 
conclusion is further supported by the observation of down-regulation of electron transport genes in 
four of the five complexes. This work also supports and builds on the observations in several other 
studies of the effect of parkin mutations on the mitochondria, and although these studies appear 
contradicting, it can be concluded that parkin is vital in the correct functioning of the mitochondria.  
 
Based on the results obtained in the present study, a model of the disease process is proposed and 
this is shown in Figure 4.1. Figure 4.1A represents the cell with wild-type parkin and Figure 4.1B 
when parkin is mutated. We speculate that parkin-null mutations lead to no parkin protein being 
produced. This leads to down-regulation of the mitochondrial electron transport genes which in turn 
causes a decrease in ATP and concomitant increased mitochondrial ROS levels. Increased ROS 
damages the mitochondria, which initially is cleared by mitophagy. Eventually, these and other 
compensatory mechanisms fail as more and more damaged mitochondria accumulate and this 
triggers the apoptotic pathway, eventually resulting in cell death. Future work will be vital in 
continuing the quest to understand the mechanisms underlying this debilitating disorder. By piecing 
together all the parts of the puzzle it is hoped that this will lead to development of neuroprotective 
strategies or ultimately a cure for not only PD but also many other neurodegenerative disorders. 
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A: Wild-type parkin 
Wild-type parkin 
Parkin protein 
Normal regulation of mitochondrial 
electron transport chain genes 
Normal levels of 
mitochondrial ROS 
Healthy mitochondria 
Normal levels of 
lipid molecules 
Normal mitochondrial 
network 
Clear vacuoles; normal 
levels of autophagy/ 
mitophagy 
A: Wild-type    
parkin 
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Deletions in parkin 
No parkin 
protein 
Down-regulation of mitochondrial 
electron transport chain genes 
Slightly enlarged, 
swollen mitochondria 
Increased levels of 
mitochondrial ROS Increased presence 
of lipids 
Fragmented 
mitochondrial network 
Numerous electron dense 
autolysosomes removing 
damaged mitochondria from 
cell 
Wrinkling of cell 
membrane & premature 
ageing of the cell 
Cell death via apoptosis 
B: PD patients with two 
parkin-null mutations 
Figure 4.1: Proposed model of the effects of parkin in a fibroblast or muscle cell in A: wild-type control and B: parkin-null PD patients 
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APPENDIX I 
Figures of genes known to cause PD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: SNCA 
B: LRRK2 
C: parkin 
D: PINK1 
E: DJ-1 
F: ATP13A2 
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APPENDIX II 
 
Solutions for various techniques used in the present study 
 
 Sodium Borate (SB) buffer (20x stock) 
38.137g Na₂B₄O₇ (di-sodium tetraborate decahydrate) dissolved in 1L distilled water 
 1x SB running buffer (Agarose gel electrophoresis): 
Dilute 100ml of 20x SB buffer in 2L distilled water 
 
 Bromophenol Blue Loading Dye 
0.2% (w/v) bromophenol blue 
50% glycerol 
10mM TRIS 
Add all above reagents and place on magnetic stirrer until properly mixed 
 
 10x TBE 
216g Trizma Base 
110g Boric Acid 
18.6g Sodium-EDTA 
 1x TBE Buffer (PAGE) 
Dilute 50ml of 10x TBE Buffer in 450ml distilled water 
 
Lysis of fibroblasts and Bradford protein concentration determination 
 
 PBS (Phosphate Buffer Saline) 
1 PBS tablet (Sigma, Germany) 
200ml ddH₂O 
Dissolve tablet in ddH₂O 
Store solution at 0-5°C 
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 IGFIR lysis buffer 
50mM Hepes 
100mM NaCl 
10mM EDTA 
1% Triton X-100 
4mM NaPPi 
2mM Na₃VO₄ 
H₂O 
pH 7.5 
 
Cell lysis buffer 
5ml IGFIR lysis buffer  
100µl 50mM PMSF 
¼ protease inhibitor tablet (Roche diagnostics, Germany). 
 
 Bradford reagent 
100mg Coomassie Brilliant Blue 
100ml Phosphoric acid 
50ml 95% ethanol 
Dilute Coomassie Brilliant Blue in phosphoric acid and then add ethanol. 
Make up to 1L with ddH₂O, stir. 
Filter 2-5X until solution has light brown colour. 
Store at room temperature in light proof container. 
 
 
Western Blot gel preparation 
 
 Resolving gel 
100µl 10% SDS  
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1.25ml Resolving buffer 
3ml 40% acrylamide (Promega, Madison Wisconsin, USA) 
75µl 10% APS (Ammonium-Perox-disulphate) 
5µl TEMED (Tertramethylethylenediamine) (Sigma, Germany) 
5.57ml ddH₂O 
 
 Stacking gel  
40µl 10% SDS 
1ml Stacking buffer 
0.39ml 40% acrylamide (Promega, Madison Wisconsin, USA) 
30µl 10% APS (Ammonium-Perox-Disulfate) 
6µl TEMED (Tertramethylethylenediamine) (Sigma, Germany) 
2.56ml ddH₂O 
 
 Resolving Gel Buffer (4X) 
109.2g Tris base 
330ml ddH₂O 
24ml 10% SDS 
pH to 8.8 using 1M HCl 
Make up to 600ml using ddH₂O 
 
 Stacking Gel Buffer (4X) 
36.3g Tris base 
330ml ddH₂O 
24ml 10% SDS 
pH to 6.8 using 1M HCl 
Make up to 600ml using ddH₂O 
 
 10x SDS Running Buffer 
30g Tris base 
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144g Glycine 
100ml 10% SDS 
ddH₂O to a final volume of 1L 
 1x SDS Running Buffer 
Dilute 100ml 10x SDS Running Buffer in 900ml distilled water 
 
 SDS loading dye 
1M Tris-HCl (50mM, pH 6.8) 
100mM DTT 
2% SDS 
0.1% Bromophenol Blue 
10% Glycerol 
 
 Transfer Buffer 
3.03g Tris base 
14.4g Glycine (192mM) 
200ml Methanol 
ddH₂O to a final volume of 1L 
 
 Milk for membrane blocking 
10g milk powder 
200ml TBST 
Mixed together and placed on magnetic stirrer until powder dissolved 
 
 TBST 
8g NaCl 
20ml 1M Tris-HCl (pH 7.6) 
1ml Tween 20 
pH 7.6 
ddH₂O to a final volume of 1L  
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APPENDIX III 
Laboratory protocols 
 
A. DNA isolation from blood  
 
Four 5ml blood samples in EDTA tubes were aliquoted into 2 sterile 50ml tubes. These were then 
filled to the 45ml mark with cold cell lysis buffer. Each tube was then well shaken and left on ice for 
10 minutes. The tubes were shaken again, after which cells were pelleted by spinning at 3000rpm for 
10 minutes. The supernatant was then poured off. 
 
The wash with the cell lysis buffer was repeated. A volume of 900µl sodium acetate (3M solution) 
and 100µl of 10% sodium dodecyl sulfate (SDS) should then be added to each pellet. The pellet was 
resuspended in this solution and 100µl of proteinase K was added to each tube. The mixture was 
then incubated at 37C overnight. 
 
The following day, 2ml of distilled water and 500µl of 3M Na-acetate was added to each tube, after 
which the solution was mixed. A volume of 2,5ml of phenol-chloroform was added to each tube and 
the mixture shaken on a shaking platform at room temperature. The mixture was then transferred to 
a 10ml glass Corex tube and spun at 7000rpm for 12 minutes at a temperature of between 4 C and 
10 C. The supernatant was then transferred to a clean Corex tube without disturbing the 
interphase. Thereafter, 2,5 ml octonal-chloroform was added to each tube. The tubes were sealed 
tightly and slowly mixed by inversion until the mixture turned milky. The tubes were then 
centrifuged without lids at 7000 rpm for 10 minutes in a Sorval centrifuge at a temperature of 
between 4C and 10 C. The supernatant was poured into a 12ml plastic tube, and 5-7ml ethanol 
was slowly added. The tube was then closed and mixed until the DNA precipitated.  
 
The DNA was transferred to a 1,5ml Eppendorf tube, which was filled with 70% ethanol and 
centrifuged at 14000rpm for 3 minutes. The supernatant was poured off and the wash was 
repeated. The pellet was then dried at room temperature for 30 minutes, after which 500µl of a 1x 
Tris-EDTA solution was added to each tube. The tubes were incubated overnight at 37C. Thereafter, 
the solutions were mixed for three days on a rotating wheel at 30rpm. The concentration of the DNA 
solution was read by the Nanodrop and the sample was diluted to a concentration of 0,1-0,2µg/µl. 
 
B. Culturing of fibroblasts (Unistel Medical Laboratories (Pty) Ltd.) 
 
1. Set up of tissue specimen 
 Flasks were labelled correctly and the work bench was prepared to ensure no 
contamination 
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2. Collagenase treatment 
 A volume of 0.3ml Collagenase + 0.3ml medium was added to the 1ml medium and 
biopsy in a falcon tube. 
 This was incubated for 20-30 min at 37˚C and shaken twice by hand during incubation 
 Incubation continued for a further 30 min. 
 The tube was centrifuged for 10 min at 1200rpm 
3. Set up cultures from biopsy 
 The collagenase solution was pipetted with a sterile Pasteur pipette until 3ml remained 
and the supernatant was discarded. 
 Using the pellet of the cell suspension, 2 cultures were set up in 50ml tissue culture 
flasks. 
 A volume of 1-2ml of medium and three drops of NEAA was added (with a Pasteur 
pipette) to each flask. 
 Incubation followed in two separate incubators. 
4. Medium change 
 Every second day cultures were fed with 1.5ml medium. 
 On day four, cultures were evaluated using an inverted microscope, with a phase 
contrast objective. Nest-like colonies of fibroblastic cells should be present. 
 After four days of incubation, the medium of the tissue culture was decanted and 
changed with the mixture medium (50:50 Chang D and Amniochrome II) and 1ml NEAA 
 Flasks were incubated at 37˚C and cell growth checked. 
5. Trypsinization: 
 
 The culture was rinsed 1x with trypsin solution (1ml + 58ml Hanks solution).   
 It was rinsed a second time and the solution was left in the flask on the warm plate for 7 -10 
min and regularly shaken   
 Using a Pasteur pipette, the monolayer of fibroblasts was bought to suspension. 
 A volume of 1ml medium was added to the culture to stop the action of the trypsin. 
 Cells were divided according, to growth, in 2 – 4 culture flasks. 
 A volume of 3ml of culture medium was added. 
 Each flask was gassed with 5% CO2 in air and incubated at 37˚C. 
 
 
C. Freezing down procedure  
 
Two 75cm² confluent flasks were trypsinized, and the cells were pooled and transferred into a 15ml 
sterile conical tube, that was topped up with culture medium. Thereafter, centrifugation occured for 
10mins at 1000rpm. The medium was discarded, and 5ml culture medium was added and re-
centrifuged as above. The medium was again discarded and the resulting cell pellet was resuspended 
in 7ml of freezing medium. 
A volume of 1ml of cell suspension was aliquoted into 7 x 2ml sterile cryotubes. 
Thereafter, a drop of the cell suspension was placed into two 35mm Petri dishes containing a sterile 
cover slip, and 2.5ml of culture medium without antibiotics was added. The plates were then 
incubated for two to three days for mycoplasma testing. 
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The 2ml cryotubes were placed in the Nalgene freezing container, containing 250ml Propyl alcohol 
and then placed in the -80°C freezer for a minimum of 4hrs. The tubes were then carried in liquid 
nitrogen to the liquid nitrogen storage containers and placed in the boxes. The location of boxes 
were immediately noted and on return to the lab entered in the Cell Bank database. One vial was 
thawed, put into a 25cm² flask containing 5ml culture medium and incubated for three days as a 
control to check for viability and exclude contamination (Freshney, 2010).  
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APPENDIX IV 
 
List of 84 genes from the mitochondrial energy metabolism PCR Array 
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APPENDIX V 
Standard curves for real-time qPCR 
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APPENDIX VI 
 
List of conferences where this work has been or will be presented 
 
1. Van der Merwe C, Blanckenberg J, Loos B, Henning F, Lombard D, Carr J, Kinnear C, Bardien 
S. Investigation into the role of mitochondrial dysfunction in Parkinson’s disease in patients 
with mutations in the parkin gene. The 55th Annual Academic Year Day, Stellenbosch 
University. August 2011. Poster presentation 
 
2. Van der Merwe C, Blanckenberg J, Loos B, Henning F, Lombard D, Carr J, Kinnear C, Bardien 
S. Investigation into the role of mitochondrial dysfunction in Parkinson’s disease in patients 
with mutations in the parkin gene. Movement Disorder Society 16th International 
Congress, Dublin, Ireland. 17th-21st June 2012. Poster presentation 
 
3. Van der Merwe C, Blanckenberg J, Loos B, Henning F, Lombard D, Carr J, Kinnear C, Bardien 
S. Investigation into the role of mitochondrial dysfunction in Parkinson’s disease in patients 
with mutations in the parkin gene. The 56th Annual Academic Year Day, Stellenbosch 
University. August 2012. Poster presentation 
 
4. Van der Merwe C, Blanckenberg J, Loos B, Henning F, Lombard D, Carr J, Kinnear C, Bardien 
S. Investigation into the role of mitochondrial dysfunction in Parkinson’s disease in patients 
with mutations in the parkin gene. MRC Early Career Scientist Conference, MRC 
Conference Centre, Cape Town. October 2012. Poster presentation 
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